0001360214 2024-01-01 2024-12-31 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2024-01-01 2024-12-31 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2024-01-01 2024-12-31 0001360214 HROW:Sec11.875SeniorNotesDue2027Member 2024-01-01 2024-12-31 0001360214 2024-06-28 0001360214 2025-03-26 0001360214 2023-01-01 2023-12-31 0001360214 2024-10-01 2024-12-31 0001360214 2024-12-31 0001360214 2023-12-31 0001360214 HROW:ProductSalesNetMember 2024-01-01 2024-12-31 0001360214 HROW:ProductSalesNetMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenuesMember 2024-01-01 2024-12-31 0001360214 HROW:OtherRevenuesMember 2023-01-01 2023-12-31 0001360214 us-gaap:CommonStockMember 2022-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001360214 us-gaap:RetainedEarningsMember 2022-12-31 0001360214 us-gaap:ParentMember 2022-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2022-12-31 0001360214 2022-12-31 0001360214 us-gaap:CommonStockMember 2023-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001360214 us-gaap:RetainedEarningsMember 2023-12-31 0001360214 us-gaap:ParentMember 2023-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2023-12-31 0001360214 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001360214 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001360214 us-gaap:ParentMember 2023-01-01 2023-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001360214 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001360214 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001360214 us-gaap:ParentMember 2024-01-01 2024-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0001360214 us-gaap:CommonStockMember 2024-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001360214 us-gaap:RetainedEarningsMember 2024-12-31 0001360214 us-gaap:ParentMember 2024-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2024-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2024-04-01 2024-04-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2024-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:CommonStockMember 2024-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:PreferredStockMember 2024-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2024-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2024-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2024-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001360214 srt:MinimumMember 2024-12-31 0001360214 srt:MaximumMember 2024-12-31 0001360214 srt:MinimumMember HROW:NewDrugApplicationsMember 2024-12-31 0001360214 srt:MaximumMember HROW:NewDrugApplicationsMember 2024-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:StockOptionsUnvestedRSUsAndUnvestedPSUsMember 2024-01-01 2024-12-31 0001360214 HROW:StockOptionsUnvestedRSUsAndUnvestedPSUsMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2024-01-01 2024-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2024-01-01 2024-12-31 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2024-12-31 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 us-gaap:PreferredStockMember HROW:MeltPharmaceuticalsIncMember 2024-12-31 0001360214 us-gaap:PreferredStockMember HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 us-gaap:CommonStockMember HROW:SurfaceOphthalmicsIncMember 2024-12-31 0001360214 us-gaap:CommonStockMember HROW:SurfaceOphthalmicsIncMember 2023-12-31 0001360214 HROW:TwoThousandAndTwentySixNotesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001360214 HROW:TwoThousandAndTwentySixNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001360214 HROW:TwoThousandAndTwentySevenNotesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001360214 HROW:TwoThousandAndTwentySevenNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001360214 HROW:OaktreeLoanMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001360214 HROW:OaktreeLoanMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001360214 HROW:ChargebacksMember 2022-12-31 0001360214 HROW:GovernmentRebatesMember 2022-12-31 0001360214 HROW:AllowancesForSalesReturnsMember 2022-12-31 0001360214 HROW:AdministrativeFeesAndOtherRebatesMember 2022-12-31 0001360214 HROW:CoPayAssistanceMember 2022-12-31 0001360214 HROW:ReservesForCashDiscountMember 2022-12-31 0001360214 HROW:ChargebacksMember 2023-01-01 2023-12-31 0001360214 HROW:GovernmentRebatesMember 2023-01-01 2023-12-31 0001360214 HROW:AllowancesForSalesReturnsMember 2023-01-01 2023-12-31 0001360214 HROW:AdministrativeFeesAndOtherRebatesMember 2023-01-01 2023-12-31 0001360214 HROW:CoPayAssistanceMember 2023-01-01 2023-12-31 0001360214 HROW:ReservesForCashDiscountMember 2023-01-01 2023-12-31 0001360214 HROW:ChargebacksMember 2023-12-31 0001360214 HROW:GovernmentRebatesMember 2023-12-31 0001360214 HROW:AllowancesForSalesReturnsMember 2023-12-31 0001360214 HROW:AdministrativeFeesAndOtherRebatesMember 2023-12-31 0001360214 HROW:CoPayAssistanceMember 2023-12-31 0001360214 HROW:ReservesForCashDiscountMember 2023-12-31 0001360214 HROW:ChargebacksMember 2024-01-01 2024-12-31 0001360214 HROW:GovernmentRebatesMember 2024-01-01 2024-12-31 0001360214 HROW:AllowancesForSalesReturnsMember 2024-01-01 2024-12-31 0001360214 HROW:AdministrativeFeesAndOtherRebatesMember 2024-01-01 2024-12-31 0001360214 HROW:CoPayAssistanceMember 2024-01-01 2024-12-31 0001360214 HROW:ReservesForCashDiscountMember 2024-01-01 2024-12-31 0001360214 HROW:ChargebacksMember 2024-12-31 0001360214 HROW:GovernmentRebatesMember 2024-12-31 0001360214 HROW:AllowancesForSalesReturnsMember 2024-12-31 0001360214 HROW:AdministrativeFeesAndOtherRebatesMember 2024-12-31 0001360214 HROW:CoPayAssistanceMember 2024-12-31 0001360214 HROW:ReservesForCashDiscountMember 2024-12-31 0001360214 HROW:TransferOfAcquiredProductSalesProfitsMember 2024-01-01 2024-12-31 0001360214 HROW:TransferOfAcquiredProductSalesProfitsMember 2023-01-01 2023-12-31 0001360214 HROW:VEVYEMember 2023-07-31 0001360214 HROW:VEVYEMember 2023-07-01 2023-07-31 0001360214 HROW:VEVYEMember 2024-12-31 0001360214 HROW:SantenProductsAcquisitionMember 2023-07-01 2023-07-31 0001360214 HROW:SantenProductsAcquisitionMember 2024-12-31 0001360214 HROW:SantenProductsAcquisitionMember 2024-01-01 2024-12-31 0001360214 HROW:OneTimePaymentMember 2023-01-01 2023-01-31 0001360214 srt:MaximumMember HROW:OneTimePaymentMember 2023-01-01 2023-01-31 0001360214 HROW:OneTimePaymentMember 2023-01-01 2023-12-31 0001360214 HROW:OneTimePaymentMember 2024-01-01 2024-01-20 0001360214 HROW:OneTimePaymentMember 2023-01-31 0001360214 HROW:AssetPurchaseAgreementMember 2024-12-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 us-gaap:SeriesBPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2024-01-01 2024-12-31 0001360214 us-gaap:SeriesBPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:MeltLoanAgreementMember 2021-09-01 0001360214 HROW:ThirdPartyInvestorMember HROW:MeltLoanAgreementMember 2022-04-30 0001360214 HROW:MeltLoanAgreementMember 2023-12-28 0001360214 HROW:SeriesBOnePreferredStockMember HROW:MeltLoanAgreementMember 2023-12-28 0001360214 us-gaap:SeriesBPreferredStockMember HROW:MeltLoanAgreementMember 2023-12-28 0001360214 HROW:SurfaceOphthalmicsIncMember 2024-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2023-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2024-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2023-12-31 0001360214 HROW:ThirdPartySoftwareLicenseMember 2024-12-31 0001360214 HROW:ThirdPartySoftwareLicenseMember 2023-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2024-01-01 2024-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2023-01-01 2023-12-31 0001360214 us-gaap:PatentsMember 2024-12-31 0001360214 HROW:LicensesMember 2024-12-31 0001360214 us-gaap:TrademarksMember 2024-01-01 2024-12-31 0001360214 us-gaap:TrademarksMember 2024-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2024-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2024-12-31 0001360214 us-gaap:TradeNamesMember 2024-12-31 0001360214 HROW:NonCompetitionClauseMember 2024-12-31 0001360214 HROW:StatePharmacyLicensesMember 2024-12-31 0001360214 us-gaap:PatentsMember 2023-12-31 0001360214 HROW:LicensesMember 2023-12-31 0001360214 us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001360214 us-gaap:TrademarksMember 2023-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2023-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2023-12-31 0001360214 us-gaap:TradeNamesMember 2023-12-31 0001360214 HROW:NonCompetitionClauseMember 2023-12-31 0001360214 HROW:StatePharmacyLicensesMember 2023-12-31 0001360214 HROW:AssetPurchaseAgreementMember 2024-01-01 2024-12-31 0001360214 us-gaap:PatentsMember 2024-01-01 2024-12-31 0001360214 us-gaap:PatentsMember 2023-01-01 2023-12-31 0001360214 HROW:LicensesMember 2024-01-01 2024-12-31 0001360214 HROW:LicensesMember 2023-01-01 2023-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2024-01-01 2024-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2023-01-01 2023-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001360214 us-gaap:TradeNamesMember 2024-01-01 2024-12-31 0001360214 us-gaap:TradeNamesMember 2023-01-01 2023-12-31 0001360214 HROW:FinancingAgreementMember 2022-08-17 2023-08-16 0001360214 HROW:FinancingAgreementMember 2023-08-17 2024-08-16 0001360214 HROW:SeniorSecuredTermLoanMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-01 2023-03-31 0001360214 HROW:TrancheBMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-07-01 0001360214 HROW:TrancheBMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2024-03-27 0001360214 HROW:TrancheBMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2024-03-27 2024-03-27 0001360214 srt:MinimumMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-01 2023-07-31 0001360214 srt:MaximumMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-01 2023-07-31 0001360214 HROW:OaktreeCreditAgreementAmendmentMember 2023-07-31 0001360214 HROW:SantenProductsAcquisitionMember HROW:OaktreeLoanMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-31 0001360214 2024-10-31 0001360214 2024-10-31 2024-10-31 0001360214 HROW:SecondAmendmentMember 2024-10-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2024-01-01 2024-12-31 0001360214 srt:MaximumMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2024-01-01 2024-12-31 0001360214 srt:MaximumMember HROW:OaktreeFundAdministrationLLCMember 2024-01-01 2024-12-31 0001360214 HROW:SecondAmendmentMember 2024-12-31 0001360214 HROW:OaktreeLoanMember 2024-01-01 2024-12-31 0001360214 HROW:OaktreeLoanMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-01-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-12-01 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-01-01 2023-01-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2024-01-01 2024-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2024-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-05-01 2021-05-31 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-01 2021-09-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2024-01-01 2024-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2023-01-01 2023-12-31 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2022-12-14 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2022-12-13 2022-12-14 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2023-01-31 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2024-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2024-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-12-31 0001360214 HROW:OaktreeLoanDueJanuaryTwoThousandTwentySixMember 2024-12-31 0001360214 HROW:OaktreeLoanDueJanuaryTwoThousandTwentySixMember 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2024-12-31 0001360214 srt:MinimumMember HROW:OfficeAndLaboratorySpaceMember 2024-12-31 0001360214 srt:MaximumMember HROW:OfficeAndLaboratorySpaceMember 2024-12-31 0001360214 HROW:CarlsbadMember 2022-01-31 0001360214 HROW:CarlsbadMember 2022-01-01 2022-01-31 0001360214 HROW:LedgewoodMember 2020-07-31 0001360214 HROW:LedgewoodMember 2020-07-01 2020-07-31 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2020-07-01 2020-07-31 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2021-05-01 2021-05-31 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2024-01-01 2024-01-31 0001360214 HROW:NashvilleMember 2020-01-31 0001360214 HROW:NashvilleMember 2020-01-01 2020-01-31 0001360214 HROW:NashvilleMember 2022-12-31 0001360214 HROW:NashvilleMember 2022-12-01 2022-12-31 0001360214 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001360214 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 srt:MinimumMember us-gaap:CommonStockMember 2024-12-31 0001360214 srt:MaximumMember us-gaap:CommonStockMember 2024-12-31 0001360214 us-gaap:OptionMember HROW:JohnSaharekMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 us-gaap:OptionMember HROW:JohnSaharekMember us-gaap:CommonStockMember 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:AndrewRBollMember 2024-01-01 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:MarkLBaumMember 2024-01-01 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:JohnSaharekMember 2024-01-01 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:JohnSaharekMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001360214 HROW:CommonStockOfferingMember 2023-12-31 0001360214 HROW:CommonStockOfferingMember 2023-01-01 2023-12-31 0001360214 HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 srt:MinimumMember HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 srt:MaximumMember HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 HROW:PerformanceStockUnitsMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember srt:DirectorMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-12-31 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-12-31 0001360214 HROW:JohnSaharekMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:JohnSaharekMember us-gaap:CommonStockMember 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 srt:MaximumMember HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2024-12-31 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2024-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2024-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2023-12-31 0001360214 HROW:EmployeesAndConsultantMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001360214 HROW:EmployeesAndDirectorsMember 2024-01-01 2024-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2023-04-01 2023-04-30 0001360214 srt:MinimumMember HROW:PerformanceStockUnitsPSUMember us-gaap:CommonStockMember 2023-04-30 0001360214 srt:MaximumMember HROW:PerformanceStockUnitsPSUMember us-gaap:CommonStockMember 2023-04-30 0001360214 HROW:PerformanceStockUnitsPSUMember 2023-01-01 2023-12-31 0001360214 us-gaap:PerformanceSharesMember 2024-12-31 0001360214 us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0001360214 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001360214 HROW:PerformanceStockUnitsMember 2024-01-01 2024-12-31 0001360214 HROW:DirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001360214 HROW:DirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001360214 HROW:StockOptionPlanOneMember 2023-12-31 0001360214 HROW:StockOptionPlanOneMember 2024-01-01 2024-12-31 0001360214 HROW:StockOptionPlanOneMember 2024-12-31 0001360214 HROW:StockOptionPlanOneMember 2022-12-31 0001360214 HROW:StockOptionPlanOneMember 2023-01-01 2023-12-31 0001360214 HROW:RangeOneMember 2024-01-01 2024-12-31 0001360214 HROW:RangeOneMember 2024-12-31 0001360214 HROW:RangeTwoMember 2024-01-01 2024-12-31 0001360214 HROW:RangeTwoMember 2024-12-31 0001360214 HROW:RangeThreeMember 2024-01-01 2024-12-31 0001360214 HROW:RangeThreeMember 2024-12-31 0001360214 HROW:RangeFourMember 2024-01-01 2024-12-31 0001360214 HROW:RangeFourMember 2024-12-31 0001360214 HROW:RangeFiveMember 2024-01-01 2024-12-31 0001360214 HROW:RangeFiveMember 2024-12-31 0001360214 HROW:RangeSixMember 2024-01-01 2024-12-31 0001360214 HROW:RangeSixMember 2024-12-31 0001360214 HROW:RangeSevenMember 2024-01-01 2024-12-31 0001360214 HROW:RangeSevenMember 2024-12-31 0001360214 HROW:RangeEightMember 2024-01-01 2024-12-31 0001360214 HROW:RangeEightMember 2024-12-31 0001360214 HROW:RangeNineMember 2024-01-01 2024-12-31 0001360214 HROW:RangeNineMember 2024-12-31 0001360214 HROW:RangeTenMember 2024-01-01 2024-12-31 0001360214 HROW:RangeTenMember 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-12-31 0001360214 HROW:ShareBasedCompensationAwardTrancheFourMember 2024-01-01 2024-12-31 0001360214 HROW:ShareBasedCompensationAwardTrancheFourMember 2024-12-31 0001360214 us-gaap:PerformanceSharesMember 2023-12-31 0001360214 us-gaap:PerformanceSharesMember 2022-12-31 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 HROW:ConsultantsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001360214 HROW:ConsultantsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0001360214 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-31 0001360214 HROW:ReasearchAndDevelopmentMember 2024-01-01 2024-12-31 0001360214 2024-11-01 2024-11-30 0001360214 HROW:AssetPurchaseLicenseandRelatedAgreementsMember 2024-01-01 2024-12-31 0001360214 HROW:AssetPurchaseLicenseandRelatedAgreementsMember 2023-01-01 2023-12-31 0001360214 HROW:AssetPurchaseAndLicenseAgreementsMember 2024-01-01 2024-12-31 0001360214 HROW:AssetPurchaseAndLicenseAgreementsMember 2023-01-01 2023-12-31 0001360214 HROW:TwoCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:NoCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:NoCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:SingleCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:SingleCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:ThreeSuppliersMember HROW:PurchasesMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:ThreeSuppliersMember HROW:PurchasesMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:ProductSalesNetMember HROW:BrandedMember 2024-01-01 2024-12-31 0001360214 HROW:ProductSalesNetMember HROW:ImprimisRxMember 2024-01-01 2024-12-31 0001360214 HROW:OtherRevenuesMember HROW:BrandedMember 2024-01-01 2024-12-31 0001360214 HROW:OtherRevenuesMember HROW:ImprimisRxMember 2024-01-01 2024-12-31 0001360214 HROW:BrandedMember 2024-01-01 2024-12-31 0001360214 HROW:ImprimisRxMember 2024-01-01 2024-12-31 0001360214 us-gaap:OperatingSegmentsMember HROW:BrandedMember 2024-01-01 2024-12-31 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2024-01-01 2024-12-31 0001360214 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001360214 us-gaap:CorporateMember 2024-01-01 2024-12-31 0001360214 HROW:ReportableSegmentAggregationResearchAndDevelopmentMember 2024-01-01 2024-12-31 0001360214 HROW:ProductSalesNetMember HROW:BrandedMember 2023-01-01 2023-12-31 0001360214 HROW:ProductSalesNetMember HROW:ImprimisRxMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenuesMember HROW:BrandedMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenuesMember HROW:ImprimisRxMember 2023-01-01 2023-12-31 0001360214 HROW:BrandedMember 2023-01-01 2023-12-31 0001360214 HROW:ImprimisRxMember 2023-01-01 2023-12-31 0001360214 us-gaap:OperatingSegmentsMember HROW:BrandedMember 2023-01-01 2023-12-31 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2023-01-01 2023-12-31 0001360214 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0001360214 us-gaap:CorporateMember 2023-01-01 2023-12-31 0001360214 HROW:ReportableSegmentAggregationResearchAndDevelopmentMember 2023-01-01 2023-12-31 0001360214 HROW:IHEEZOMember 2024-01-01 2024-12-31 0001360214 HROW:IHEEZOMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:IHEEZOMember 2023-01-01 2023-12-31 0001360214 HROW:IHEEZOMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:VEVYEMember 2024-01-01 2024-12-31 0001360214 HROW:VEVYEMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:VEVYEMember 2023-01-01 2023-12-31 0001360214 HROW:VEVYEMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:OtherProductsMember 2024-01-01 2024-12-31 0001360214 HROW:OtherProductsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:OtherProductsMember 2023-01-01 2023-12-31 0001360214 HROW:OtherProductsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenueMember 2024-01-01 2024-12-31 0001360214 HROW:OtherRevenueMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0001360214 HROW:OtherRevenueMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenueMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember HROW:BrandedMember 2024-01-01 2024-12-31 0001360214 us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember HROW:BrandedMember 2023-01-01 2023-12-31 0001360214 us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember HROW:ImprimisRxMember 2024-01-01 2024-12-31 0001360214 us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember HROW:ImprimisRxMember 2023-01-01 2023-12-31 0001360214 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2024-01-01 2024-12-31 0001360214 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2023-01-01 2023-12-31 0001360214 us-gaap:SubsequentEventMember 2025-02-01 2025-02-28 0001360214 us-gaap:SubsequentEventMember 2025-03-01 2025-03-31 0001360214 srt:MinimumMember us-gaap:SubsequentEventMember 2025-02-28 0001360214 srt:MinimumMember us-gaap:SubsequentEventMember 2025-03-31 0001360214 srt:MaximumMember us-gaap:SubsequentEventMember 2025-02-28 0001360214 srt:MaximumMember us-gaap:SubsequentEventMember 2025-03-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 iso4217:USD shares iso4217:USD shares pure HROW:Segment utr:sqft false FY 0001360214 P3Y P2Y P1Y P5Y P2Y P3Y 10-K true 2024-12-31 --12-31 2024 false 001-35814 HARROW, INC. DE 45-0567010 1A Burton Hills Blvd. Suite 200 Nashville TN 37215 (615) 733-4730 Common Stock, $0.001 par value per share HROW NASDAQ 8.625% Senior Notes due 2026 HROWL NASDAQ 11.875% Senior Notes due 2027 HROWM NASDAQ Yes No Yes Yes Non-accelerated Filer true false true false false 678000000 35654171 Portions of the registrant’s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders to be held on June 18, 2025 are incorporated by reference in Part III of this Annual Report on Form 10-K, to the extent stated herein. We are subject to cybersecurity threats that could have a material adverse impact on our results of operations, financial condition and cash flows, as well as our operations—including our manufacturing and marketing capabilities. We operate a risk-based cybersecurity program which is designed to: (i) ensure the security, confidentiality, integrity and availability of our information and systems; (ii) protect against anticipated or actual cyber threats to our information and systems; and (iii) protect against unauthorized access and/or use of our information and systems. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zlMLx05ZN7A6">Overall cybersecurity risk reporting is integrated with our enterprise risk management program, is included in discussions with the Audit Committee of our Board of Directors and disclosed where appropriate.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zR9lBZpX3wFj">Our information technology and cybersecurity function is headed by our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zeHUnZ8kryv5">Chief Executive Officer</span> (“CEO”), and Vice President of Information Technology, who are responsible for managerial oversight of our cybersecurity program. Our Vice President of Information Technology reports directly to our CEO.</span><span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zI2uxpsDZCY7">We utilize a layered approach in assessing, identifying, evaluating and managing material risks from cybersecurity threats, and leverage outside partners to gain intelligence on threats. We take input from industry activities, third party assessments and internal simulations and continuously adjust our protection mechanisms to be effective. We also assess operational and data security risks associated with our use of third-party service providers, understanding where failure points may exist within our supply chain operations and data protections. If we learn of a cybersecurity incident at a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zZYIjqtgPeZ3">third-party service provider</span>, our information technology department will maintain communication with that third-party service provider and communicate any cybersecurity incidents to the Vice President of Information Technology and CEO</span>. All Harrow employees receive information security training (including data protection and fraud awareness) on an annual basis, and we use industry standard technology to monitor systems for anomalous behavior. We also require employees in certain roles to complete additional role-based, specialized cybersecurity trainings. In the event an incident were to occur, a Security Incident Response Team would be convened that consists of members from many functions, including legal counsel, the Vice President of Information Technology and the CEO.</span> true Our information technology and cybersecurity function is headed by our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zeHUnZ8kryv5">Chief Executive Officer</span> (“CEO”), and Vice President of Information Technology, who are responsible for managerial oversight of our cybersecurity program. Our Vice President of Information Technology reports directly to our CEO. true true true Our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_ze844siFVqXf">Board of Directors</span> has the ultimate oversight of the Company’s risks—including cybersecurity risks—with our Audit Committee assisting the Board of Directors in its oversight of cyber and information security risks. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zJ4mZnYmG7n4">Members of management that possess information security certifications and many years of experience work with our legal, finance and corporate governance functions to identify, define and report cybersecurity risks, policies and procedures and incident response plans.</span> The Audit Committee receives updates on our cybersecurity program from management on a regular basis and more frequently as determined to be necessary or advisable. Updates to the Audit Committee include policies, processes, procedures and any significant developments related to the identification, mitigation and remediation of cybersecurity risks, as well as effectiveness and changes in our ability to monitor, protect, detect and respond to incidents, risk reviews and industry news briefings. The Audit Committee also ensures that management provides a cyber and information security update to the Board of Directors at least annually. Finally, in the event a material cybersecurity incident were to occur, the CEO and Vice President of Information Technology would brief the Audit Committee which would then be responsible for assessing the materiality of the incident and making the determination of materiality and any related disclosure. true Members of management that possess information security certifications and many years of experience work with our legal, finance and corporate governance functions to identify, define and report cybersecurity risks, policies and procedures and incident response plans. false false false false false 173 170 Crowe LLP Costa Mesa, California KMJ Corbin & Company LLP Glendora, California 47247000 74085000 8681000 116373000 36261000 10702000 10867000 15329000 9588000 189651000 139482000 3734000 3521000 1751000 2138000 8554000 6785000 184949000 159906000 332000 332000 388971000 312164000 41406000 24581000 39900000 18432000 9496000 5450000 44000 75000 497000 806000 91343000 49344000 8792000 6524000 219539000 185885000 319674000 241753000 0.001 0.001 50000000 50000000 35622214 35622214 35168260 35168260 35000 35000 221002000 204635000 -151385000 -133904000 69652000 70766000 -355000 -355000 69297000 70411000 388971000 312164000 198619000 117447000 995000 12746000 199614000 130193000 49245000 39640000 150369000 90553000 129064000 83090000 12230000 6652000 253000 380000 141547000 90122000 8822000 431000 22786000 21324000 -3171000 3092000 -5465000 -185000 -444000 -26142000 -24141000 -17320000 -23710000 161000 701000 -17481000 -24411000 -0.49 -0.49 -0.75 -0.75 35650714 35650714 32616777 32616777 29901530 30000 137058000 -109493000 27595000 -355000 27240000 3887324 4000 64516000 64520000 64520000 10000 85000 85000 85000 235975 294000 294000 294000 1847876 2000 -2000 714445 1000 13012000 13013000 13013000 15696000 15696000 15696000 -24411000 -24411000 -24411000 35168260 35000 204635000 -133904000 70766000 -355000 70411000 35168260 35000 204635000 -133904000 70766000 -355000 70411000 259024 1110000 1110000 1110000 332517 137587 2362000 2362000 2362000 17619000 17619000 17619000 -17481000 -17481000 -17481000 35622214 35000 221002000 -151385000 69652000 -355000 69297000 35622214 35000 221002000 -151385000 69652000 -355000 69297000 -17481000 -24411000 1850000 1530000 11783000 10082000 904000 728000 120000 332000 4205000 4097000 -3171000 3092000 -168000 -253000 -380000 -5465000 17619000 15696000 80232000 30344000 -165000 4326000 6072000 5647000 37498000 31795000 4046000 1425000 -31000 -38000 -22202000 3840000 5510000 79000 18000 -37000000 -151075000 1595000 1460000 -33164000 -152553000 0.11875 4961000 29780000 73552000 2362000 13013000 1110000 379000 55879000 59750000 64520000 28528000 126528000 -26838000 -22185000 74085000 96270000 47247000 74085000 374000 20594000 18887000 1950000 1050000 2713000 873000 81000 299000 3230000 -557000 331000 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ztSmZgngidY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 1. <span id="xdx_829_zdGW0DcceSDb">ORGANIZATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harrow, Inc. (together with its consolidated subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Harrow”) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. The Company owns commercial rights to one of the largest portfolios of branded ophthalmic pharmaceutical products in the U.S. all of which are marketed under its Harrow name. The Company also owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns non-controlling equity interests in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective September 29, 2023, the Company changed its corporate name from Harrow Health, Inc. to Harrow, Inc. pursuant to a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z5q4X4hOZZN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 2. <span id="xdx_825_zNXH5c8mUuEe">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcODkk065291" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harrow has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity. The Company consolidates <span id="xdx_907_ecustom--ConsolidationBasisDescription_c20240101__20241231_zjftTpzojMba" title="Consolidation basis description">(i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zlPMJ4UN2fUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, renewal periods and discount rates for leases, realizability of inventories, recoverability of investments, realizability of deferred tax assets, recoverability of long-lived assets and goodwill, valuations and purchase price allocations related to business combinations and asset acquisitions, fair value of loans payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zeeSv3g1yhxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Risks and Uncertainties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products or subject the Company to enforcement actions. The Company’s 503B facility was inspected in 2024. The Company has been in discussions with the U.S. Food and Drug Administration (“FDA”) regarding the 2024 and other past FDA inspections of its 503B facility and has developed action plans to address observations made by FDA during these inspections and has communicated those plans to FDA. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, it could have a material impact on the Company’s financial condition, liquidity and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b> </b></p> <p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z1xmRdUVXwdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Liquidity</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In January 2026 the Oaktree Loan (see Note 13) becomes due which totals $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231_zLQO0G8h5WP5" title="Outstanding principal amount">107,500,000</span> principal amount outstanding at December 31, 2024. The maturity of this debt obligation without a refinancing event could raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently in discussions with its current senior lender, Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “Oaktree”), and other potential lenders about refinancing the Oaktree Loan. Management expects to move into more definitive discussions and negotiations with Oaktree and potential lenders in the summer and fall of 2025. Management believes it is probable that the Company will be able to refinance the Oaktree Loan based on the Company’s collateral strength and expected cash flows from operations; however, there can be no assurance that the Company will obtain the refinancing on terms acceptable to it, or at all. If the Company is unable to successfully refinance the Oaktree Loan, the Company does not expect to have the ability to repay the Oaktree Loan in full.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that one of the other alternatives available to it in lieu of refinancing the Oaktree Loan is the sale of one or more of the Company’s assets. There can be no assurance that any sale could be completed on a timely basis or on terms acceptable to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements are prepared on a going concern basis and do not include any adjustments that might result from the outcome of the uncertainty regarding the Company’s ability to refinance the Oaktree Loan or sell some of its assets to meet its obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zNtRvEY28DLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Credit Losses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at December 31, 2024 and 2023 are net of allowances for credit losses of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zkxQ3ZJAaEyi" title="Accounts receivable, net of allowances for credit losses">416,000</span> and $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zGPsd6f6NiXd" title="Accounts receivable, net of allowances for credit losses">371,000</span>, respectively. The following table provides a roll-forward of the allowance for credit losses that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected at December 31, 2024 and 2023:</p> <p id="xdx_892_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zFWWZu0VYYul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zr6T2QxqneTg" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS</span></span></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%">Balance at January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20230101__20231231_zVHLE3S4eDJk" style="width: 12%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zz4WiHA8SgP3" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_z5Zri3O5yCc2" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20240101__20241231_zuZaXIjOkS58" style="text-align: right" title="Beginning balance">371,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 13.5pt">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20240101__20241231_zAy1YnDJuwA9" style="text-align: right" title="Change in expected credit losses">120,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20240101__20241231_z0v3fRYqqnVf" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(75,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_c20240101__20241231_zF5pkgo3COe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">416,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zKoKGVucLpC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zZmPu5hndE6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Business Combinations and Asset Acquisitions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 805, <i>Business Combinations</i>, requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including any contingent assets and liabilities, and any non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. The Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, <i>Business Combinations – Related Issues</i>, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity or a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s financial statements. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired, and liabilities assumed, whichever is more clearly evident and more reliably measurable. The obligation for contingent consideration payments is recorded when probable and reasonably estimable. Contingent consideration recognized is included in the initial cost of the assets acquired and any subsequent changes in the recorded amount of contingent consideration are recognized as an adjustment to the cost basis of the acquired assets and allocated to the acquired assets based on the relative fair value at the date of acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--NoncontrollingInterestPolicyTextBlock_zPzT5qYxWxTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Noncontrolling Interests</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. <span id="xdx_90B_eus-gaap--MinorityInterestDescription_c20240101__20241231_zI15egXJniIh" title="Noncontrolling interest, description">Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights.</span> When applicable, and in prior periods, the Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides in the consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">net income or loss;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">each component of other income or loss.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The noncontrolling interests in the consolidated balance sheets as of December 31, 2024 and 2023, relate to consolidated subsidiaries for which the Company does not own 100% of the equity interests, and that no longer have active operations, assets and related financial activity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsWnANzqKpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition and Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue at the time of transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services (see Note 3).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zimax8jok4n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cost of Sales</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, depreciation and amortization of certain intangible assets and the write-off of obsolete inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zM77ujRpaOy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (“R&amp;D”) expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts. The Company expenses all costs related to R&amp;D as they are incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upfront and milestone payments related to the acquisition and licensing of technology for drug and product candidates that are not yet approved by the FDA are considered acquisition of in process R&amp;D and expensed as R&amp;D in the period in which the expense occurs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zkQtkleSkSC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Debt Issuance Costs and Debt Discount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Debt issuance costs and the debt discount are recorded net of notes payable in the consolidated balance sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zesZtORqQu0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see “Goodwill and Intangible Assets” below). If costs are not capitalized, they are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_z44L9azYWPx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under the provisions of ASC 740, <i>Income Taxes</i>. As of December 31, 2024 and 2023, there was $<span id="xdx_905_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20241231_zwIS0Lcvxwv4" title="Unrecognized tax benefits">2,858,000</span> and $<span id="xdx_900_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20231231_zOmhldujzogl" title="Unrecognized tax benefits">2,822,000</span>, respectively, of unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had an accrual for interest or penalties of $<span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20241231_zsCI1Q2Cyg4l" title="Accrual for interest and penalties">69,000</span> and $<span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20231231_z9ujBQtRfK0a" title="Accrual for interest and penalties">40,000</span> in the consolidated balance sheets at December 31, 2024 and 2023, respectively, and have recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2024 and 2023 of $<span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20240101__20241231_zp1DXoCLh583" title="Recognized interest and penalties">69,000</span> and $<span id="xdx_90A_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20230101__20231231_z6d0boVb1xC4" title="Recognized interest and penalties">40,000</span>, respectively. The Company is subject to taxation in the U.S., New Jersey, Tennessee, and various other states. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z8lReZ8pZDce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and Cash Equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z2Avo5dqutTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zFSGWHeElyne" title="Cash, FDIC Insured Amount">250,000</span> per owner. The Company believes the majority of its cash deposits are covered under FDIC limits, however there are various accounts in which the Company has deposits in excess of FDIC limits.</p> <p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zRa5IdMH9AD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><br/> Investment in Eton Pharmaceuticals, Inc.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s investment in Eton Pharmaceuticals, Inc. (“Eton”) consisted of common stock with a readily determinable fair value which was carried at fair value with changes in fair value recognized in earnings. In accordance with ASC 321, <i>Investments — Equity Securities</i>, the Company recorded an unrealized holding gain from its Eton common stock position of $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_c20230101__20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zvdNl4VGjZZd" title="Investments related to change in fair market value of its investment">3,092,000</span> during the year ended December 31, 2023 related to the change in fair market value of its investment in Eton during the measurement period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company owned <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z2g8t54Ve7yj" title="Number of shares owned">1,982,000</span> shares of Eton common stock, which represented less than <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zaMxBwB4Hvck" title="Equity method investment ownership, percentage">10</span>% of the equity interests of Eton. In April 2024, the Company sold all of its shares for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240401__20240430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zES2fJ8zYwLi" title="Proceeds from sale of equity">5,510,000</span> and recognized a loss of $<span id="xdx_909_eus-gaap--GainLossOnInvestments_c20240401__20240430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zLZ9EzJStTGk" title="Recognized a loss on investment">3,171,000</span>. As of December 31, 2024 and 2023, the fair market value of the Company’s investment in Eton was $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zAs7QdFeJqei" title="Investment owned, at fair value">0</span> and $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zPftenA53NFf" title="Investment owned, at fair value">8,681,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_zoXEgR1Tzu0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable is stated net of allowances for credit losses and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. The Company’s gross product revenues are subject to a variety of contractual deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Accounts receivable at December 31, 2024 are presented net of allowances for credit losses of $<span id="xdx_900_ecustom--AccountsReceivables_iI_c20241231_z5ozIbFExnS8" title="Accounts receivable, net">416,000</span> and $<span id="xdx_90F_ecustom--AccountsReceivableContractualAdjustments_iI_c20241231_zZrLMmNBrf2b" title="Accounts receivable, contractual adjustments">19,731,000</span> for contractual adjustments (in aggregate $<span id="xdx_903_eus-gaap--AccountsReceivableNet_iI_c20241231_z4SzyKHy44Bb" title="Accounts Receivable, after Allowance for Credit Loss">20,147,000</span>) and at December 31, 2023, net of allowances for credit losses of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zeDcwZA24f4b" title="Accounts receivable, net of allowances for credit losses">371,000</span> and $<span id="xdx_908_ecustom--AccountsReceivableContractualAdjustments_iI_c20231231_zVJEokRLVjh8" title="Accounts receivable, contractual adjustments">14,875,000</span> for contractual adjustments (in aggregate $<span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20231231_zd1jOafhsIdc" title="Accounts Receivable, after Allowance for Credit Loss">15,246,000</span>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> <p id="xdx_845_eus-gaap--InventoryPolicyTextBlock_zFo4T3pmjMW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inventories</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--InvestmentOnePolicyTextBlock_zTphRitLMHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Melt Pharmaceuticals, Inc. – Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns <span id="xdx_90E_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zcuuuXFC6T79" title="Investment owned balance shares">3,500,000</span> shares of common stock and <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zEl6gIF775Ie" title="Investment owned balance shares">2,334,256</span> shares of preferred stock of Melt (representing in aggregate approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zeacmUmK7qqb" title="Ownership percentage">45</span>% of the equity interests as of December 31, 2024). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its investment in Melt to $<span id="xdx_90D_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zTLRjCe2Upt4" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of December 31, 2022, and at the time of entering into the Melt Loan Agreement (see Note 5), the Company owned <span id="xdx_907_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zH4OkAn0biXa" title="Investment interest rate">100</span>% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_900_ecustom--ReductionInInvestment_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zul3bhOii4Zf" title="Reduction in investment">0</span>, the Company began recording <span id="xdx_904_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zb8Zf1DfwAUi" title="Investment interest rate">100</span>% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treated interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduced its investment in Melt accordingly, rather than recording interest income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. During the year ended December 31, 2023, the Melt Loan Agreement (as defined in Note 5) was settled in exchange for Melt preferred stock (see Note 5 for loan settlement disclosure). The Company reduced the Melt Loan Agreement and subsequent preferred stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInInvestment_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zNcT6kqQEaR6" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses of Melt. The Company has no other investments in Melt and no other requirements to advance funds to Melt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpekqaddZBU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zjIwDCBqtb6k" style="display: none">SCHEDULE OF INVESTMENT</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity <br/>Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify">Common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzO2pCgRN0t4" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z3qkORYjiPh8" title="Cost basis">5,810,000</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpJAyHhRJ2s5" title="Share of Equity Method Losses"><span id="xdx_904_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqLtUwT0U33" title="Share of Equity Method Losses">(5,810,000</span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmMu7eyga3z2" title="Net Carrying Value"><span id="xdx_90E_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zg79bisqK7Xk" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0704"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zFqMVXj5VcZ7" title="Cost basis"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGwjYFWi1K7" title="Cost basis">18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEG5x0QV2Ita" title="Share of Equity Method Losses"><span id="xdx_909_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzXNuhUSA9gc" title="Share of Equity Method Losses">(18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zY3tIEjytp8c" title="Net Carrying Value"><span id="xdx_908_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zbg2trkqYEh3" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0716"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMCqnutGxlL5" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjsFU5u5nQc9" title="Cost basis">24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6eMExFBrIJf" title="Share of Equity Method Losses"><span id="xdx_901_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zceXgvbF1tJ6" title="Share of Equity Method Losses">(24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--Investments_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRmH5X6aVfCl" title="Net Carrying Value"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVdk4jPWyjK6" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0728"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z64SDV6Jnao3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024 and 2023, the Company recorded $<span id="xdx_90F_eus-gaap--OtherLiabilitiesCurrent_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zAJ4DyqUfZ15" title="Due from related parties">0</span> and $<span id="xdx_907_eus-gaap--OtherLiabilitiesCurrent_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWat9osq1Dyh" title="Due from related parties">89,000</span>, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”), which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 5 for more information and related party disclosure regarding Melt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_840_ecustom--InvestmentTwoPolicyTextBlock_zxeD1Dt2dgTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Surface Ophthalmics, Inc. – Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zc0WQGsWtf2e" title="Investment owned balance shares">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zLYX0GNf4hZa" title="Ownership percentage">20</span>% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_908_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zTwj6fzcer03" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface and no other requirements to advance funds to Surface.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5ImUQeYas1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_ze01gnZ3LbJ">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5rPf53ot3bk" title="Cost Basis"><span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zBFE2hqwxDgi" title="Cost Basis">5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zRjQLaOw3Gc7" title="Share of Equity Method Losses"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1fkMaDnDsp9" title="Share of Equity Method Losses">(5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zs7dMIg5tNu5" title="Net carrying value"><span id="xdx_90A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zxNRXpkzS9Ei" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0754"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zLv0OFF6fsab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 6 for more information and related party disclosure regarding Surface.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9vaQtqjjFta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Property, Plant and Equipment</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and finance lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer hardware and furniture and equipment are depreciated over <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zVx5Qb5nY166" title="Property, plant and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0760">three</span></span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zaq9Gv1Hu6Fh" title="Property, plant and equipment, useful life">five years</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zM88yQ1PKOj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capitalized Software Costs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company capitalizes certain costs related to the development of internal-use software. Costs incurred during the application development phase are capitalized only when the Company believes it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include consulting fees for third-party developers working on these projects. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Internal-use software is amortized on a straight-line basis over the estimated useful life of the asset, which ranges from <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zeAp1t0tP624" title="Finite lived intangible asset useful life::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0766">two</span></span> to <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zNtwOtfAkGRi" title="Finite lived intangible asset useful life">five years</span>. When internal-use software that was previously capitalized is abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Fully amortized capitalized internal-use software costs are removed from their respective accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zwJhCux8WGId" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and successfully prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zzSxVIXEBt8" title="Estimated useful life">20</span> years, using the straight-line method. Acquired product rights, including new drug applications (“NDAs”), are amortized over their estimated useful lives, generally <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zmLZgd6WGdl8" title="Estimated useful life">4</span>-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zXkNeUdzebAg" title="Estimated useful life">15</span> years, based on a straight-line method. Trademarks are an indefinite-lived intangible asset and are assessed for impairment based on future projected cash flows as further described below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant underperformance of the Company’s business relative to expected operating results;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant adverse economic and industry trends;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">expectations that a reporting unit will be sold or otherwise disposed.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The goodwill impairment test consists of a two-step process as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, goodwill is considered impaired and the Company then performs the second step of the impairment test to measure the impairment loss. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 2. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of its assessment in 2024, the Company concluded that goodwill is not impaired as of December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zFoM5kHvfM3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Other Long-Lived Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Other long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such circumstances could include, but are not limited to (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The fair value of the asset is based on the discounted value of its estimated future cash flows</span>. <span style="font-size: 10pt">Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_z2NX0CmJXMMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the inception of a contract the Company determines if the arrangement is, or contains, a lease. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, discounted using the Company’s incremental borrowing rate of the debt outstanding. Lease expense is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months of less) and (ii) combines lease and non-lease elements of its operating leases as a single lease component. As of December 31, 2024 and 2023, the Company did not have any finance leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNWbtKnJ7pde" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton was classified as Level 1 as the fair value was determined using quoted market prices in an active market for the same securities. As of December 31, 2023, the fair market value of the Company’s investment in Eton was $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zh0Ya4GZQVyl" title="Investment owned at fair value">8,681,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <br/> The Company’s 2026 Notes (as defined in Note 13) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as defined in Note 13) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 13) is carried at face value less the original issue discount and unamortized debt issuance costs on the consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zr205lAcTxwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the estimated fair values and the carrying values:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zxJ9ZfkPB4qd" style="display: none">SCHEDULE OF ESTIMATED FAIR VALUE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">2026 Notes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z4u2L4PU8HG5" style="width: 12%; text-align: right" title="Carrying value">74,002,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zeHdePGpR6mc" style="width: 12%; text-align: right" title="Fair value">75,840,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zUSWO8bVU6o4" style="width: 12%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z3rZKDtbL4a9" style="width: 12%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_ziTWK9T1WZi2" style="text-align: right" title="Carrying value">38,130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2bHe1WhrcM" style="text-align: right" title="Fair value">42,198,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zdfQguBwwqhl" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zUHkYNXsNMt7" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zuBSNPhimVt" style="text-align: right" title="Carrying value">107,407,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zjMYT8jlDGrd" style="text-align: right" title="Fair value">112,932,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zhQ0m5nbKOXj" style="text-align: right" title="Carrying value">75,254,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_ztf4UEZMAf" style="text-align: right" title="Fair value">78,633,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_ziQHeX7Y6Url" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating lease liabilities approximate their respective fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zFcPJj4i6th8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”), performance stock units (“PSUs) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. The Company provides newly issued shares of common stock to satisfy the exercise and vesting for stock-based compensation awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z4ej1geOm8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing net loss attributable to Harrow, Inc. for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to Harrow, Inc. for the year by the weighted average number of common and common equivalent shares, such as stock options, RSUs, PSUs, and warrants, outstanding during the year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs, and unvested PSUs were <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_z9DjSUacZTz7" title="Stock options, unvested RSUs, and unvested PSUs">4,390,124</span> and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zFC8qM9o0w7" title="Stock options, unvested RSUs, and unvested PSUs">4,642,259</span> at December 31, 2024 and 2023, respectively, and are excluded in the calculation of diluted net loss per share for the periods presented, because the effect is anti-dilutive for that time period. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at December 31, 2024 and 2023 was <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl3PLhHRaoe3" title="Vested RSU">211,020</span> and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2z9AI4BnRJ7" title="Vested RSU">215,539</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zb7MBcPrSl5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z2WpUzSE824h" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_49D_20240101__20241231_z3CaV0Twl9Ee" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zsgmEaFMFhSh" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zhRRATCrbVo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(17,481,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zcBVSBuwBH5e" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zE9vtmv6JWv6" title="Weighted average number of shares of common stock outstanding, diluted">35,650,714</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z4k8k1IaYLY9" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zIQnKUrd0EJh" title="Weighted average number of shares of common stock outstanding, diluted">32,616,777</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zitT0vF8ydtl" title="Basic net loss per share of common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zMU7sgMCDCW9" title="Diluted net loss per share of common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zxYthrHOOJSa" title="Basic net loss per share of common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPmjdAZsGGz7" title="Diluted net loss per share of common stock">(0.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zhYCTFmoN4Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zl8kSXumnAXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recently Adopted Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards update (“ASU”) 2023-07, <i>Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures</i>, which enhances the disclosures required for operating segments in the Company’s annual and interim consolidated financial statements. The Company adopted ASU 2023-07 on a retrospective basis as of December 31, 2024. The adoption did not impact the Company’s financial statements, other than with respect to expanded disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_ecustom--AccountingGuidanceIssuedButNotAdoptedPolicyTextBlock_z6TxmQxNsEki" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Accounting Guidance Issued but Not Adopted at December 31, 2024</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2023, FASB issued ASU 2023-05, <i>Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement</i>, which applies to the formation of entities that meet the definition of a joint venture (or a corporate joint venture) and requires joint ventures to initially measure all contributions received upon formation at fair value. The new guidance does not impact accounting by the venturers. The new guidance is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. Joint ventures formed prior to the effective date may elect to apply the new guidance retrospectively back to their original formation date. The Company will apply the guidance in ASU 2023-05 prospectively to any future arrangements meeting the definition of a joint venture.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</i>. This ASU modifies the disclosure or presentation requirements of a variety of topics in the codification by aligning them with the SEC’s regulations. The amendments to the various topics should be applied prospectively, and the effective date for the Company for each amendment will be determined based on the effective date of the SEC’s removal of the related disclosure from Regulation S-X or Regulation S-K. If the SEC has not removed the applicable requirement by June 30, 2027, then the related amendment in ASU 2023-06 will be removed from the codification and will not become effective. Early adoption of this ASU is prohibited. The Company does not expect the amendments in this ASU to have a material impact on the disclosures or presentation in its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</i>, which enhances the disclosures required for income taxes in the Company’s annual consolidated financial statements. Notably, this ASU requires entities to disclose specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for the Company in its annual reporting for fiscal 2025 on a prospective basis. Early adoption and retrospective reporting are permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures</i>, to improve the disclosures by a public business entity about the types of expenses in commonly presented expense captions. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_ziBI6YIUGdYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Reclassification of Prior Year Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. A reclassification has been made to the consolidated balance sheet at December 31, 2023, to reclassify the Oaktree Loan exit fee to be included in the net debt amount (see Note 13).</p> <p id="xdx_854_zlckNMLCQzgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcODkk065291" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harrow has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity. The Company consolidates <span id="xdx_907_ecustom--ConsolidationBasisDescription_c20240101__20241231_zjftTpzojMba" title="Consolidation basis description">(i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. <p id="xdx_84F_eus-gaap--UseOfEstimates_zlPMJ4UN2fUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, renewal periods and discount rates for leases, realizability of inventories, recoverability of investments, realizability of deferred tax assets, recoverability of long-lived assets and goodwill, valuations and purchase price allocations related to business combinations and asset acquisitions, fair value of loans payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zeeSv3g1yhxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Risks and Uncertainties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products or subject the Company to enforcement actions. The Company’s 503B facility was inspected in 2024. The Company has been in discussions with the U.S. Food and Drug Administration (“FDA”) regarding the 2024 and other past FDA inspections of its 503B facility and has developed action plans to address observations made by FDA during these inspections and has communicated those plans to FDA. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, it could have a material impact on the Company’s financial condition, liquidity and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b> </b></p> <p id="xdx_841_ecustom--LiquidityPolicyTextBlock_z1xmRdUVXwdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Liquidity</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">In January 2026 the Oaktree Loan (see Note 13) becomes due which totals $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231_zLQO0G8h5WP5" title="Outstanding principal amount">107,500,000</span> principal amount outstanding at December 31, 2024. The maturity of this debt obligation without a refinancing event could raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently in discussions with its current senior lender, Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “Oaktree”), and other potential lenders about refinancing the Oaktree Loan. Management expects to move into more definitive discussions and negotiations with Oaktree and potential lenders in the summer and fall of 2025. Management believes it is probable that the Company will be able to refinance the Oaktree Loan based on the Company’s collateral strength and expected cash flows from operations; however, there can be no assurance that the Company will obtain the refinancing on terms acceptable to it, or at all. If the Company is unable to successfully refinance the Oaktree Loan, the Company does not expect to have the ability to repay the Oaktree Loan in full.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that one of the other alternatives available to it in lieu of refinancing the Oaktree Loan is the sale of one or more of the Company’s assets. There can be no assurance that any sale could be completed on a timely basis or on terms acceptable to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements are prepared on a going concern basis and do not include any adjustments that might result from the outcome of the uncertainty regarding the Company’s ability to refinance the Oaktree Loan or sell some of its assets to meet its obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 107500000 <p id="xdx_84B_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zNtRvEY28DLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Credit Losses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at December 31, 2024 and 2023 are net of allowances for credit losses of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zkxQ3ZJAaEyi" title="Accounts receivable, net of allowances for credit losses">416,000</span> and $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zGPsd6f6NiXd" title="Accounts receivable, net of allowances for credit losses">371,000</span>, respectively. The following table provides a roll-forward of the allowance for credit losses that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected at December 31, 2024 and 2023:</p> <p id="xdx_892_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zFWWZu0VYYul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zr6T2QxqneTg" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS</span></span></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%">Balance at January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20230101__20231231_zVHLE3S4eDJk" style="width: 12%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zz4WiHA8SgP3" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_z5Zri3O5yCc2" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20240101__20241231_zuZaXIjOkS58" style="text-align: right" title="Beginning balance">371,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 13.5pt">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20240101__20241231_zAy1YnDJuwA9" style="text-align: right" title="Change in expected credit losses">120,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20240101__20241231_z0v3fRYqqnVf" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(75,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_c20240101__20241231_zF5pkgo3COe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">416,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zKoKGVucLpC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> 416000 371000 <p id="xdx_892_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zFWWZu0VYYul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zr6T2QxqneTg" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS</span></span></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%">Balance at January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20230101__20231231_zVHLE3S4eDJk" style="width: 12%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zz4WiHA8SgP3" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_z5Zri3O5yCc2" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_c20240101__20241231_zuZaXIjOkS58" style="text-align: right" title="Beginning balance">371,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 13.5pt">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20240101__20241231_zAy1YnDJuwA9" style="text-align: right" title="Change in expected credit losses">120,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20240101__20241231_z0v3fRYqqnVf" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs, net of recoveries">(75,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_c20240101__20241231_zF5pkgo3COe9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">416,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 73000 332000 34000 371000 120000 75000 416000 <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_zZmPu5hndE6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Business Combinations and Asset Acquisitions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 805, <i>Business Combinations</i>, requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including any contingent assets and liabilities, and any non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. The Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, <i>Business Combinations – Related Issues</i>, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity or a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s financial statements. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired, and liabilities assumed, whichever is more clearly evident and more reliably measurable. The obligation for contingent consideration payments is recorded when probable and reasonably estimable. Contingent consideration recognized is included in the initial cost of the assets acquired and any subsequent changes in the recorded amount of contingent consideration are recognized as an adjustment to the cost basis of the acquired assets and allocated to the acquired assets based on the relative fair value at the date of acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--NoncontrollingInterestPolicyTextBlock_zPzT5qYxWxTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Noncontrolling Interests</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. <span id="xdx_90B_eus-gaap--MinorityInterestDescription_c20240101__20241231_zI15egXJniIh" title="Noncontrolling interest, description">Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights.</span> When applicable, and in prior periods, the Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides in the consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">net income or loss;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">each component of other income or loss.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The noncontrolling interests in the consolidated balance sheets as of December 31, 2024 and 2023, relate to consolidated subsidiaries for which the Company does not own 100% of the equity interests, and that no longer have active operations, assets and related financial activity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights. <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsWnANzqKpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition and Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue at the time of transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services (see Note 3).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_zimax8jok4n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cost of Sales</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, depreciation and amortization of certain intangible assets and the write-off of obsolete inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zM77ujRpaOy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (“R&amp;D”) expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts. The Company expenses all costs related to R&amp;D as they are incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upfront and milestone payments related to the acquisition and licensing of technology for drug and product candidates that are not yet approved by the FDA are considered acquisition of in process R&amp;D and expensed as R&amp;D in the period in which the expense occurs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zkQtkleSkSC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Debt Issuance Costs and Debt Discount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Debt issuance costs and the debt discount are recorded net of notes payable in the consolidated balance sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zesZtORqQu0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see “Goodwill and Intangible Assets” below). If costs are not capitalized, they are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_z44L9azYWPx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under the provisions of ASC 740, <i>Income Taxes</i>. As of December 31, 2024 and 2023, there was $<span id="xdx_905_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20241231_zwIS0Lcvxwv4" title="Unrecognized tax benefits">2,858,000</span> and $<span id="xdx_900_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20231231_zOmhldujzogl" title="Unrecognized tax benefits">2,822,000</span>, respectively, of unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had an accrual for interest or penalties of $<span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20241231_zsCI1Q2Cyg4l" title="Accrual for interest and penalties">69,000</span> and $<span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20231231_z9ujBQtRfK0a" title="Accrual for interest and penalties">40,000</span> in the consolidated balance sheets at December 31, 2024 and 2023, respectively, and have recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2024 and 2023 of $<span id="xdx_909_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20240101__20241231_zp1DXoCLh583" title="Recognized interest and penalties">69,000</span> and $<span id="xdx_90A_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20230101__20231231_z6d0boVb1xC4" title="Recognized interest and penalties">40,000</span>, respectively. The Company is subject to taxation in the U.S., New Jersey, Tennessee, and various other states. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 2858000 2822000 69000 40000 69000 40000 <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z8lReZ8pZDce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and Cash Equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z2Avo5dqutTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zFSGWHeElyne" title="Cash, FDIC Insured Amount">250,000</span> per owner. The Company believes the majority of its cash deposits are covered under FDIC limits, however there are various accounts in which the Company has deposits in excess of FDIC limits.</p> 250000 <p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zRa5IdMH9AD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><br/> Investment in Eton Pharmaceuticals, Inc.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s investment in Eton Pharmaceuticals, Inc. (“Eton”) consisted of common stock with a readily determinable fair value which was carried at fair value with changes in fair value recognized in earnings. In accordance with ASC 321, <i>Investments — Equity Securities</i>, the Company recorded an unrealized holding gain from its Eton common stock position of $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_c20230101__20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zvdNl4VGjZZd" title="Investments related to change in fair market value of its investment">3,092,000</span> during the year ended December 31, 2023 related to the change in fair market value of its investment in Eton during the measurement period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company owned <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z2g8t54Ve7yj" title="Number of shares owned">1,982,000</span> shares of Eton common stock, which represented less than <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zaMxBwB4Hvck" title="Equity method investment ownership, percentage">10</span>% of the equity interests of Eton. In April 2024, the Company sold all of its shares for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240401__20240430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zES2fJ8zYwLi" title="Proceeds from sale of equity">5,510,000</span> and recognized a loss of $<span id="xdx_909_eus-gaap--GainLossOnInvestments_c20240401__20240430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zLZ9EzJStTGk" title="Recognized a loss on investment">3,171,000</span>. As of December 31, 2024 and 2023, the fair market value of the Company’s investment in Eton was $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zAs7QdFeJqei" title="Investment owned, at fair value">0</span> and $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zPftenA53NFf" title="Investment owned, at fair value">8,681,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 3092000 1982000 0.10 5510000 3171000 0 8681000 <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_zoXEgR1Tzu0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable is stated net of allowances for credit losses and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. The Company’s gross product revenues are subject to a variety of contractual deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Accounts receivable at December 31, 2024 are presented net of allowances for credit losses of $<span id="xdx_900_ecustom--AccountsReceivables_iI_c20241231_z5ozIbFExnS8" title="Accounts receivable, net">416,000</span> and $<span id="xdx_90F_ecustom--AccountsReceivableContractualAdjustments_iI_c20241231_zZrLMmNBrf2b" title="Accounts receivable, contractual adjustments">19,731,000</span> for contractual adjustments (in aggregate $<span id="xdx_903_eus-gaap--AccountsReceivableNet_iI_c20241231_z4SzyKHy44Bb" title="Accounts Receivable, after Allowance for Credit Loss">20,147,000</span>) and at December 31, 2023, net of allowances for credit losses of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zeDcwZA24f4b" title="Accounts receivable, net of allowances for credit losses">371,000</span> and $<span id="xdx_908_ecustom--AccountsReceivableContractualAdjustments_iI_c20231231_zVJEokRLVjh8" title="Accounts receivable, contractual adjustments">14,875,000</span> for contractual adjustments (in aggregate $<span id="xdx_90D_eus-gaap--AccountsReceivableNet_iI_c20231231_zd1jOafhsIdc" title="Accounts Receivable, after Allowance for Credit Loss">15,246,000</span>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> 416000 19731000 20147000 371000 14875000 15246000 <p id="xdx_845_eus-gaap--InventoryPolicyTextBlock_zFo4T3pmjMW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inventories</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--InvestmentOnePolicyTextBlock_zTphRitLMHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Melt Pharmaceuticals, Inc. – Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns <span id="xdx_90E_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zcuuuXFC6T79" title="Investment owned balance shares">3,500,000</span> shares of common stock and <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zEl6gIF775Ie" title="Investment owned balance shares">2,334,256</span> shares of preferred stock of Melt (representing in aggregate approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zeacmUmK7qqb" title="Ownership percentage">45</span>% of the equity interests as of December 31, 2024). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its investment in Melt to $<span id="xdx_90D_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zTLRjCe2Upt4" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of December 31, 2022, and at the time of entering into the Melt Loan Agreement (see Note 5), the Company owned <span id="xdx_907_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zH4OkAn0biXa" title="Investment interest rate">100</span>% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_900_ecustom--ReductionInInvestment_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zul3bhOii4Zf" title="Reduction in investment">0</span>, the Company began recording <span id="xdx_904_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zb8Zf1DfwAUi" title="Investment interest rate">100</span>% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treated interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduced its investment in Melt accordingly, rather than recording interest income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. During the year ended December 31, 2023, the Melt Loan Agreement (as defined in Note 5) was settled in exchange for Melt preferred stock (see Note 5 for loan settlement disclosure). The Company reduced the Melt Loan Agreement and subsequent preferred stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInInvestment_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zNcT6kqQEaR6" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses of Melt. The Company has no other investments in Melt and no other requirements to advance funds to Melt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpekqaddZBU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zjIwDCBqtb6k" style="display: none">SCHEDULE OF INVESTMENT</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity <br/>Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify">Common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzO2pCgRN0t4" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z3qkORYjiPh8" title="Cost basis">5,810,000</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpJAyHhRJ2s5" title="Share of Equity Method Losses"><span id="xdx_904_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqLtUwT0U33" title="Share of Equity Method Losses">(5,810,000</span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmMu7eyga3z2" title="Net Carrying Value"><span id="xdx_90E_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zg79bisqK7Xk" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0704"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zFqMVXj5VcZ7" title="Cost basis"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGwjYFWi1K7" title="Cost basis">18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEG5x0QV2Ita" title="Share of Equity Method Losses"><span id="xdx_909_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzXNuhUSA9gc" title="Share of Equity Method Losses">(18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zY3tIEjytp8c" title="Net Carrying Value"><span id="xdx_908_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zbg2trkqYEh3" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0716"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMCqnutGxlL5" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjsFU5u5nQc9" title="Cost basis">24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6eMExFBrIJf" title="Share of Equity Method Losses"><span id="xdx_901_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zceXgvbF1tJ6" title="Share of Equity Method Losses">(24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--Investments_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRmH5X6aVfCl" title="Net Carrying Value"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVdk4jPWyjK6" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0728"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z64SDV6Jnao3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024 and 2023, the Company recorded $<span id="xdx_90F_eus-gaap--OtherLiabilitiesCurrent_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zAJ4DyqUfZ15" title="Due from related parties">0</span> and $<span id="xdx_907_eus-gaap--OtherLiabilitiesCurrent_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWat9osq1Dyh" title="Due from related parties">89,000</span>, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”), which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 5 for more information and related party disclosure regarding Melt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 3500000 2334256 0.45 0 1 0 1 0 <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpekqaddZBU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zjIwDCBqtb6k" style="display: none">SCHEDULE OF INVESTMENT</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity <br/>Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify">Common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzO2pCgRN0t4" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z3qkORYjiPh8" title="Cost basis">5,810,000</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpJAyHhRJ2s5" title="Share of Equity Method Losses"><span id="xdx_904_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqLtUwT0U33" title="Share of Equity Method Losses">(5,810,000</span></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmMu7eyga3z2" title="Net Carrying Value"><span id="xdx_90E_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zg79bisqK7Xk" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0704"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zFqMVXj5VcZ7" title="Cost basis"><span id="xdx_907_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGwjYFWi1K7" title="Cost basis">18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEG5x0QV2Ita" title="Share of Equity Method Losses"><span id="xdx_909_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzXNuhUSA9gc" title="Share of Equity Method Losses">(18,397,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zY3tIEjytp8c" title="Net Carrying Value"><span id="xdx_908_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zbg2trkqYEh3" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0716"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMCqnutGxlL5" title="Cost basis"><span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjsFU5u5nQc9" title="Cost basis">24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6eMExFBrIJf" title="Share of Equity Method Losses"><span id="xdx_901_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zceXgvbF1tJ6" title="Share of Equity Method Losses">(24,207,000</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--Investments_iI_c20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRmH5X6aVfCl" title="Net Carrying Value"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVdk4jPWyjK6" title="Net Carrying Value"><span style="-sec-ix-hidden: xdx2ixbrl0728"><span style="-sec-ix-hidden: xdx2ixbrl0730">-</span></span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5810000 5810000 5810000 5810000 18397000 18397000 18397000 18397000 24207000 24207000 24207000 24207000 0 89000 <p id="xdx_840_ecustom--InvestmentTwoPolicyTextBlock_zxeD1Dt2dgTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Surface Ophthalmics, Inc. – Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zc0WQGsWtf2e" title="Investment owned balance shares">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zLYX0GNf4hZa" title="Ownership percentage">20</span>% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_908_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zTwj6fzcer03" title="Reduction in investment">0</span> as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface and no other requirements to advance funds to Surface.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5ImUQeYas1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_ze01gnZ3LbJ">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5rPf53ot3bk" title="Cost Basis"><span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zBFE2hqwxDgi" title="Cost Basis">5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zRjQLaOw3Gc7" title="Share of Equity Method Losses"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1fkMaDnDsp9" title="Share of Equity Method Losses">(5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zs7dMIg5tNu5" title="Net carrying value"><span id="xdx_90A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zxNRXpkzS9Ei" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0754"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zLv0OFF6fsab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 6 for more information and related party disclosure regarding Surface.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 3500000 0.20 0 <p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5ImUQeYas1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_ze01gnZ3LbJ">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost <br/>Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net <br/>Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedAtCost_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z5rPf53ot3bk" title="Cost Basis"><span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zBFE2hqwxDgi" title="Cost Basis">5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zRjQLaOw3Gc7" title="Share of Equity Method Losses"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1fkMaDnDsp9" title="Share of Equity Method Losses">(5,320,000</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20241231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zs7dMIg5tNu5" title="Net carrying value"><span id="xdx_90A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zxNRXpkzS9Ei" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0754"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></span></span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5320000 5320000 5320000 5320000 <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9vaQtqjjFta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Property, Plant and Equipment</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and finance lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer hardware and furniture and equipment are depreciated over <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zVx5Qb5nY166" title="Property, plant and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0760">three</span></span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zaq9Gv1Hu6Fh" title="Property, plant and equipment, useful life">five years</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> P5Y <p id="xdx_84E_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zM88yQ1PKOj2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capitalized Software Costs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company capitalizes certain costs related to the development of internal-use software. Costs incurred during the application development phase are capitalized only when the Company believes it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include consulting fees for third-party developers working on these projects. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Internal-use software is amortized on a straight-line basis over the estimated useful life of the asset, which ranges from <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zeAp1t0tP624" title="Finite lived intangible asset useful life::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0766">two</span></span> to <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zNtwOtfAkGRi" title="Finite lived intangible asset useful life">five years</span>. When internal-use software that was previously capitalized is abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Fully amortized capitalized internal-use software costs are removed from their respective accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> P5Y <p id="xdx_844_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zwJhCux8WGId" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and successfully prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231_zzSxVIXEBt8" title="Estimated useful life">20</span> years, using the straight-line method. Acquired product rights, including new drug applications (“NDAs”), are amortized over their estimated useful lives, generally <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zmLZgd6WGdl8" title="Estimated useful life">4</span>-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zXkNeUdzebAg" title="Estimated useful life">15</span> years, based on a straight-line method. Trademarks are an indefinite-lived intangible asset and are assessed for impairment based on future projected cash flows as further described below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant underperformance of the Company’s business relative to expected operating results;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant adverse economic and industry trends;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">expectations that a reporting unit will be sold or otherwise disposed.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The goodwill impairment test consists of a two-step process as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, goodwill is considered impaired and the Company then performs the second step of the impairment test to measure the impairment loss. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 2. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of its assessment in 2024, the Company concluded that goodwill is not impaired as of December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> P20Y P4Y P15Y <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zFoM5kHvfM3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Other Long-Lived Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Other long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such circumstances could include, but are not limited to (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The fair value of the asset is based on the discounted value of its estimated future cash flows</span>. <span style="font-size: 10pt">Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_z2NX0CmJXMMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the inception of a contract the Company determines if the arrangement is, or contains, a lease. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, discounted using the Company’s incremental borrowing rate of the debt outstanding. Lease expense is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months of less) and (ii) combines lease and non-lease elements of its operating leases as a single lease component. As of December 31, 2024 and 2023, the Company did not have any finance leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNWbtKnJ7pde" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2023, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton was classified as Level 1 as the fair value was determined using quoted market prices in an active market for the same securities. As of December 31, 2023, the fair market value of the Company’s investment in Eton was $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zh0Ya4GZQVyl" title="Investment owned at fair value">8,681,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <br/> The Company’s 2026 Notes (as defined in Note 13) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as defined in Note 13) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 13) is carried at face value less the original issue discount and unamortized debt issuance costs on the consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zr205lAcTxwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the estimated fair values and the carrying values:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zxJ9ZfkPB4qd" style="display: none">SCHEDULE OF ESTIMATED FAIR VALUE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">2026 Notes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z4u2L4PU8HG5" style="width: 12%; text-align: right" title="Carrying value">74,002,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zeHdePGpR6mc" style="width: 12%; text-align: right" title="Fair value">75,840,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zUSWO8bVU6o4" style="width: 12%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z3rZKDtbL4a9" style="width: 12%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_ziTWK9T1WZi2" style="text-align: right" title="Carrying value">38,130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2bHe1WhrcM" style="text-align: right" title="Fair value">42,198,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zdfQguBwwqhl" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zUHkYNXsNMt7" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zuBSNPhimVt" style="text-align: right" title="Carrying value">107,407,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zjMYT8jlDGrd" style="text-align: right" title="Fair value">112,932,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zhQ0m5nbKOXj" style="text-align: right" title="Carrying value">75,254,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_ztf4UEZMAf" style="text-align: right" title="Fair value">78,633,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_ziQHeX7Y6Url" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating lease liabilities approximate their respective fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> 8681000 <p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zr205lAcTxwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the estimated fair values and the carrying values:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zxJ9ZfkPB4qd" style="display: none">SCHEDULE OF ESTIMATED FAIR VALUE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">2026 Notes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z4u2L4PU8HG5" style="width: 12%; text-align: right" title="Carrying value">74,002,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zeHdePGpR6mc" style="width: 12%; text-align: right" title="Fair value">75,840,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zUSWO8bVU6o4" style="width: 12%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_z3rZKDtbL4a9" style="width: 12%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_ziTWK9T1WZi2" style="text-align: right" title="Carrying value">38,130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2bHe1WhrcM" style="text-align: right" title="Fair value">42,198,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zdfQguBwwqhl" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zUHkYNXsNMt7" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zuBSNPhimVt" style="text-align: right" title="Carrying value">107,407,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zjMYT8jlDGrd" style="text-align: right" title="Fair value">112,932,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zhQ0m5nbKOXj" style="text-align: right" title="Carrying value">75,254,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFairValue_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_ztf4UEZMAf" style="text-align: right" title="Fair value">78,633,000</td><td style="text-align: left"> </td></tr> </table> 74002000 75840000 73218000 70260000 38130000 42198000 37413000 40363000 107407000 112932000 75254000 78633000 <p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zFcPJj4i6th8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”), performance stock units (“PSUs) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. The Company provides newly issued shares of common stock to satisfy the exercise and vesting for stock-based compensation awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_z4ej1geOm8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing net loss attributable to Harrow, Inc. for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to Harrow, Inc. for the year by the weighted average number of common and common equivalent shares, such as stock options, RSUs, PSUs, and warrants, outstanding during the year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs, and unvested PSUs were <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_z9DjSUacZTz7" title="Stock options, unvested RSUs, and unvested PSUs">4,390,124</span> and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zFC8qM9o0w7" title="Stock options, unvested RSUs, and unvested PSUs">4,642,259</span> at December 31, 2024 and 2023, respectively, and are excluded in the calculation of diluted net loss per share for the periods presented, because the effect is anti-dilutive for that time period. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at December 31, 2024 and 2023 was <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl3PLhHRaoe3" title="Vested RSU">211,020</span> and <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2z9AI4BnRJ7" title="Vested RSU">215,539</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zb7MBcPrSl5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z2WpUzSE824h" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_49D_20240101__20241231_z3CaV0Twl9Ee" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zsgmEaFMFhSh" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zhRRATCrbVo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(17,481,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zcBVSBuwBH5e" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zE9vtmv6JWv6" title="Weighted average number of shares of common stock outstanding, diluted">35,650,714</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z4k8k1IaYLY9" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zIQnKUrd0EJh" title="Weighted average number of shares of common stock outstanding, diluted">32,616,777</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zitT0vF8ydtl" title="Basic net loss per share of common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zMU7sgMCDCW9" title="Diluted net loss per share of common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zxYthrHOOJSa" title="Basic net loss per share of common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPmjdAZsGGz7" title="Diluted net loss per share of common stock">(0.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zhYCTFmoN4Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 4390124 4642259 211020 215539 <p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zb7MBcPrSl5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z2WpUzSE824h" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_49D_20240101__20241231_z3CaV0Twl9Ee" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zsgmEaFMFhSh" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zhRRATCrbVo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(17,481,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zcBVSBuwBH5e" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zE9vtmv6JWv6" title="Weighted average number of shares of common stock outstanding, diluted">35,650,714</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z4k8k1IaYLY9" title="Weighted average number of shares of common stock outstanding, basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zIQnKUrd0EJh" title="Weighted average number of shares of common stock outstanding, diluted">32,616,777</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zitT0vF8ydtl" title="Basic net loss per share of common stock"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zMU7sgMCDCW9" title="Diluted net loss per share of common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zxYthrHOOJSa" title="Basic net loss per share of common stock"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zPmjdAZsGGz7" title="Diluted net loss per share of common stock">(0.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -17481000 -24411000 35650714 35650714 32616777 32616777 -0.49 -0.49 -0.75 -0.75 <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zl8kSXumnAXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recently Adopted Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards update (“ASU”) 2023-07, <i>Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures</i>, which enhances the disclosures required for operating segments in the Company’s annual and interim consolidated financial statements. The Company adopted ASU 2023-07 on a retrospective basis as of December 31, 2024. The adoption did not impact the Company’s financial statements, other than with respect to expanded disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_ecustom--AccountingGuidanceIssuedButNotAdoptedPolicyTextBlock_z6TxmQxNsEki" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Accounting Guidance Issued but Not Adopted at December 31, 2024</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2023, FASB issued ASU 2023-05, <i>Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement</i>, which applies to the formation of entities that meet the definition of a joint venture (or a corporate joint venture) and requires joint ventures to initially measure all contributions received upon formation at fair value. The new guidance does not impact accounting by the venturers. The new guidance is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. Joint ventures formed prior to the effective date may elect to apply the new guidance retrospectively back to their original formation date. The Company will apply the guidance in ASU 2023-05 prospectively to any future arrangements meeting the definition of a joint venture.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</i>. This ASU modifies the disclosure or presentation requirements of a variety of topics in the codification by aligning them with the SEC’s regulations. The amendments to the various topics should be applied prospectively, and the effective date for the Company for each amendment will be determined based on the effective date of the SEC’s removal of the related disclosure from Regulation S-X or Regulation S-K. If the SEC has not removed the applicable requirement by June 30, 2027, then the related amendment in ASU 2023-06 will be removed from the codification and will not become effective. Early adoption of this ASU is prohibited. The Company does not expect the amendments in this ASU to have a material impact on the disclosures or presentation in its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</i>, which enhances the disclosures required for income taxes in the Company’s annual consolidated financial statements. Notably, this ASU requires entities to disclose specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for the Company in its annual reporting for fiscal 2025 on a prospective basis. Early adoption and retrospective reporting are permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures</i>, to improve the disclosures by a public business entity about the types of expenses in commonly presented expense captions. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_ziBI6YIUGdYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Reclassification of Prior Year Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. A reclassification has been made to the consolidated balance sheet at December 31, 2023, to reclassify the Oaktree Loan exit fee to be included in the net debt amount (see Note 13).</p> <p id="xdx_806_eus-gaap--RevenueFromContractWithCustomerTextBlock_zeov6QsDQyf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3. <span id="xdx_82E_zV7tb2LoSRF7">REVENUES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for contracts with customers in accordance with ASC 606, <i>Revenues from Contracts with Customers</i>. The Company has three primary streams of revenue: (1) product revenues, including revenue recognized from sales of products through its pharmacy and outsourcing facility and sales of branded products to wholesalers through a third-party logistics (“3PL”) partner, (2) revenue recognized from transfer of acquired product sales and profits, and (3) revenue recognized from intellectual property licenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Product Revenues</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s pharmacy services includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><i>Identify the contract(s) with a customer:</i> A contract is deemed to exist when the customer places an order through receipt of a prescription, via an online order or via receipt of a purchase order from a customer. For branded products, orders are received through the Company’s 3PL partner, and the customer takes title of the products via formal purchase orders placed and fulfilled.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><i>Identify the performance obligations in the contract:</i> Obligations for fulfillment of the Company’s contracts consist of delivering the product to customers at their specified destination. For shipping and handling activities under ASC 606, if the customer takes control of the goods after shipment, shipping and handling activities would always be considered a fulfillment activity and not treated as a separate performance obligation. If the customer takes control of the goods before shipment, entities must make an accounting policy election to treat shipping and handling activities as either a fulfillment cost or as a separate performance obligation. The Company has elected to treat its shipping and handling activities as a fulfillment cost.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><i>Determine the transaction price:</i> The transaction price is based on an amount that reflects the consideration to which the Company expects to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts, copay assistance and other deductions (collectively, sales deductions) and an estimate for returns and replacements established at the time of sale. The Company utilizes the services of a third-party professional services firm to estimate rebates and chargebacks associated with sales of its branded products. The transfer of promised goods is satisfied within a year, and therefore there are no significant financing components. There is no non-cash consideration related to product sales.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><i>Allocate the transaction price to the performance obligations in the contract:</i> Because there is only one performance obligation for product sales, no allocation is necessary.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><i>Recognize revenue when (or as) the entity satisfies a performance obligation:</i> Revenue from products is recognized upon transfer of control of a product to a customer. This generally occurs upon shipment unless contractual terms with a customer state that transfer of control occurs at delivery.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Variable Consideration</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of branded pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative fees, co-pay assistance and other rebates, and prompt pay discounts. Estimates for these elements of variable consideration require significant judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Chargebacks</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chargebacks, primarily from distributors and wholesalers, result from arrangements with indirect customers establishing prices for products which the indirect customer purchases through a wholesaler. Alternatively, the Company may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, the Company provides a chargeback credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price, typically Wholesale Acquisition Cost (“WAC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior period chargebacks claimed by wholesalers are analyzed to determine the actual net price per package (“NPP”) for each product. This calculation is performed by product, by wholesaler. NPPs can be affected by several factors such as:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">Changes in customer mix</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">Changes in negotiated terms with customers</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Changes in the volume of off-contract purchases</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Changes in WAC</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As necessary, NPPs are adjusted based on anticipated changes in the factors above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The difference between NPP and WAC is recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets, at the time revenue is recognized from the product sale. The Company continually monitors chargeback activity and adjusts NPPs when the Company believes that actual selling prices will differ from current NPPs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Government Rebates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government rebates reserve consists of estimated payments due to governmental agencies for utilization of the Company’s products by beneficiaries under such governmental programs. The two largest government programs are Medicaid and Medicare.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>  </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company participates in the Medicaid Drug Rebate Program and pays rebates to the states related to Medicaid beneficiary utilization of the Company’s products. Medicaid rebates are billed within 60-90 days of the end of the quarter in which the product was dispensed to a Medicaid beneficiary. Medicaid rebate amounts per product unit are established by law, based on the Average Manufacturer Price (“AMP”), which is reported on a monthly and quarterly basis, and, in the case of branded products, best price, which is reported on a quarterly basis. Medicaid reserves are based on expected claims from state Medicaid programs. Estimates for expected claims are driven by patient usage, sales mix, calculated AMP or best price, as well as inventory in the distribution channel that will be subject to a Medicaid rebate. As a result of the delay between selling the products, dispensing the products and rebate billing, the Medicaid rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. Many of the Company’s branded products are also covered under Medicare. The Company participates in the Coverage Gap Discount Program in order for its branded products to be covered by Medicare Part D and must provide a rebate for any products sold under NDAs dispensed to Medicare Part D beneficiaries while the beneficiaries are in the Coverage Gap phase of the benefit. This applies to all products sold under NDAs. Estimates for these discounts are based on historical experience with Medicare rebates for products. Medicare rebates are billed quarterly for drugs dispensed to Medicare beneficiaries in the prior quarter, which is typically 120 days after the product is shipped. As a result of the delay between selling the products, dispensing the products and rebate billing, Medicare rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to Medicare Part D participants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To evaluate the adequacy of the government rebate reserves, reserves are reviewed on a quarterly basis against actual claims data to ensure the liability is fairly stated. The Company continually monitors the government rebate reserve and adjusts estimates if it is expected that actual government rebates may differ from established accruals. Accruals for government rebates are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to accrued rebates in the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Returns</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A returns policy is in place that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date to up to one year after its expiration date. Product returns are settled through the issuance of a credit to the customer. The estimate for returns is based upon historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. The Company continually monitors estimates for returns and adjusts when it is expected that actual product returns may differ from the established accruals. Accruals for returns are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to the accrued expenses in the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Administrative Fees and Other Rebates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Administrative fees or rebates are offered to wholesalers, group purchasing organizations, and indirect customers. Fees and rebates are accrued, by product by wholesaler, at the time of sale based on contracted rates and NPP. To evaluate the adequacy of the administrative fee accruals, on-hand inventory counts are obtained from the wholesalers. The Company continually monitors administrative fee activity and adjusts accruals when it is expected that actual administrative fees may differ from the accruals. Accruals for administrative fees and other rebates are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable or accrued expenses in the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Co-payment Assistance</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients who meet certain eligibility requirements may receive co-payment assistance funded by the Company. The Company records contra-revenue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. An accrued liability is recorded on unredeemed co-payment assistance related to products for which control has been transferred to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Prompt Payment Discounts</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Sales discounts may be granted to customers for prompt payment. The reserve for prompt payment discounts is based on invoices outstanding. Based on past experience, it is assumed that all available discounts will be taken. Accruals for prompt payment discounts are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89E_ecustom--ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_zuTnn4kDyvQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes activity and ending balances of the Company’s variable consideration provisions in the consolidated financial statements for the years ended December 31, 2024, and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zmM69LA6Ulg">SCHEDULE OF ACCRUALS AND ALLOWANCES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--ChargebacksMember_zenqzurFqCP5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Chargebacks</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--GovernmentRebatesMember_zKt6hVEpKeo3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Government Rebates</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--AllowancesForSalesReturnsMember_zzdn3McXxB89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Returns</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--AdministrativeFeesAndOtherRebatesMember_z2p6i3JXBUi7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Administrative Fees and Other Rebates</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td> </td> <td id="xdx_4B9_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--CoPayAssistanceMember_zeoi7PsUR6fi"><b>Co-Pay Assistance</b>  </td> <td> </td> <td> </td> <td colspan="2" id="xdx_4B6_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--ReservesForCashDiscountMember_zKTXMJCCbIme" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Prompt Pay Discounts</td> <td> </td> <td> </td> <td> </td> <td id="xdx_4B0_z1x5szH9vvWa" style="text-align: right">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accruals for Chargebacks, Returns, and Other Allowances <b></b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Chargebacks</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Government Rebates</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Returns</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Administrative Fees and Other Rebates</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Co-Pay Assistance</b></td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Prompt Pay Discounts</td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20230101__20231231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zlCNLG9lpkdl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; padding-bottom: 1pt">Balance at December 31, 2022 <span id="xdx_F41_z07dZ95JFDp4">(1)</span></td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">256,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">49,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">370,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; text-align: right; width: 6%"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">31,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; text-align: right; width: 6%">706,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesAdjustments_zbT7hlrAfJH8" style="vertical-align: bottom; background-color: White"> <td style="text-indent: 9pt">Accruals/Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,093,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,153,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,576,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,498,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">1,310,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">49,172,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesDeductions_zYnX8MZNcnWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Credits Taken Against Reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,539,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,568,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(854,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,799,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(339,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(472,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(16,571,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43C_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zFZC0QoBWJIl" style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2023 <span id="xdx_F40_zSBiGCppKPY6">(1)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,810,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">771,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,069,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">971,000</td> <td></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,101,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,307,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_437_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zGZFkvbXfvF7" style="display: none; vertical-align: bottom; background-color: White"> <td>Beginning, balance <span id="xdx_F4A_zy4Uifo1WDxc">(1)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,810,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">771,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,069,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td>971,000</td> <td></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,101,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,307,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesAdjustments_zHYp3ShYuL9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 9pt">Accruals/Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,607,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,968,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,089,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,722,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">98,052,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,941,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215,379,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesDeductions_zcRz2P8bPtWd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Credits Taken Against Reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,457,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,193,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,411,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(72,918,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(89,411,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,665,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(189,055,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_433_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iE_zlPfLjxWMyQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 <span id="xdx_F41_zSlArhdGh2Mc">(1)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">960,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,360,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,449,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">32,873,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">9,612,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,377,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">59,631,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iE_zFChoAVBMi7j" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending, balance <span id="xdx_F40_zXBlO5LhUCxb">(1)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">960,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,360,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,449,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">32,873,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double">9,612,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,377,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">59,631,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td id="xdx_F03_zz19uQJYerlc" style="width: 0.25in">(1)</td><td id="xdx_F1B_ztlaF9KapJJh" style="text-align: justify">Chargebacks and other allowances are included as an offset to accounts receivable in the consolidated balance sheets. Administrative Fees and Other Rebates, Prompt Payment Discounts and Returns are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Government Rebates are included in accrued government rebates and copay assistance in the consolidated balance sheets.</td></tr></table> <p id="xdx_8A7_zZX39EW9G1Zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenues From Transfer of Acquired Product Sales and Profits</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into agreements whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic products from other pharmaceutical companies (the “Sellers”). During a temporary, transition period, the Sellers continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The revenue recognized by the Company from the transfer of net profit was recognized at the time profit from the product sales were calculated by the Sellers and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. On a quarterly basis, the Sellers invoice the Company for all credits and reimbursements (“Chargebacks”) made to customers related to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net sales and profit transferred. The estimated Chargebacks are recorded as a reduction in revenues from transfer of acquired product sales and profits in the Company’s consolidated statements of operations, and recorded as a reduction to accounts receivable in the consolidated balance sheets, at the time the revenue is recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Intellectual Property License Revenues</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently holds five intellectual property licenses and related agreements pursuant to which the Company has agreed to license or sell to a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time that the performance obligation is met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverables are delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjVyjgMfrqof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue disaggregated by revenue source for the years ended December 31, 2024 and 2023, consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span id="xdx_8B0_zeCBtDWdqoj6" style="display: none">SCHEDULE OF DISAGGREGATED REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zBKiqN2bVahl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zeVQHFPNp4oc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_z15e69x9PDwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: bold; text-align: justify">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,619,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfAcquiredProductSalesProfitsMember_zI3QoTKSqm8d" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Transfer of acquired product sales/profits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zCzVNXO5jEsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">199,614,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zJ7gZyvNTRi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred revenue and customer deposits at December 31, 2024 and 2023, were $<span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20241231_zz8NLDPLRNnd" title="Deferred revenue and customer deposits">44,000</span> and $<span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20231231_z10KbDENVWM8" title="Deferred revenue and customer deposits">75,000</span>, respectively. All deferred revenue and customer deposit amounts at December 31, 2023 were recognized as revenue during the year ended December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_89E_ecustom--ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_zuTnn4kDyvQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes activity and ending balances of the Company’s variable consideration provisions in the consolidated financial statements for the years ended December 31, 2024, and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zmM69LA6Ulg">SCHEDULE OF ACCRUALS AND ALLOWANCES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--ChargebacksMember_zenqzurFqCP5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Chargebacks</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B1_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--GovernmentRebatesMember_zKt6hVEpKeo3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Government Rebates</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--AllowancesForSalesReturnsMember_zzdn3McXxB89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Returns</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--AdministrativeFeesAndOtherRebatesMember_z2p6i3JXBUi7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Administrative Fees and Other Rebates</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td> </td> <td id="xdx_4B9_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--CoPayAssistanceMember_zeoi7PsUR6fi"><b>Co-Pay Assistance</b>  </td> <td> </td> <td> </td> <td colspan="2" id="xdx_4B6_us-gaap--ValuationAllowancesAndReservesTypeAxis_custom--ReservesForCashDiscountMember_zKTXMJCCbIme" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Prompt Pay Discounts</td> <td> </td> <td> </td> <td> </td> <td id="xdx_4B0_z1x5szH9vvWa" style="text-align: right">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accruals for Chargebacks, Returns, and Other Allowances <b></b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Chargebacks</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Government Rebates</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Returns</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Administrative Fees and Other Rebates</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Co-Pay Assistance</b></td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Prompt Pay Discounts</td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_434_c20230101__20231231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zlCNLG9lpkdl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; padding-bottom: 1pt">Balance at December 31, 2022 <span id="xdx_F41_z07dZ95JFDp4">(1)</span></td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">256,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">49,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">370,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; text-align: right; width: 6%"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 6%; text-align: right">31,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; text-align: right; width: 6%">706,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesAdjustments_zbT7hlrAfJH8" style="vertical-align: bottom; background-color: White"> <td style="text-indent: 9pt">Accruals/Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,093,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,153,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,576,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,498,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">1,310,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">49,172,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesDeductions_zYnX8MZNcnWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Credits Taken Against Reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,539,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,568,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(854,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,799,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(339,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(472,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(16,571,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43C_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zFZC0QoBWJIl" style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2023 <span id="xdx_F40_zSBiGCppKPY6">(1)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,810,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">771,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,069,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">971,000</td> <td></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,101,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,307,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_437_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iS_zGZFkvbXfvF7" style="display: none; vertical-align: bottom; background-color: White"> <td>Beginning, balance <span id="xdx_F4A_zy4Uifo1WDxc">(1)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,810,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,585,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">771,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,069,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td>971,000</td> <td></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,101,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">33,307,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesAdjustments_zHYp3ShYuL9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 9pt">Accruals/Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,607,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,968,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,089,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,722,000</td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: right">98,052,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,941,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215,379,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ValuationAllowancesAndReservesDeductions_zcRz2P8bPtWd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Credits Taken Against Reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,457,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,193,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,411,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(72,918,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(89,411,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,665,000</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(189,055,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_433_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iE_zlPfLjxWMyQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 <span id="xdx_F41_zSlArhdGh2Mc">(1)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">960,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,360,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,449,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">32,873,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">9,612,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,377,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">59,631,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20240101__20241231_eus-gaap--ValuationAllowancesAndReservesBalance_iE_zFChoAVBMi7j" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending, balance <span id="xdx_F40_zXBlO5LhUCxb">(1)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">960,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,360,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,449,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">32,873,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double">9,612,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,377,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">59,631,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td id="xdx_F03_zz19uQJYerlc" style="width: 0.25in">(1)</td><td id="xdx_F1B_ztlaF9KapJJh" style="text-align: justify">Chargebacks and other allowances are included as an offset to accounts receivable in the consolidated balance sheets. Administrative Fees and Other Rebates, Prompt Payment Discounts and Returns are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Government Rebates are included in accrued government rebates and copay assistance in the consolidated balance sheets.</td></tr></table> 256000 49000 370000 31000 706000 6093000 5153000 1576000 33498000 1310000 1542000 49172000 -3539000 -1568000 -854000 -9799000 -339000 -472000 -16571000 2810000 3585000 771000 24069000 971000 1101000 33307000 2810000 3585000 771000 24069000 971000 1101000 33307000 8607000 11968000 9089000 81722000 98052000 5941000 215379000 -10457000 -3193000 -8411000 -72918000 -89411000 -4665000 -189055000 960000 12360000 1449000 32873000 9612000 2377000 59631000 960000 12360000 1449000 32873000 9612000 2377000 59631000 <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zjVyjgMfrqof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue disaggregated by revenue source for the years ended December 31, 2024 and 2023, consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span id="xdx_8B0_zeCBtDWdqoj6" style="display: none">SCHEDULE OF DISAGGREGATED REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zBKiqN2bVahl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zeVQHFPNp4oc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_z15e69x9PDwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: bold; text-align: justify">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,619,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfAcquiredProductSalesProfitsMember_zI3QoTKSqm8d" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Transfer of acquired product sales/profits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zCzVNXO5jEsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">199,614,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 198619000 117447000 995000 12746000 199614000 130193000 44000 75000 <p id="xdx_805_eus-gaap--BusinessCombinationDisclosureTextBlock_zx7BUHGP1vP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4. <span id="xdx_82E_zPXkphDn2LBi">RECENT PRODUCT ACQUISITIONS AND LICENSES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of VEVYE^TM U.S. and Canadian Commercial Rights</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2023, the Company acquired commercial rights of VEVYE (cyclosporine ophthalmic solution) <span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230731__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zpFRwY3JTqrk" title="Business acquired percentage">0.1</span>%, an ophthalmic drug product, for the U.S. and Canadian markets (the “VEVYE Acquisition”). The Company acquired the commercial rights to VEVYE by entering into a license agreement with Novaliq GmbH (“Novaliq”). As consideration, the Company made initial payments to Novaliq totaling $<span id="xdx_909_eus-gaap--PaymentsForRoyalties_c20230701__20230731__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zyN87nXkp4Mc" title="Royalty payments">8,000,000</span> and will pay low double-digit royalties on net sales of VEVYE along with potential commercial milestone payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounted for the VEVYE Acquisition as an acquisition of assets and capitalized the initial payments of $<span id="xdx_90A_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_iI_c20241231__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zj6zS9GoNHDg" title="Acquisition of assets and capitalized the initial payments">8,000,000</span> and costs of $<span id="xdx_90C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_c20241231__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zAzlJffhiU8f" title="Costs associated transaction">70,000</span> associated with the transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of Certain U.S. and Canadian Commercial Rights to Santen and Eyevance Products</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2023, the Company entered into an Asset Purchase Agreement with Eyevance Pharmaceuticals, LLC and a License Agreement with Santen S.A.S. (collectively, the “Santen Agreements”), each a subsidiary of Santen Pharmaceuticals Co., Ltd. (collectively, “Santen”). Pursuant to the Santen Agreements, the Company acquired the exclusive commercial rights to assets associated with the following ophthalmic products (collectively, the “Santen Products”): FLAREX, NATACYN, ZERVIATE, VERKAZIA and FRESHKOTE in the U.S., and VERKAZIA and CATIONORM PLUS in Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transactions pursuant to the Santen Agreements are referred to in these notes as the “Santen Products Acquisition.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Santen Agreements, the Company made an initial one-time payment of $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--SantenProductsAcquisitionMember_zhgbgPaaOe55" title="Royalty payments">8,000,000</span>. In addition, the Santen Agreements provide for various one-time contingent milestone payments associated with certain manufacturing-related events as well as low-double digit royalty payments on net sales of VERKAZIA and high-single digit royalty payments on net sales of CATIONORM PLUS. Under the Santen Agreements, the Company also assumed certain obligations associated with other third parties that require mid-single digit royalties on sales of FRESHKOTE and ZERVIATE. Immediately following the closing and subject to certain conditions, prior to the transfer of the Santen Products NDAs and other marketing authorizations to the Company, Santen continued to sell the Santen Products on the Company’s behalf and transfer the net profit from the sale of the Santen Products to the Company. In October 2023, the Company completed the transfer of the U.S. NDAs and rights of the Santen Products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assets acquired in the Santen Products Acquisition are identifiable intangible asset groups in similar asset classes and all directly related to the product NDAs and marketing authorizations acquired. The developed technology is within one major intangible asset class. No workforce/employees were included in the Santen Products Acquisition and the Company is required to utilize its own business inputs/processes to transfer and commercialize the Santen Products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company incurred $<span id="xdx_909_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20241231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zv8dMb5P4pR5" title="Costs incurred">139,000</span> in costs associated with the Santen Products Acquisition, the payment of $<span id="xdx_90B_ecustom--MilestonePayment_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zsVsyOHTo10l" title="Acquisition costs, the payment">8,000,000</span> at closing and a near term milestone of $<span id="xdx_908_ecustom--TermMilestonePayment_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zQz6JFdeRDv" title="Term milestone payment">500,000</span>. The total purchase price of the Santen Products Acquisition was $<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zAo2EbYqxj85" title="Purchase price acquisition">8,639,000</span> and was accounted for as an asset acquisition. At the time of the Santen Products Acquisition and as of December 31, 2023 and 2024, the remaining contingent consideration due was not considered probable and reasonably estimable and therefore, no amount was included in the purchase price of the Santen Products Acquisition. At the time the contingent consideration due becomes probable and reasonably estimable the additional consideration, if any, paid will be allocated to all of the assets on a pro rata basis based on their initial estimated fair values as a percent of the total purchase price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>Acquisition of ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2022, the Company entered into an Asset Purchase Agreement (the “NVS 5 APA”) with Novartis Technology, LLC and Novartis Innovative Therapies AG (together, “Novartis”), pursuant to which the Company agreed to purchase from Novartis the exclusive commercial rights to assets associated with the following ophthalmic products (collectively the “NVS 5 Products”) in the U.S. (the “NVS 5 Acquisition”): ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Under the terms of the NVS 5 APA, the Company made a one-time payment of $<span id="xdx_901_ecustom--MilestonePayment_c20230101__20230131__srt--StatementScenarioAxis__custom--OneTimePaymentMember_zHdMgZWdV2D2" title="Milestone payment">130,000,000</span> at closing in January 2023, with up to another $<span id="xdx_908_ecustom--MilestonePayment_c20230101__20230131__srt--StatementScenarioAxis__custom--OneTimePaymentMember__srt--RangeAxis__srt--MaximumMember_zCHTuTegKgyg" title="Milestone payment">45,000,000</span> due in a milestone payment related to the timing of the commercial availability of TRIESENCE. The milestone payment due upon commercial availability for TRIESENCE decreased from $<span id="xdx_90F_ecustom--MilestonePayment_c20230101__20231231__srt--StatementScenarioAxis__custom--OneTimePaymentMember_z1Q71mwtjPHb" title="Milestone payment">45,000,000</span> to $<span id="xdx_907_ecustom--MilestonePayment_c20240101__20240120__srt--StatementScenarioAxis__custom--OneTimePaymentMember_zFlx0ajMka6f" title="Milestone payment">37,000,000</span> on January 20, 2024. Pursuant to the NVS 5 APA and various ancillary agreements, immediately following the closing and subject to certain conditions and prior to the transfer of the NVS 5 Products NDAs to the Company, Novartis continued to sell the NVS 5 Products on the Company’s behalf and transfer the net profit from the sale of the NVS 5 Products to the Company. Novartis has agreed to supply certain NVS 5 Products to the Company for a period of time after the NDAs are transferred and to assist with technology transfer of the NVS 5 Products manufacturing to other third-party manufacturers, if needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assets acquired in the NVS 5 Acquisition are identifiable intangible asset groups in similar asset classes and all directly related to the five product NDAs acquired. The developed technology is within one major intangible asset class. No workforce/employees were included in the NVS 5 Acquisition, and the Company is required to utilize its own business inputs/processes to transfer and commercialize the NVS 5 Products and NDAs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company incurred $<span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20230131__srt--StatementScenarioAxis__custom--OneTimePaymentMember_zX8WD3ELTnH5" title="Costs incurred">558,000</span> in costs associated with the NVS 5 Acquisition. Including such acquisition costs and the payment of $<span id="xdx_901_ecustom--MilestonePayment_c20230101__20230131__srt--StatementScenarioAxis__custom--OneTimePaymentMember_zLrmPkJkuxsk" title="Milestone payment">130,000,000</span> at closing, the total purchase price of the NVS 5 Acquisition was $<span id="xdx_903_eus-gaap--BusinessCombinationPriceOfAcquisitionExpected_c20230101__20230131__srt--StatementScenarioAxis__custom--OneTimePaymentMember_zk71fWMdQZba" title="Purchase price acquisition">130,558,000</span> and was accounted for as an asset acquisition. At the time of the NVS 5 Acquisition and as of December 31, 2023, the contingent consideration due related to the commercial availability of TRIESENCE was not considered probable and reasonably estimable and, therefore, no amount was included in the purchase price of the NVS 5 Acquisition. In 2024, the Company determined the milestone related to the commercial availability of TRIESENCE was probable of being achieved, and recognized the $<span id="xdx_904_ecustom--MilestonesReceivableBasedOnAgreedRevenues_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z74hokjSgp67" title="Milestones receivable based on agreed revenues">37,000,000</span> milestone payment as an increase in the amount of intangible assets and allocated to all of the assets on a pro rata basis based on their initial estimated fair values as a percent of the total purchase price. The Company does not consider any amounts related to TRIESENCE to be in-process research and development (IPR&amp;D) as considered within the scope of ASC 730, <i>Research and Development</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 0.001 8000000 8000000 70000 8000000 139000 8000000 500000 8639000 130000000 45000000 45000000 37000000 558000 130000000 130558000 37000000 <p id="xdx_803_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zgUaR1BzOjSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5. <span id="xdx_823_zVE9FyinUFse">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS – RELATED PARTY TRANSACTIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt APA”). Pursuant to the terms of the Melt APA, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt APA, Melt is required to make mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2019, the Company entered into the Melt MSA, whereby the Company provided to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt was required to pay the Company a monthly amount of $<span id="xdx_90C_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_z8pDcejcaEi" title="Administrative fees expense">10,000</span>. The Melt MSA was terminated effective July 1, 2023. During the years ended December 31, 2024, and 2023, the Company recorded $<span id="xdx_903_eus-gaap--OtherExpenses_c20240101__20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTKrqnlyK2Te" title="Reimbursable expenses">0</span> and $<span id="xdx_90C_eus-gaap--OtherExpenses_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zI7gG6S41fe6" title="Reimbursable expenses">89,000</span>, respectively, due from Melt for reimbursable expenses and amounts payable pursuant to the Melt MSA, which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. As of each of December 31, 2024 and 2023, the Company was due $228,000 from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the year ended December 31, 2024. The Company made a cash advance to Melt of $<span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zI8WDu1BiuBe" title="Cash advance to related party debt">500,000</span> and Melt repaid the $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zLp6HEvVT5ze" title="Repaid of related parties">500,000</span> cash advance during the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the years ended December 31, 2024 and 2023, Melt raised over $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zxWWYZYb0yRb" title="Gross proceeds from third party investors">3,300,000</span> and $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJKorHf5CxL8" title="Gross proceeds from third party investors">20,586,000</span>, respectively, in gross proceeds from third party investors related to its Series B Preferred Stock offerings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company’s Chief Executive Officer, Mark L. Baum, is a member of the Melt board of directors. The Melt board of directors consists of five members, including Mr. Baum. Mr. Baum is the only representative of the Company on Melt’s board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>Melt Note Receivable – Settled and Terminated in 2023</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 1, 2021, the Company entered into a loan and security agreement in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zEvCKq72PYib" title="Face amount">13,500,000</span> (the “Melt Loan Agreement”), as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bore interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zF808bpWp2U9" title="Debt instrument interest rate stated percentage">12.50</span>% per annum, which interest could have been paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permitted Melt to pay interest only on the principal amount loaned thereunder through the term and all amounts owed were previously due and payable on September 1, 2022. In April 2022, the Company entered into a First Amendment and in September 2022, a Second Amendment (together, the “Amendments”) to the Melt Loan Agreement. The Amendments (i) extended the maturity date of the Melt Loan Agreement to September 1, 2023, which could have been extended further to September 1, 2026 upon Melt completing a qualifying financing of a minimum amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zA0JYgb6SRph" title="Loan amount">10,000,000</span> from third-party investors, (ii) added conditions related to minimum cash amounts following a qualifying financing, and (iii) clarified the definition of material adverse effects. Melt could have elected to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty. The net funds received by Melt excluded $<span id="xdx_901_ecustom--ReimbursableExpenses_c20240101__20241231_zGzC99jB56td" title="Reimbursable expenses">908,000</span> owed to the Company for reimbursable expenses and amounts due under the Melt MSA prior to the effective date of the note receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt’s drug candidates for a period of five years following the effective date of the Melt Loan Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 28, 2023, the Company terminated the Melt Loan Agreement. As of the date of termination, approximately $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zGYMWKHLcJEb" title="Face amount">18,395,000</span> remained outstanding under the Melt Loan Agreement. Pursuant to the terms of a Settlement and Payoff Agreement, dated as of December 28, 2023, by and between the Company and Melt (the “Settlement Agreement”), the Company received <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zvR9NZa71Wsa" title="Received shares">2,260,000</span> shares of Melt’s Series B-1 Preferred Stock and <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjsjsK5nN7Gd" title="Received shares">74,256</span> shares of Melt’s Series B Preferred Stock (which both series have similar rights and preferences) in consideration for the full payment of all amounts outstanding under the Melt Loan Agreement. The Settlement Agreement contains customary representations, warranties and releases of the parties and requires the parties to enter into a registration rights agreement providing the Company with rights consistent with other holders of preferred stock of Melt. The Company concluded the Settlement Agreement is in substance a funding of the Company’s share of prior unrecorded losses and, therefore, those suspended losses must be recognized first against the value of the new preferred stock investments. This resulted in reducing the carrying value of the Company’s investment in Melt, including the carrying value of the Preferred Stock received, to zero (the consideration received in the form of an equivalent fair value of Melt’s Preferred Stock to settle the full outstanding note receivable balance of $<span id="xdx_903_eus-gaap--DebtInstrumentFairValue_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zaxliRzlIPXa" title="Fair value">18,400,000</span> is offset by an equal amount of the funding of prior unrecorded losses). Accordingly, this settlement transaction had no quantitative effect on either the Company’s consolidated balance sheet or consolidated statement of operations for the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 323, <i>Investments – Equity Method and Joint Ventures</i>, the carrying amount of the note receivable and other investments in Melt have been reduced by the Company’s allocated share of Melt’s losses based on its ownership of Melt and its total indebtedness (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_898_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zwilK6dwMCf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed results of operations information of Melt is summarized below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zGwcTF49aMhf" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBXXiThGyF3l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBKLAewh8V1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwovnmwbloAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zLg0T1bPMaL6" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: justify">Loss from operations</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,687,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(7,581,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zKwaffRrMCtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(13,238,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11,271,000</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A0_zXL7Y3lKWhc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_899_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zxI1BmO0iDjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed balance sheet information of Melt is summarized below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zZmtsxZkkGb9" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zikFcXx4fxvl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zvTAt7AUracg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsCurrent_iI_zowZ3qILEfL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1pt">Current assets</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3,068,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">13,404,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zDEQvxFHSIQ" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,068,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_zV51wlxHZTw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,008,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,922,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--StockholdersEquity_iI_znwnXXbLZAxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">60,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,482,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zbddGvm4DLCb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,068,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zsPyqnO66XOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 10000 0 89000 500000 500000 3300000 20586000 13500000 0.1250 10000000 908000 18395000 2260000 74256 18400000 <p id="xdx_898_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zwilK6dwMCf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed results of operations information of Melt is summarized below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zGwcTF49aMhf" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBXXiThGyF3l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBKLAewh8V1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwovnmwbloAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zLg0T1bPMaL6" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: justify">Loss from operations</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,687,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(7,581,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zKwaffRrMCtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(13,238,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11,271,000</td><td style="text-align: left">)</td></tr> </table> -13687000 -7581000 -13238000 -11271000 <p id="xdx_899_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zxI1BmO0iDjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed balance sheet information of Melt is summarized below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zZmtsxZkkGb9" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20241231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zikFcXx4fxvl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zvTAt7AUracg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsCurrent_iI_zowZ3qILEfL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1pt">Current assets</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3,068,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">13,404,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zDEQvxFHSIQ" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,068,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_zV51wlxHZTw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,008,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,922,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--StockholdersEquity_iI_znwnXXbLZAxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">60,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,482,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zbddGvm4DLCb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,068,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3068000 13404000 3068000 13404000 3008000 3922000 60000 9482000 3068000 13404000 <p id="xdx_80A_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_z10WZbo0KHx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6. <span id="xdx_826_z5IwQs04M5Oj">INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024 and 2023, the Company owned <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--SurfaceOphthalmicsIncMember_z2qDDUGC8aU8" title="Investment owned shares"><span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__us-gaap--RelatedPartyTransactionAxis__custom--SurfaceOphthalmicsIncMember_zhPcERc1Lra3" title="Investment owned shares">3,500,000</span></span> shares of Surface common stock. Adrienne Graves and Perry J. Sternberg, directors of the Company, also are directors of Surface. Mark L. Baum, who is the Company’s Chief Executive Officer, was previously a member of the Surface board of directors and resigned from his position as a director of Surface on March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 3500000 3500000 <p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_z7dgmUu5Ou31" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7. <span id="xdx_822_zxI9iSciP8Oi">INVENTORIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBiFEpYXP4C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2024 and 2023 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zsGt8URCDBAb" style="display: none">SCHEDULE OF INVENTORIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zOHxXYhLRL8d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_zRM1VN5YoYdh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_zJu5ISW5JmZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,362,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,477,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zp9orDBUkDId" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">858,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_maCzfns_zpnNDdPqnqW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,482,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,336,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtCzfns_znVTJ6ZMoHb3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,702,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,867,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zEXC6TaG4E4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zBiFEpYXP4C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2024 and 2023 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zsGt8URCDBAb" style="display: none">SCHEDULE OF INVENTORIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zOHxXYhLRL8d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_zRM1VN5YoYdh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_zJu5ISW5JmZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,362,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,477,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zp9orDBUkDId" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">858,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_maCzfns_zpnNDdPqnqW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,482,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,336,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtCzfns_znVTJ6ZMoHb3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,702,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,867,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5362000 5477000 858000 54000 4482000 5336000 10702000 10867000 <p id="xdx_803_eus-gaap--OtherAssetsDisclosureTextBlock_zTgxeRp93Yge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8. <span id="xdx_82D_zYlkdEWWqcY">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zpUwoNRFIHNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zZkgqrvF09g1" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zbpr1dBycO4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zqyJD0KPTue7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maCz7yK_z85ZgldcPWX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Prepaid insurance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,326,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,241,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidComputerSoftwareLicensesAndRelatedExpenses_iI_maCz7yK_ziSDhFJ12s2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid computer software related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,613,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrefundedAssistance_iI_maCz7yK_z6Yi7Ui0ebJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prefunded co-pay assistance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,514,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_zohjVGacaG0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,435,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">906,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ReceivableDueFromRelatedParty_iI_maCz7yK_zT5lmBhQTzQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidPrescriptionDrugUserFees_iI_maCz7yK_zKt1F60dWrKl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Annual user fees (PDUFA)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,651,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,438,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredCommitmentFee_iI_maCz7yK_zfxhxebyqP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred Oaktree commitment fee (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zbYIxb6Cop2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,410,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,753,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zTpcuE0TXEdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,329,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,588,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zf78JHNuKkG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zpUwoNRFIHNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zZkgqrvF09g1" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_zbpr1dBycO4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zqyJD0KPTue7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maCz7yK_z85ZgldcPWX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Prepaid insurance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,326,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,241,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidComputerSoftwareLicensesAndRelatedExpenses_iI_maCz7yK_ziSDhFJ12s2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid computer software related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,613,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrefundedAssistance_iI_maCz7yK_z6Yi7Ui0ebJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prefunded co-pay assistance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,514,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_zohjVGacaG0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,435,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">906,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ReceivableDueFromRelatedParty_iI_maCz7yK_zT5lmBhQTzQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidPrescriptionDrugUserFees_iI_maCz7yK_zKt1F60dWrKl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Annual user fees (PDUFA)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,651,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,438,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredCommitmentFee_iI_maCz7yK_zfxhxebyqP0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred Oaktree commitment fee (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zbYIxb6Cop2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,410,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,753,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zTpcuE0TXEdg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,329,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,588,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1326000 1241000 765000 1613000 4514000 1435000 906000 228000 228000 3651000 3438000 409000 3410000 1753000 15329000 9588000 <p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zQ9Y6gnVRt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 9. <span id="xdx_82B_zR12A0lK9clh">PROPERTY, PLANT AND EQUIPMENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zPPOSxsKdOyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property, plant and equipment, net at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zHGQ8TejYwQ2" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zAJnc1qhgUoi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zIoKFnMaMiRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zZ1CEiqukIYe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">Computer hardware</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,195,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,322,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_ztjyOTqIIZ4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">956,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zcVMxMamf9sl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,306,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zTCfC2llB9o7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,291,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,771,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zNJvDNqNFf37" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,748,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,593,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_z4xgnz9dYVV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,014,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,072,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_z8eNPUBgBoCg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,734,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,521,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zKtj1QO4Wnv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023, the Company disposed of property, plant and equipment with a net book value of $<span id="xdx_90C_eus-gaap--GainLossOnDispositionOfAssets1_c20230101__20231231_zg0aT5EUt5l3" title="Gain loss on disposition of assets">168,000</span> related to the discontinued use of certain lab equipment, which is included in other expense, net in the consolidated statement of operations. The Company recorded depreciation and amortization expense of $<span id="xdx_900_eus-gaap--DepreciationAmortizationAndAccretionNet_c20240101__20241231_zDpwPuIbecYf" title="Depreciation and amortization expenses">1,269,000</span> and $<span id="xdx_903_eus-gaap--DepreciationAmortizationAndAccretionNet_c20230101__20231231_zBJtplVjmCy8" title="Depreciation and amortization expenses">1,055,000</span> during the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zPPOSxsKdOyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property, plant and equipment, net at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zHGQ8TejYwQ2" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zAJnc1qhgUoi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zIoKFnMaMiRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zZ1CEiqukIYe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">Computer hardware</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,195,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,322,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_ztjyOTqIIZ4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">956,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zcVMxMamf9sl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,306,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zTCfC2llB9o7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,291,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,771,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zNJvDNqNFf37" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,748,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,593,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_z4xgnz9dYVV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,014,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,072,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_z8eNPUBgBoCg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,734,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,521,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1195000 1322000 956000 936000 5306000 4564000 7291000 6771000 14748000 13593000 11014000 10072000 3734000 3521000 168000 1269000 1055000 <p id="xdx_80F_ecustom--CapitalizedSoftwareCostsTextBlock_zW3TdQG9vw7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10. <span id="xdx_82E_zZdrGlmXZcm8">CAPITALIZED SOFTWARE COSTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_89B_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zdkXouXSXFrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Capitalized software costs at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zfDEmwDoIy78" style="display: none">SCHEDULE OF CAPITALIZED SOFTWARE COSTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zFgsFH14Scr5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231_zflyJvt6DWg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized software costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zBe1iYmACjs5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,395,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,780,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zaod0W2McL17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">205,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">159,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzLFa_zd9pTXe19hge" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0in; text-align: left; padding-bottom: 1pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,939,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzLFa_z3TBgzxdKIm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,849,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzLFa_zOJHm5HnkCu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">467,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzLFa_zuYyUIi8My8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total capitalized software costs net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,751,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,138,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zrQACyoa61Rg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded amortization expense of $<span id="xdx_902_eus-gaap--AdjustmentForAmortization_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zrSlU03Vmg05" title="Amortization expenses">581,000</span> and $<span id="xdx_90E_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_z0j9D7pG58p4" title="Amortization expenses">475,000</span> during the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p> <p id="xdx_89B_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zdkXouXSXFrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Capitalized software costs at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zfDEmwDoIy78" style="display: none">SCHEDULE OF CAPITALIZED SOFTWARE COSTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zFgsFH14Scr5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231_zflyJvt6DWg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized software costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zBe1iYmACjs5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,395,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,780,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zaod0W2McL17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">205,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">159,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzLFa_zd9pTXe19hge" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0in; text-align: left; padding-bottom: 1pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,939,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzLFa_z3TBgzxdKIm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,849,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzLFa_zOJHm5HnkCu1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">467,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzLFa_zuYyUIi8My8h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total capitalized software costs net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,751,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,138,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3395000 2780000 205000 159000 3600000 2939000 1849000 1268000 467000 1751000 2138000 581000 475000 <p id="xdx_808_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zKkBOwqm6lle" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11. <span id="xdx_823_zRosyBbBnMsh">INTANGIBLE ASSETS AND GOODWILL</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zi3idkknPasb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s intangible assets at December 31, 2024 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zxa4L3B2Dzvi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Weighted-average</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">useful life</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0EJ5drWcz6">19</span> years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zX77fLtfqN2a" style="width: 12%; text-align: right" title="Cost">611,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdmbp5CTiaUa" style="width: 12%; text-align: right" title="Accumulated amortization">(216,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjE8kwUAly36" style="width: 12%; text-align: right" title="Impairment">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zoQ636cPH22h" style="width: 12%; text-align: right" title="Net Carrying value">142,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zh8jj4pq73Gl">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeQFwHhDiu93" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zDX5CKoBKZsi" style="text-align: right" title="Accumulated amortization">(36,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zaPPFHvCgOX6" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zTmFGqIDz3jj" style="text-align: right" title="Net Carrying value">14,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zeqrHpfLtWTj" title="Useful life, description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEn9RNla1eTl" style="text-align: right" title="Cost">230,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOZKPNRJD27f" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z8baw04FWw3g" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1JcFcJW1tX" style="text-align: right" title="Net Carrying value">230,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zFgbnWKbGGa">14</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zdYkby8Iwx34" style="text-align: right" title="Cost">207,398,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zWv0t4kpPL5e" style="text-align: right" title="Accumulated amortization">(22,962,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zV6V0qZYAbY8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zoVXWvdH50U9" style="text-align: right" title="Net Carrying value">184,436,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMFXl6fHi7Oc">7</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zFJmfHi3cxG1" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxhwyXYwPVp8" style="text-align: right" title="Accumulated amortization">(542,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1YX0ioq9dAg" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zuuFhsigCDp9" style="text-align: right" title="Net Carrying value">54,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zV3KrUA8fMLi" title="Useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zS7WRPIoLoFa" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zbKNl7Suyi25" style="text-align: right" title="Accumulated amortization">(7,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEO9Aofqztnl" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zLK8xMNMy5kl" style="text-align: right" title="Net Carrying value">68,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqnaUo0sP4Ca">4</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgAxUOAxqlve" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEWJ0WvifFEe" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zyCs3tQJYIM8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zFlrcrVeedtb" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">State pharmacy licenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgzv1FhG6XWj" title="Intangible assets, Useful life">25</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zsPKj25fsESb" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSz26WhnLXQh" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(3,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z6h33lfUxfX" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z7jd6PeWrg5l" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value">5,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231_zscl6BrOg6y8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Cost">209,018,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231_zhQEWuUcWBhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Accumulated amortization">(23,816,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231_zKWEPVPdVNPi" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(253,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231_zcxNCccnxMMf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Net Carrying value">184,949,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s intangible assets at December 31, 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Weighted-average</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">useful life</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1hZHLZ19d5b">19</span> years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeb5KwlpEf1a" style="width: 12%; text-align: right" title="Cost">984,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlXAIqHvIbh" style="width: 12%; text-align: right" title="Accumulated amortization">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zT7EUqSLh0Qe" style="width: 12%; text-align: right" title="Impairment">(276,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7BOWyM6fwLb" style="width: 12%; text-align: right" title="Net Carrying value">455,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zWiQBBq4cl42">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zOQwUhbMVih7" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zlQz7t8bIrW" style="text-align: right" title="Accumulated amortization">(30,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIyV1bADnI4l" style="text-align: right" title="Impairment">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zn2ZnQrD0Qtd" style="text-align: right" title="Net Carrying value">48,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPT4q8lrQnMj" title="Useful life, description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKRyPw3dmKpe" style="text-align: right" title="Cost">281,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSS5AcsAI4Y3" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zindTPzZ72Ib" style="text-align: right" title="Impairment">(82,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zddnvaLqZrDl" style="text-align: right" title="Net Carrying value">199,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zCgRbFsY2IW9">14</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zEanpEKgls5k" style="text-align: right" title="Cost">170,353,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_z6pQO8eEdhh4" style="text-align: right" title="Accumulated amortization">(11,300,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zVFDfRr7dVdj" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zNvXqTJKpARj" style="text-align: right" title="Net Carrying value">159,053,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z9h767Robx5e">7 </span>years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc8My3kh08z4" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1pDmD5Sc9A9" style="text-align: right" title="Accumulated amortization">(516,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4SIYboEN7O8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWM6Fx9AdqSd" style="text-align: right" title="Net Carrying value">80,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zzrt3l0mMKDa" title="Useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ztXksPMvhdde" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zyXnnexa2Jg4" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zr1bCDXEyl59" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zCAq35hAEg8f" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z7jCxHJcLaI4">4 </span>years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zcG70NDBFQjh" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPlygBE3bOT3" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zYaVz6KQfSo5" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zZvSs6RRNJrh" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">State pharmacy licenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zR69Vh4YOkZi" title="Useful life">25</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z56QvUEyKHZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zOtgiX5RH6T3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgxhY1B4CKX4" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zbouWzg1Ig82" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zQTgw8Ye5Fo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">172,447,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z9IDcizyKfeb" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(12,161,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231_zKwAGW5rZis5" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(380,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_z29TKc32MEv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">159,906,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z6WlBjA76lfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2024 and 2023, the Company recorded a charge of $<span id="xdx_905_ecustom--FiniteLivedIntangibleAssetsImpairment_iNI_di_c20241231_z1Cahyoyyo79" title="Impairment charge">253,000</span> and $<span id="xdx_905_ecustom--FiniteLivedIntangibleAssetsImpairment_iNI_di_c20231231_zEiFmLgisk6k" title="Impairment charge">380,000</span>, respectively, related to the impairment of certain licenses, trademarks, patents and patent applications. The Company determined that the sum of the expected undiscounted cash flows attributable to these intangible assets was less than their carrying value and that an impairment charge was required. Accordingly, the Company calculated the estimated fair value of the intangible assets based on the present value of the expected cash flows over their estimated lives. The impairment amount was calculated by deducting the present value of the expected cash flows from the carrying value. Significant estimates and assumptions used by the Company included sales and expense growth rates, and discounted projected cash flows. The estimates and assumptions used in the Company’s assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. The assumptions used in the impairment analysis are inherently subject to uncertainty and, therefore, changes in these assumptions could have a significant impact on the concluded fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 4 related to other intangible assets acquired during the year ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zzbTmU0mBvYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for intangible assets for the years ended December 31, 2024 and 2023 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zV0skhaakoFc" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zW1Pvervs9m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zFzAaKOiutdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1mAmVSSGOV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">56,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">84,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zqdhhUfofOlj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zqLcyGGLiQB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,669,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,937,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zjGI6sG2lrxa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEWtqDcBObte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Trade name</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AmortizationOfIntangibleAssets_zRjCxbRP63bh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense of intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,783,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,082,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zMsoUq4teWtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAgKKuRkYHil" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated future amortization expense for the Company’s intangible assets at December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjFLplMNBiOc" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Years ending December 31,</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_z08L8QHUePl3"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzNeK_z49P0JXNfSvf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,903,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzNeK_z3xmY5710k2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,903,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzNeK_zu06Go5TYOUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,612,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzNeK_zOoTsCeCcSGf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,205,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzNeK_zr1T3tJQh2k2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,095,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzNeK_zxhCZmd9hK0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">102,001,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzNeK_zjWjAoEQ1Mqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zLqMzkQetlWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with an asset purchase agreement between Novartis and the Company, the Company recognized a $<span id="xdx_901_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zvvjMIeu2Atb" title="Payment to acquire intangible assets">37,000,000</span> milestone payment during 2024 following the release of the first commercially available batch of TRIESENCE. The milestone payment was recognized as an increase in the amount of intangible assets for Acquired NDAs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were <span id="xdx_90B_eus-gaap--GoodwillPeriodIncreaseDecrease_do_c20240101__20241231_zPOxuxu6X7E5" title="Carrying value of goodwill"><span id="xdx_90B_eus-gaap--GoodwillPeriodIncreaseDecrease_do_c20230101__20231231_zvNAZRYxl6Ge" title="Carrying value of goodwill">no</span></span> changes in the carrying value of the Company’s goodwill during the years ended December 31, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zi3idkknPasb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s intangible assets at December 31, 2024 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zxa4L3B2Dzvi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Weighted-average</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">useful life</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0EJ5drWcz6">19</span> years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zX77fLtfqN2a" style="width: 12%; text-align: right" title="Cost">611,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdmbp5CTiaUa" style="width: 12%; text-align: right" title="Accumulated amortization">(216,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjE8kwUAly36" style="width: 12%; text-align: right" title="Impairment">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zoQ636cPH22h" style="width: 12%; text-align: right" title="Net Carrying value">142,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zh8jj4pq73Gl">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeQFwHhDiu93" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zDX5CKoBKZsi" style="text-align: right" title="Accumulated amortization">(36,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zaPPFHvCgOX6" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zTmFGqIDz3jj" style="text-align: right" title="Net Carrying value">14,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zeqrHpfLtWTj" title="Useful life, description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEn9RNla1eTl" style="text-align: right" title="Cost">230,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOZKPNRJD27f" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z8baw04FWw3g" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1JcFcJW1tX" style="text-align: right" title="Net Carrying value">230,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zFgbnWKbGGa">14</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zdYkby8Iwx34" style="text-align: right" title="Cost">207,398,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zWv0t4kpPL5e" style="text-align: right" title="Accumulated amortization">(22,962,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zV6V0qZYAbY8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zoVXWvdH50U9" style="text-align: right" title="Net Carrying value">184,436,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMFXl6fHi7Oc">7</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zFJmfHi3cxG1" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxhwyXYwPVp8" style="text-align: right" title="Accumulated amortization">(542,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1YX0ioq9dAg" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zuuFhsigCDp9" style="text-align: right" title="Net Carrying value">54,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zV3KrUA8fMLi" title="Useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zS7WRPIoLoFa" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zbKNl7Suyi25" style="text-align: right" title="Accumulated amortization">(7,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEO9Aofqztnl" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zLK8xMNMy5kl" style="text-align: right" title="Net Carrying value">68,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqnaUo0sP4Ca">4</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgAxUOAxqlve" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEWJ0WvifFEe" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zyCs3tQJYIM8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zFlrcrVeedtb" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">State pharmacy licenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgzv1FhG6XWj" title="Intangible assets, Useful life">25</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zsPKj25fsESb" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSz26WhnLXQh" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(3,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z6h33lfUxfX" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z7jd6PeWrg5l" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value">5,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20241231_zscl6BrOg6y8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Cost">209,018,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20241231_zhQEWuUcWBhb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Accumulated amortization">(23,816,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20241231_zKWEPVPdVNPi" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(253,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20241231_zcxNCccnxMMf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Net Carrying value">184,949,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s intangible assets at December 31, 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Weighted-average</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">useful life</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">amortization</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1hZHLZ19d5b">19</span> years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeb5KwlpEf1a" style="width: 12%; text-align: right" title="Cost">984,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlXAIqHvIbh" style="width: 12%; text-align: right" title="Accumulated amortization">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zT7EUqSLh0Qe" style="width: 12%; text-align: right" title="Impairment">(276,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7BOWyM6fwLb" style="width: 12%; text-align: right" title="Net Carrying value">455,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zWiQBBq4cl42">20</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zOQwUhbMVih7" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zlQz7t8bIrW" style="text-align: right" title="Accumulated amortization">(30,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIyV1bADnI4l" style="text-align: right" title="Impairment">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zn2ZnQrD0Qtd" style="text-align: right" title="Net Carrying value">48,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPT4q8lrQnMj" title="Useful life, description">Indefinite</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKRyPw3dmKpe" style="text-align: right" title="Cost">281,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSS5AcsAI4Y3" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zindTPzZ72Ib" style="text-align: right" title="Impairment">(82,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zddnvaLqZrDl" style="text-align: right" title="Net Carrying value">199,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zCgRbFsY2IW9">14</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zEanpEKgls5k" style="text-align: right" title="Cost">170,353,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_z6pQO8eEdhh4" style="text-align: right" title="Accumulated amortization">(11,300,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zVFDfRr7dVdj" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zNvXqTJKpARj" style="text-align: right" title="Net Carrying value">159,053,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z9h767Robx5e">7 </span>years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc8My3kh08z4" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1pDmD5Sc9A9" style="text-align: right" title="Accumulated amortization">(516,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4SIYboEN7O8" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWM6Fx9AdqSd" style="text-align: right" title="Net Carrying value">80,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zzrt3l0mMKDa" title="Useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ztXksPMvhdde" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zyXnnexa2Jg4" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zr1bCDXEyl59" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zCAq35hAEg8f" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z7jCxHJcLaI4">4 </span>years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zcG70NDBFQjh" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPlygBE3bOT3" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zYaVz6KQfSo5" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zZvSs6RRNJrh" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">State pharmacy licenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zR69Vh4YOkZi" title="Useful life">25</span> years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z56QvUEyKHZ2" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zOtgiX5RH6T3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgxhY1B4CKX4" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zbouWzg1Ig82" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zQTgw8Ye5Fo5" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">172,447,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z9IDcizyKfeb" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(12,161,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231_zKwAGW5rZis5" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(380,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_z29TKc32MEv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">159,906,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P19Y 611000 -216000 -253000 142000 P20Y 50000 -36000 14000 Indefinite 230000 230000 P14Y 207398000 -22962000 184436000 P7Y 596000 -542000 54000 P5Y 75000 -7000 68000 P4Y 50000 -50000 P25Y 8000 -3000 5000 209018000 -23816000 -253000 184949000 P19Y 984000 -253000 -276000 455000 P20Y 100000 -30000 -22000 48000 Indefinite 281000 -82000 199000 P14Y 170353000 -11300000 159053000 P7Y 596000 -516000 80000 P5Y 75000 -5000 70000 P4Y 50000 -50000 P25Y 8000 -7000 1000 172447000 -12161000 -380000 159906000 -253000 -380000 <p id="xdx_89D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zzbTmU0mBvYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for intangible assets for the years ended December 31, 2024 and 2023 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zV0skhaakoFc" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zW1Pvervs9m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zFzAaKOiutdl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z1mAmVSSGOV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">56,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">84,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zqdhhUfofOlj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zqLcyGGLiQB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,669,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,937,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zjGI6sG2lrxa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEWtqDcBObte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Trade name</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AmortizationOfIntangibleAssets_zRjCxbRP63bh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense of intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,783,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,082,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 56000 84000 35000 7000 11669000 9937000 22000 54000 1000 11783000 10082000 <p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAgKKuRkYHil" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated future amortization expense for the Company’s intangible assets at December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjFLplMNBiOc" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Years ending December 31,</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_z08L8QHUePl3"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzNeK_z49P0JXNfSvf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,903,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzNeK_z3xmY5710k2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,903,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzNeK_zu06Go5TYOUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,612,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzNeK_zOoTsCeCcSGf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,205,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzNeK_zr1T3tJQh2k2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,095,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzNeK_zxhCZmd9hK0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">102,001,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzNeK_zjWjAoEQ1Mqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 16903000 16903000 16612000 16205000 16095000 102001000 184719000 37000000 0 0 <p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z7zPmkwYUq5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 12. <span id="xdx_82F_zylYX5XhhrR2">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zwLQFeAdvnu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts payable and accrued expenses at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zSLbzygUU382" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_zaVczNEjbS84" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_z3WLyDwe4drd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_ztjID0yLhxn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Accounts payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">38,762,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,424,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maAPAALzsSJ_zfvDKaWhUDlk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued insurance premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">873,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zXxEWq6PKxgf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accrued interest (see Note 13)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">2,538,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">1,978,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzsSJ_ztLRAII52dl7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">106,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">306,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzsSJ_zleut6vKzES5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,406,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,581,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zPXjd1y1TQVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company financed all insurance policies for the policy terms of August 17, 2023 through August 16, 2024. The financing agreements had an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20220817__20230816__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zFUARxsIWXVf" title="Debt instrument interest rate, during period">7.48</span>% per annum and required eight monthly payments of $<span id="xdx_902_ecustom--AccruedMonthlyPayments_c20230817__20240816__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zxFueUbpM076" title="Accrued monthly payments">169,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zwLQFeAdvnu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts payable and accrued expenses at December 31, 2024 and 2023 consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zSLbzygUU382" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_zaVczNEjbS84" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_z3WLyDwe4drd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_ztjID0yLhxn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Accounts payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">38,762,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,424,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maAPAALzsSJ_zfvDKaWhUDlk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued insurance premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">873,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zXxEWq6PKxgf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accrued interest (see Note 13)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">2,538,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">1,978,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAALzsSJ_ztLRAII52dl7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">106,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">306,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzsSJ_zleut6vKzES5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,406,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,581,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 38762000 21424000 873000 2538000 1978000 106000 306000 41406000 24581000 0.0748 169000 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_z9mQLFjYJol5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 13. <span id="xdx_824_zdH1iLnlETCe">DEBT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Oaktree Loan Due 2026</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2023, the Company entered into a Credit Agreement and Guaranty, (the “Oaktree Loan”) with Oaktree, providing for a senior secured term loan facility to the Company with a principal amount of up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredTermLoanMember_zHAPDVvnXu9k" title="Laon maximum borrowing capacity">100,000,000</span>. Upon entering into the Oaktree Loan, the Company drew a principal amount of $<span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zDAYEZ1cuSC4" title="Principal amount drawn">65,000,000</span> (“Tranche A”) from the Oaktree Loan and used the net proceeds to repay all amounts owed by the Company pursuant to the Loan and Security Agreement the Company previously entered into with B. Riley Commercial Capital, LLC on December 14, 2022 (the “B. Riley Loan”) – see subheading <i>B. Riley Loan and Security Agreement – Paid in Full </i>within this Note 13. The additional principal loan amount of up to $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230701__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--CreditFacilityAxis__custom--TrancheBMember_zeUhbcpDWtP3" title="Laon maximum borrowing capacity">35,000,000</span> available under the Oaktree Loan (“Tranche B”) was available to the Company upon the commercialization of TRIESENCE. Since Tranche B was not drawn by the Company on or before March 27, 2024, the amount available under Tranche B was reduced to $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240327__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--CreditFacilityAxis__custom--TrancheBMember_zeih2xAKtzT4" title="Loan maximum borrowing capacity">30,000,000</span>. While undrawn, the Company was required to pay a commitment fee related to Tranche B amount equal to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20240327__20240327__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--CreditFacilityAxis__custom--TrancheBMember_z1GCt9HkDrB4" title="Commitment fee percentage for undrawn amount">2</span>% per annum, payable quarterly. This fee was recorded within prepaid expenses and other current assets and is being amortized on a straight-line basis over the access period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2023, the Company entered into the First Amendment to the Oaktree Loan (the “Oaktree Amendment”). Under the Oaktree Amendment, the overall credit facility size was increased from $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MinimumMember_zk8qFwaPqngg" title="Debt instrument, increase (decrease)">100,000,000</span> to $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MaximumMember_zBoBiH3v8KRg" title="Debt instrument, increase (decrease)">112,500,000</span>, and the Company made other changes related to the Santen Products Acquisition (see Note 4). The Company drew down a principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember_zwLkKkGFpgc7" title="Debt instrument, face amount">12,500,000</span> (the “Loan Increase”) to fund the initial one-time payment associated with the Santen Products Acquisition and for other working capital and general corporate purposes. No other material changes to the Oaktree Loan were made pursuant to the Oaktree Amendment. Following entry into the Oaktree Amendment and the funding of the Loan Increase upon closing of the Santen Products Acquisition, the Company had drawn down a total principal loan amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_znP9fESvYJ89" title="Debt instrument, face amount">77,500,000</span> under the Oaktree Loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2024, the Company entered into the Second Amendment to Credit Agreement and Guaranty with Oaktree (“Second Amendment”). Upon satisfaction of certain conditions to funding, the Company drew down the principal amount of the Tranche B commitment of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20241031_znN71mt2o0R5" title="Principal amount">30,000,000</span> (the “$<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241031_zlrMzaA5gYw" title="Draw down">30,000,000</span> Draw”) to partially fund a one-time milestone payment to Novartis. Under its asset purchase agreement with Novartis, the Company made a one-time milestone payment to Novartis equal to $<span id="xdx_900_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_c20241031__20241031_zoeg8tQeBKj4" title="Payment of costs">37,000,000</span> upon the commercial availability of TRIESENCE, which the Company paid in October 2024. In connection with the Second Amendment, the Company incurred approximately $<span id="xdx_905_eus-gaap--CostsAndExpenses_c20241031__20241031_zPMkwZ8AAbPg" title="Costs">120,000</span> of costs. In connection with the Second Amendment and following the $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20241031__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_zcLegcXtPEub" title="Draw down">30,000,000</span> Draw, the Company has drawn down a total principal loan amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20241031__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_z6hFgovqbFni" title="Principal amount">107,500,000</span> under the Oaktree Loan and no additional principal loan amount remains available to the Company under the Oaktree Loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Oaktree Loan is secured by nearly all of the assets, including intellectual property, of the Company and its material subsidiaries. The Oaktree Loan has a maturity date of January 19, 2026 and carries an interest rate equal to the Secured Overnight Financing Rate plus <span id="xdx_908_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zn7lbAO4TZvk" title="Commitment fee percentage for undrawn amount">6.5</span>% per annum (totaling <span id="xdx_909_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__srt--RangeAxis__srt--MaximumMember_z8JST7d5biE3" title="Commitment fee percentage for undrawn amount">11.2</span>% at December 31, 2024). The Oaktree Loan also carries an exit fee equal to <span id="xdx_90F_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20240101__20241231__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__srt--RangeAxis__srt--MaximumMember_zyodXy9E3jqi" title="Commitment fee percentage for undrawn amount">3.5</span>% of the aggregate principal amount owed, payable at maturity. The total exit fee of $<span id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecondAmendmentMember_zaOhhyF6ETk1" title="Fee">3,763,000</span> has been recorded as a debt discount. The original issue discount, fees and expenses (including the exit fee) are being amortized over the term of the Oaktree Loan using the effective interest rate method. The Oaktree Loan requires quarterly interest-only payments with all of the unpaid principal, interest and fees due on the maturity date, January 19, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Oaktree Loan contains customary guarantees and covenants, including financial covenants related to minimum liquidity and minimum net revenues. As of December 31, 2024, the Company was in compliance with the financial covenants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Interest expense related to the Oaktree Loan totaled $<span id="xdx_904_eus-gaap--InterestExpenseOtherLongTermDebt_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zdO4sc9qZ3uj" title="Interest expense other than long term debt">12,568,000</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zIuoTwSUFPga" title="Interest expense other than long term debt">8,804,000</span> for the years ended December 31, 2024 and 2023, respectively, and included the amortization of debt issuance costs and discount of $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zxscR64sVP8l" title="Amortization of financing costs and discount">2,705,000</span> and $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zeqjYf4iJWy5" title="Amortization of financing costs and discount">1,680,000</span>, respectively. Also included in interest expense is the amortization of deferred commitment fees of $<span id="xdx_90A_eus-gaap--AmortizationOfDeferredLoanOriginationFeesNet_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zDR76NPgUBS8" title="Amortization of deferred commitment fees">601,000</span> and $<span id="xdx_902_eus-gaap--AmortizationOfDeferredLoanOriginationFeesNet_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zgtiKGu23RGd" title="Amortization of deferred commitment fees">543,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>HROWM - 11.875% Senior Notes Due 2027</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2022 and in January 2023, the Company closed an offering of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zKJlDMThFSr7" title="Face amount">35,000,000</span> and $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zCnUUL9AYUk2" title="Face amount">5,250,000</span>, respectively, aggregate principal amount of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zezYtOWuJwNk" title="Interest rate"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zzwJ5p1uQvHj" title="Interest rate">11.875</span></span>% senior notes due in December 2027 (the “2027 Notes”). The 2027 Notes were sold to investors at a par value of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zZYWWHBDlS9b" title="Shares issued price per share"><span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zQBwzxD53Wv7" title="Shares issued price per share">25.00</span></span> per 2027 Note, and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20221201__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zuoyYmswh3mf" title="Proceeds from issuance of debt"><span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20230101__20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zRF5fhbowDAh" title="Proceeds from issuance of debt">36,699,000</span></span> after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_ztrjE2J8VA4" title="Deducting underwriting discounts and commissions and expenses"><span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_znlf2PWxKZMb" title="Deducting underwriting discounts and commissions and expenses">3,551,000</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The 2027 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of the Company’s other existing and future senior unsecured and unsubordinated indebtedness. The 2027 Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The 2027 Notes bear interest at the rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zeZwMNWj8k9e" title="Interest rate, during period">11.875</span>% per annum. Interest on the 2027 Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on January 31, 2023. The 2027 Notes will mature on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z95qQAUDdf22" title="Debt instrument maturity date">December 31, 2027</span>. The issuance costs were recorded as a debt discount and are being amortized as interest expense over the term of the 2027 Notes using the effective interest rate method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company may redeem the 2027 Notes for cash in whole or in part at any time at its option <span id="xdx_901_eus-gaap--DebtInstrumentRedemptionDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zHumz9BbD4Gj" title="Redemption description">(i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note</span>, plus accrued and unpaid interest to, but excluding, the date of redemption, upon occurrence of certain events including the occurrence of a Material Change, as defined in the Second Supplemental Indenture. The 2027 Notes trade on the Nasdaq Stock Market LLC under the symbol “HROWM.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Interest expense related to the 2027 Notes totaled $<span id="xdx_904_eus-gaap--InterestExpenseOtherLongTermDebt_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zfBOdWsqRi8h" title="Interest expense other than long term debt">5,496,000</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zKe0vxebGqRb" title="Interest expense other than long term debt">5,516,000</span> for the years ended December 31, 2024 and 2023, respectively, and included the amortization of debt issuance costs and discount of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zgrszeYrvkcf" title="Amortization of financing costs and discount">716,000</span> and $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zbT017QS6th4" title="Amortization of financing costs and discount">736,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company’s Chief Executive Officer, Mark L. Baum, Chief Financial Officer, Andrew R. Boll, and former directors R. Lawrence Van Horn and Dr. Richard Lindstrom, in the aggregate, purchased $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zFxLPUFBIWrj" title="Face amount">950,000</span> in principal amount of the 2027 Notes at the time of their offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>HROWL – 8.625% Senior Notes Due 2026</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In April 2021, the Company closed an offering of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zeUdlSdqtAa4" title="Face amount">50,000,000</span> aggregate principal amount of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zLP6zJnwnbuk" title="Interest rate">8.625</span>% senior notes due April 2026, and in May 2021 issued an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zWXYfPocIowg" title="Debt instrument increase (decrease) period for net">5,000,000</span> of such notes pursuant to the full exercise of the underwriters’ option to purchase additional notes (collectively, the “April Notes”). The April Notes were sold to investors at a par value of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z5bFb0Nyhpb7" title="Shares issued price per share">25.00</span> per April Note and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z33QUwlR7NK1" title="Proceeds from issuance of debt">51,909,000</span> after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zxjYYOokLjZh" title="Deducting underwriting discounts and commissions and expenses">3,091,000</span>. In September 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zj4U1YQ8A40c" title="Debt instrument increase (decrease) for period net">20,000,000</span> aggregate principal amount of such notes (the “September Notes,” and together with the April Notes, the “2026 Notes”), at a price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zKYPOmqZSyGe" title="Shares issued price per share">25.75</span> per September Note, with interest of $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zKQTvqIBPYu3" title="Interest expense debt">278,000</span> on the September Notes being accrued from April 20, 2021, the date of issuance of the April Notes. The September offering resulted in net proceeds to the Company of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zwv3ihzaEPKc" title="Proceeds from issuance of debt">19,164,000</span> after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zUbnLPH0ZRa7" title="Deducting underwriting discounts and commissions and expenses">1,158,000</span> and a premium on note issuance of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zvjgVvjkiJT5" title="Debt instrument unamortized premium">322,000</span>. The September Notes are treated as a single series with the April Notes under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the initial offering price and issue date). The 2026 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of the Company’s other existing and future senior unsecured and unsubordinated indebtedness. The 2026 Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The 2026 Notes bear interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z3ar6pZqHbI4" title="Interest rate, during period">8.625</span>% per annum. Interest on the 2026 Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The 2026 Notes will mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zn96ijkosyOl" title="Debt instrument maturity date">April 30, 2026</span>. The issuance costs were recorded as a debt discount and are being amortized as interest expense, net of the amortization of the premium on note issuance, over the term of the 2026 Notes using the effective interest rate method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Prior to February 1, 2026, the Company may, at its option, redeem the 2026 Notes, in whole at any time or in part from time to time, at a <span id="xdx_909_eus-gaap--DebtInstrumentRedemptionDescription_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zU7kAIl6GDT7" title="Redemption description">redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed</span>, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2026 Notes for cash in whole or in part at any time at its option on or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. The 2026 Notes trade on the Nasdaq Stock Market LLC under the symbol “HROWL”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense related to the 2026 Notes totaled $<span id="xdx_90D_eus-gaap--InterestExpenseOtherLongTermDebt_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zO3xdcwYiXu3" title="Interest expense other than long term debt">7,253,000</span> and $<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zQfy8RdEsmDb" title="Interest expense other than long term debt">7,251,000</span> for the years ended December 31, 2024 and 2023, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zaG8qEFmYYul" title="Amortization of financing costs and discount">784,000</span>, and $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zr8Xwgx15dJd" title="Amortization of financing costs and discount">782,000</span> for the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>B. Riley Loan and Security Agreement – Paid in Full</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 14, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “BR Loan”) with B. Riley Commercial Capital, LLC, as administrative agent for the lenders. The BR Loan provided for a loan facility of up to $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_ziXyP5eKkX34" title="Debt principal amount">100,000,000</span> to the Company with a maturity date of <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20221213__20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zHWhdMhQp4Yk" title="Debt instrument maturity date">December 14, 2025</span> (the “Maturity Date”), at an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_ztwjivW1Wcyj" title="Interest rate">10.875</span>% per annum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In January 2023, $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zzbZlQTJNq55" title="Debt principal amount">59,750,000</span> of principal amount was funded pursuant to the BR Loan simultaneously with the consummation of the NVS 5 Acquisition (see Note 4). In March 2023, the Company repaid all amounts owed under the BR Loan, in connection with the Oaktree Loan, and no exit or prepayment fees were paid as a result of the payoff of the BR Loan pursuant to a side letter agreement among the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Interest expense related to the BR Loan totaled $<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zD96jYp9Wo48" title="Interest expense">1,565,000</span> for the year ended December 31, 2023, and included amortization of debt issuance costs and debt discount of $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zMJb0KppQJBk" title="Amortization of debt issuance costs and debt discount">356,000</span>. The Company recorded a loss of $<span id="xdx_90F_eus-gaap--ExtinguishmentOfDebtAmount_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zH8smDBUG9N5" title="Loss on extinguishment of debt">5,465,000</span> related to the early extinguishment of debt associated with the BR Loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p id="xdx_894_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zJK4CUiTfqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A summary of the Company’s debt at December 31, 2024 and 2023 is described as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z3zJrgDXgLF5" style="display: none">SCHEDULE OF LONG TERM DEBT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_z1a6YXBUjghj" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_zqUPrLgi2rMk" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zlYldWcVyK2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zxbm5e6zvLMj" title="Debt instrument interest rate, during period">8.625</span>% Senior Notes due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zxeaBntBOQWk" title="Maturity period">April 2026</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zS5TT7Br205g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z14dQPlISwx5" title="Debt instrument interest rate, during period">11.875</span>% Senior Notes due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zwB0cxKKcfb5" title="Maturity period">December 2027</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--OaktreeLoanDueJanuaryTwoThousandTwentySixMember_zLWo2mtH1B4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Oaktree Loan due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zyH3YCp0oWch" title="Maturity period">January 2026</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">111,263,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,213,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iI_zyUBy6cD68N4" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,513,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,463,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zPE76067omxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Unamortized debt discount and issuance costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--LongTermNotesPayable_iI_z7c8gQoovbA2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,539,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,885,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zK3tdz1JzIZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the years ended December 31, 2024 and 2023, the total effective interest rate of the Company’s debt was <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240101__20241231_zZT3OEtrle2l" title="Effective interest rate">10.74</span>%, and <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230101__20231231_zzssvHJ7idSd" title="Effective interest rate">10.58</span>%, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXxgqZoHHLn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, future minimum payments under the Company’s debt were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zeHWvKfjlsg7" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zRVezDMfUVQ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zwm06dfk9kCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">23,877,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_z2r7KA9DXuu4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,830,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_zdG1PkwGaFx2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,030,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zsqBVwqAZ2xi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,737,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zUCTivj4RWP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(36,224,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zsKcHn3IR4n1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,513,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zmw095avwAq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_zhlxrDe6FDAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,539,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zQW7XjWPM80a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 100000000 65000000 35000000 30000000 0.02 100000000 112500000 12500000 77500000 30000000 30000000 37000000 120000 30000000 107500000 0.065 0.112 0.035 3763000 12568000 8804000 2705000 1680000 601000 543000 35000000 5250000 0.11875 0.11875 25.00 25.00 36699000 36699000 3551000 3551000 0.11875 2027-12-31 (i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note 5496000 5516000 716000 736000 950000 50000000 0.08625 5000000 25.00 51909000 3091000 20000000 25.75 278000 19164000 1158000 322000 0.08625 2026-04-30 redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed 7253000 7251000 784000 782000 100000000 2025-12-14 0.10875 59750000 1565000 356000 5465000 <p id="xdx_894_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zJK4CUiTfqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A summary of the Company’s debt at December 31, 2024 and 2023 is described as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z3zJrgDXgLF5" style="display: none">SCHEDULE OF LONG TERM DEBT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_z1a6YXBUjghj" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_zqUPrLgi2rMk" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zlYldWcVyK2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zxbm5e6zvLMj" title="Debt instrument interest rate, during period">8.625</span>% Senior Notes due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zxeaBntBOQWk" title="Maturity period">April 2026</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zS5TT7Br205g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z14dQPlISwx5" title="Debt instrument interest rate, during period">11.875</span>% Senior Notes due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zwB0cxKKcfb5" title="Maturity period">December 2027</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--OaktreeLoanDueJanuaryTwoThousandTwentySixMember_zLWo2mtH1B4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Oaktree Loan due <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBERUJUIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_pid_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--OaktreeLoanMember_zyH3YCp0oWch" title="Maturity period">January 2026</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">111,263,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,213,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iI_zyUBy6cD68N4" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,513,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,463,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zPE76067omxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Unamortized debt discount and issuance costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--LongTermNotesPayable_iI_z7c8gQoovbA2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,539,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,885,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.08625 April 2026 75000000 75000000 0.11875 December 2027 40250000 40250000 January 2026 111263000 80213000 226513000 195463000 -6974000 -9578000 219539000 185885000 0.1074 0.1058 <p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXxgqZoHHLn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024, future minimum payments under the Company’s debt were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zeHWvKfjlsg7" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zRVezDMfUVQ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zwm06dfk9kCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">23,877,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_z2r7KA9DXuu4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193,830,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_zdG1PkwGaFx2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">45,030,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zsqBVwqAZ2xi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,737,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zUCTivj4RWP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(36,224,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zsKcHn3IR4n1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,513,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zmw095avwAq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_zhlxrDe6FDAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,539,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 23877000 193830000 45030000 262737000 36224000 226513000 -6974000 219539000 <p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zzoXmx6SGS4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 14. <span id="xdx_82F_zkdL5DOHKJ6j">LEASES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have remaining terms between <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zrusmGTxVKze" title="Lease term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1582">one</span></span> to <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zK8q62MhJ7gg" title="Lease term">five years</span> and contain various clauses for renewal at the Company’s option.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">An operating lease for <span id="xdx_90C_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220131__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVCFp7kaGJw2" title="Area of land">5,800</span> square feet of office space in Carlsbad, California, which commenced in January 2022 that expires in <span id="xdx_90C_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220131__srt--StatementGeographicalAxis__custom--CarlsbadMember_zD3gT3UluV3a" title="Lease expiration date, description">March 2025</span>.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">An operating lease for <span id="xdx_902_eus-gaap--AreaOfLand_iI_uSquareFoot_c20200731__srt--StatementGeographicalAxis__custom--LedgewoodMember_zkimSHvvU41a" title="Area of land">38,200</span> square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in <span id="xdx_906_ecustom--LeaseExpirationDateDescription_dd_c20200701__20200731__srt--StatementGeographicalAxis__custom--LedgewoodMember_zpQmAffKymn5" title="Lease expiration date, description">July 2027</span>, with an option to extend the term for two additional five-year periods. This lease was amended, effective July 2020, to extend the term of the original lease and add <span id="xdx_907_ecustom--AdditionalAreaOfLand_uSquareFoot_c20200701__20200731__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zmWQGRJresqg" title="Area of land">1,400</span> of additional square footage to the lease, amended again in May 2021 to extend the term of the lease to <span id="xdx_909_ecustom--LeaseExpirationDateDescription_dd_c20210501__20210531__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zgeCS2cyqqA7" title="Lease expiration date, description">July 2027</span> and add <span id="xdx_902_ecustom--AdditionalAreaOfLand_uSquareFoot_c20210501__20210531__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zesNJsH7mfQb" title="Additional area of land">8,900</span> square feet of space, and amended in May 2023 to add another <span id="xdx_90F_ecustom--AdditionalAreaOfLand_uSquareFoot_c20240101__20240131__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_z7SGHcINZAxh" title="Area of land">2,861</span> square feet of space to the existing lease, which the Company took possession of in January 2024.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">An operating lease for <span id="xdx_90F_eus-gaap--AreaOfLand_iI_uSquareFoot_c20200131__srt--StatementGeographicalAxis__custom--NashvilleMember_zDvXkTMtrRHh" title="Area of land">17,700</span> square feet of office space in Nashville, Tennessee that expires in <span id="xdx_90F_ecustom--LeaseExpirationDateDescription_dd_c20200101__20200131__srt--StatementGeographicalAxis__custom--NashvilleMember_zH3thNFmRIR3" title="Lease expiration date, description">June 2032</span>, and includes options to extend the lease term to June 2042.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">An operating lease for <span id="xdx_901_eus-gaap--AreaOfLand_iI_uSquareFoot_c20221231__srt--StatementGeographicalAxis__custom--NashvilleMember_zAAGAH4W7A1e" title="Area of land">11,600</span> square feet of lab and office space in Nashville, Tennessee which commenced in September 2022 and expires in <span id="xdx_901_ecustom--LeaseExpirationDateDescription_dd_c20221201__20221231__srt--StatementGeographicalAxis__custom--NashvilleMember_zc5ePD5Rw1ab" title="Lease expiration date, description">September 2027</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024 and 2023, the weighted-average discount rate and the weighted-average remaining lease term for the operating leases held by the Company were <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20241231_zOhyhfrhcfUk" title="Weighted average incremental borrowing rate">8.0</span>% and <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zEchWlrJ3fwd" title="Weighted average incremental borrowing rate">6.6</span>%, respectively, and <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_znoGrRYnfd8h" title="Weighted average remaining lease term">10.2</span> years and <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_z8USyzcnhGmh" title="Weighted average remaining lease term">10.4</span> years, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2024 and 2023, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20240101__20241231_z15MveXpylGf" title="Operating lease payments">1,301,000</span> and $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20230101__20231231_z2oBl5p2vpll" title="Cash paid for amounts included for operating lease liabilities">1,231,000</span>, respectively, and the Company recorded operating lease expense of $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFJsTBM1PKg9" title="Operating lease expense">1,515,000</span> and $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zJCLmXlW7j17" title="Operating lease expense">1,232,000</span>, respectively, included in selling, general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzxIodPqmVG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future lease payments under operating leases as of December 31, 2024 were as follows<b>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4UllXaes3e7" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_492_20241231_zs60tNl5bQP7" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Operating Leases</b></span></td> <td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zvjB4zlrMN6d" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%"><span style="font-size: 10pt">2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 18%; text-align: right"><span style="font-size: 10pt">1,223,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_zbjFmkKWhQn3" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">2026</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,551,000</span></td> <td> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_zVleDqPmSN2b" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">2027</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,425,000</span></td> <td> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zkBfdtltVNu4" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">2028</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,288,000</span></td> <td> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzv0z_zItDa5ezYP3i" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">2029</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,304,000</span></td> <td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_zKF8mhDBCH6l" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Thereafter</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">6,667,000</span></td> <td> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_zkReiOt2lHEc" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Total minimum lease payments</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">13,458,000</span></td> <td> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zmHfVYZAVmbi" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing imputed interest payments</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(4,169,000</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zKyz3pYUG5H5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.125in"><span style="font-size: 10pt">Total operating lease liabilities</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">9,289,000</span></td> <td> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zOpjlTXDeN2b" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Less: current portion, operating lease liabilities</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(497,000</span></td> <td><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Operating lease obligations, net of current portion</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,792,000</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8A4_zlz4iuNvlZ1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b> </b></p> P5Y 5800 March 2025 38200 July 2027 1400 July 2027 8900 2861 17700 June 2032 11600 September 2027 0.080 0.066 P10Y2M12D P10Y4M24D 1301000 1231000 1515000 1232000 <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zzxIodPqmVG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future lease payments under operating leases as of December 31, 2024 were as follows<b>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4UllXaes3e7" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_492_20241231_zs60tNl5bQP7" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Operating Leases</b></span></td> <td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zvjB4zlrMN6d" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%"><span style="font-size: 10pt">2025</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 18%; text-align: right"><span style="font-size: 10pt">1,223,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_zbjFmkKWhQn3" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">2026</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,551,000</span></td> <td> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_zVleDqPmSN2b" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">2027</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,425,000</span></td> <td> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zkBfdtltVNu4" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">2028</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,288,000</span></td> <td> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzv0z_zItDa5ezYP3i" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">2029</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">1,304,000</span></td> <td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_zKF8mhDBCH6l" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Thereafter</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">6,667,000</span></td> <td> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_zkReiOt2lHEc" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Total minimum lease payments</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">13,458,000</span></td> <td> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zmHfVYZAVmbi" style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing imputed interest payments</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(4,169,000</span></td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zKyz3pYUG5H5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 0.125in"><span style="font-size: 10pt">Total operating lease liabilities</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">9,289,000</span></td> <td> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zOpjlTXDeN2b" style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Less: current portion, operating lease liabilities</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(497,000</span></td> <td><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Operating lease obligations, net of current portion</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">8,792,000</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 1223000 1551000 1425000 1288000 1304000 6667000 13458000 4169000 9289000 497000 8792000 <p id="xdx_80F_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zyuBeg69yrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 15. <span id="xdx_827_zePwebYYdLUj">STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2024 and 2023, the Company had <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zC8ZCOqnGXA1" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNMJbC9MKH5f" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zIuwvdijH7Z" title="Preferred stock, par or stated value per share"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zHOKQ4aC6YP8" title="Preferred stock, par or stated value per share">0.001</span></span> par value, authorized and <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_ztgGrXZ3nX3i" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_zsQWFaHk6SUk" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zu1tUgPS0Zab" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zyL3Jrsw09ke" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of preferred stock issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At each of December 31, 2024 and 2023, the Company had <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zuujDNLnv7ak" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zjL54Ivc20cg" title="Common stock, par value">50,000,000</span></span> shares of common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zK1BbxmkeD7f" title="Common stock, par or stated value per share"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zhmZQWWunI5" title="Common stock, par or stated value per share">0.001</span></span> par value, authorized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December 31, 2024</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">The Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiGWJ2T0az1" title="Number of share issued">152,102</span> shares of common stock and received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromStockOptionsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5M9P67tPdag" title="Proceeds from stock option exercised">1,110,000</span> upon the exercise of options to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zENu4ajiMcs4" title="Exercise of option, shares">152,102</span> shares of common stock with exercise prices ranging from $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPjELzO4RYc" title="Exercise price, minimum">1.70</span> to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvKFU1tthwy5" title="Exercise price, maximum">25.86</span> per share.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">The Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjAUHCAWd9i2" title="Number of shares of common stock">32,955</span> shares of common stock upon the cashless exercise of options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znU57ptQ5Vpk" title="Options exercise price">39,710</span> shares with exercise prices ranging from $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z3NmPWQGO6t6" title="Exercise price per share">1.70</span> to $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z0ptu0seZS5l" title="Exercise price per share">8.00</span> per share.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">The Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zQJEqZFCVV29" title="Number of shares of common stock">44,860</span> shares of common stock to John Saharek, the Company’s Chief Commercial Officer, upon the cashless exercise of options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zSAtDMgOVx75" title="Options exercise price">90,000</span> shares at an exercise price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zeDMQyTPm6Ll" title="Exercise price per share">7.37</span>. The Company withheld <span id="xdx_903_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zEtNfVidh3ed" title="Shares withheld for tax withholding obligation, shares">29,107</span> shares of common stock for payroll tax withholdings totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zHadjteXsRNf" title="Payroll tax obligations, value">1,205,000</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHCtBrLye2T9" title="Number of shares granted">45,000</span> RSUs granted in February 2021 to Andrew R. Boll, the Company’s Chief Financial Officer, vested, and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkJnSLhsLaDe" title="Number of shares issued">26,520</span> shares of the Company’s common stock were issued to Mr. Boll, net of <span id="xdx_900_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfJmDNIfBWY3" title="Shares withheld for tax withholding obligation, shares">18,480</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_905_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsVZzn5pogx9" title="Payroll tax obligations, value">197,000</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxNImh1Asj4l" title="Number of shares granted">150,000</span> RSUs granted in February 2021 to Mark L. Baum, the Company’s Chief Executive Officer, vested, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLJszpGjaNi6" title="Number of shares issued">90,164</span> shares of the Company’s common stock were issued to Mr. Baum, net of <span id="xdx_90D_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkWEcOZVBPX8" title="Shares withheld for tax withholding obligation, shares">59,836</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90D_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZRgNReH0mf3" title="Payroll tax obligations, value">638,000</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z531P8gwqRRl" title="Number of shares granted">30,000</span> RSUs granted in February 2021 to John Saharek, the Company’s Chief Commercial Officer, vested, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yjAw9aRo56" title="Number of shares issued">17,384</span> shares of the Company’s common stock were issued to Mr. Saharek, net of <span id="xdx_90A_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGZonKSHN2Xg" title="Shares withheld for tax withholding obligation, shares">12,616</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_907_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR7C2fWP6XK8" title="Payroll tax obligations, value">135,000</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBskwCoKBeLk" title="Number of shares granted">50,000</span> RSUs granted in February 2021 to various other employees, vested, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFB8jU7iHLMh" title="Number of shares issued for vesting">32,452</span> shares of the Company’s common stock were issued, net of <span id="xdx_90B_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjtPZwmMiqhl" title="Shares withheld for tax withholding obligation, shares">17,548</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_908_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3XrP3WtDLN4" title="Payroll tax obligations, value">187,000</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">The Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5Byaw4NG549" title="Number of shares issued of common stock">57,517</span> shares of its common stock underlying RSUs held by a director that ceased providing services to the Company. The RSUs had previously vested, including <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8MNrcrxc7Sl" title="Number of shares vested of common stock">3,872</span> RSUs that vested during the year ended December 31, 2024, but the issuance and delivery of the shares were deferred until the director ceased providing services to the Company.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAZtFnTJaOJc" title="Number of shares issued for services">41,126</span> shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the applicable directors cease providing services to the Company.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.25pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHpcZISgW1w7" title="Number of shares issued for services">8,000</span> shares of the Company’s common stock underlying RSUs issued to consultants vested, but the issuance and delivery of these shares has not occurred.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December 31, 2023</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company closed a public offering of shares of its common stock at an offering price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_zdqsWXXAMGUd" title="Offering price per share">17.75</span> per share (the “Offering”). The Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_z2oFgHRkV254" title="Number of shares sold">3,887,324</span> shares of its common stock in the Offering, resulting in the Company receiving aggregate net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_zoJTnso0S2v4" title="Proceeds from issuance of common stock">64,520,000</span>, after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_903_ecustom--OtherExpense_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_zuj07QrXU3k9" title="Other expenses">4,480,000</span>;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company settled <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zUk7xfw5VPw2" title="Number of shares outstanding">1,567,913</span> outstanding PSUs as a result of the achievement of the total stockholder returns (“TSR”) targets set forth in equity incentive awards (the “PSU Agreements”) previously issued to members of the Company’s management team in 2021 (the “2021 Awards”). The 2021 Awards were separated into four tranches and required that the Company achieve and maintain certain levels of TSR ranging from <span id="xdx_90D_ecustom--PercentageOfStockholdersReturn_iI_pid_dp_uPure_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember__srt--RangeAxis__srt--MinimumMember_z0uDok77cp1g" title="TSR percentage">50</span>% to <span id="xdx_90A_ecustom--PercentageOfStockholdersReturn_iI_dp_uPure_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember__srt--RangeAxis__srt--MaximumMember_zzk2YKU1tCD4" title="TSR percentage">175</span>% per share during the five-year period following the grant date. TSR was based on the aggregate of: (i) the percent increase of the closing price of the Company’s common stock from July 22, 2021; and (ii) any dividends or like stockholder distributions as specified in the PSU Agreements. In connection with the settlement of the 2021 Awards, an aggregate of <span id="xdx_902_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_z5IvArUSE847" title="Number of shares withheld">616,984</span> shares of the Company’s common stock was withheld by Harrow for payroll tax obligations totaling $<span id="xdx_906_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zQIl6dAv6J8l" title="Payroll tax obligations">11,273,000</span>;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Ehm8I9z1Id" title="Number of common stock issued">168,963</span> shares of its common stock underlying RSUs held by directors that ceased providing services to the Company. The RSUs had previously vested, including <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfPhI1ZQNzh7" title="Number of common stock vested">21,620</span> RSUs during the year ended December 31, 2023, but the issuance and delivery of the shares were deferred until the director ceased providing services to the Company;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBzsWq8NTLOf" title="Number of share issued">65,148</span> shares of common stock and received proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQxp45Ggx3ib" title="Proceeds from stock option exercise">379,000</span> upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziTJX9CRG3wk" title="Exercise of option, shares">65,148</span> shares of common stock with exercise prices ranging from $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSyQ9jXG2oG2" title="Exercise price, minimum">1.70</span> to $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSLeYffypOu4" title="Exercise price, maximum">8.50</span> per share;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdEnyVHo4o6h" title="Number of granted, sharess">62,367</span> shares of common stock to Mark L. Baum, the Company’s Chief Executive Officer, upon the cashless exercise of options to purchase <span id="xdx_907_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3fZneFNdffi" title="Cashless exercise of options, shares">180,000</span> shares at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zZKhjJZy8X7a" title="Exercise price per share">8.99</span> per share. The Company withheld from Mr. Baum <span id="xdx_908_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze4a9wzKliRl" title="Shares withheld for tax withholding obligation">77,167</span> shares as consideration for the cashless exercise and an additional <span id="xdx_905_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvACjVymJLnk" title="Additional shares withheld for tax withholding obligation">40,466</span> shares for payroll tax obligations totaling $<span id="xdx_909_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_za9x8RYNdxCi" title="Payroll tax obligations, value">849,000</span>;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWbxgnhEtqZe" title="Number of shares issued">55,558</span> shares of common stock to Andrew R. Boll, the Company’s Chief Financial Officer, upon the cashless exercise of options to purchase <span id="xdx_909_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaEz382xxJ9h" title="Cashless exercise of options, shares">90,000</span> shares at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zcs9Gq6BsZzc" title="Exercise price per share">6.00</span> per share. The Company withheld from Mr. Boll <span id="xdx_904_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV1YRxCg6qQb" title="Shares withheld for tax withholding obligation">25,521</span> shares as consideration for the cashless exercise and an additional <span id="xdx_90F_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHHqvRtKgy6j" title="Additional shares withheld for tax withholding obligation">8,921</span> shares for payroll tax obligations totaling $<span id="xdx_90D_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zEl1QwVJpyB2" title="Payroll tax obligations, value">189,000</span>; </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdzU3aLA8rfd" title="Number of shares issued">10,222</span> shares of common stock to John Saharek, the Company’s Chief Commercial Officer, upon the cashless exercise of options to purchase <span id="xdx_904_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziwXASRnVEu6" title="Cashless exercise of options, shares">20,000</span> shares at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember_zyde8qZzXoEh" title="Exercise price per share">4.16</span> per share. The Company withheld from Mr. Saharek <span id="xdx_90D_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z210el1dCTNa" title="Shares withheld for tax withholding obligation">6,485</span> shares as consideration for the cashless exercise and an additional <span id="xdx_90B_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkY9w8GWBhIe" title="Additional shares withheld for tax withholding obligation">3,293</span> shares for payroll tax obligations totaling $<span id="xdx_902_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember_z29OVnOQP5V6" title="Payroll tax obligations, value">41,000</span>; </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">upon vesting of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFItrjlmX3g" title="Number of shares granted">23,000</span> RSUs granted in January 2020 to Andrew R. Boll, the Company’s Chief Financial Officer, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCgweIoqMf91" title="Number of shares issued">13,398</span> shares of common stock to Mr. Boll, net of <span id="xdx_90E_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZBzgtZqGq58" title="Shares withheld for tax withholding obligation, shares">9,602</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8U7U1TtqR4i" title="Payroll tax obligations, value">142,000</span>;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">upon vesting of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDKjh10LQ0J8" title="Number of shares granted">88,000</span> RSUs granted in January 2020 to Mark L. Baum, the Company’s Chief Executive Officer, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfJq6lRdHUtj" title="Number of shares issued">52,821</span> shares of common stock to Mr. Baum, net of <span id="xdx_904_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zISoU88NDWJ1" title="Shares withheld for tax withholding obligation, shares">35,179</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90B_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9zx6pdIi5H9" title="Payroll tax obligations, value">519,000</span>; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgouZs08OgH1" title="Number of shares granted">43,023</span> shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares were deferred until the applicable director ceased providing services to the Company.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>Stock Option Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, as subsequently amended (the “2007 Plan:). The 2007 Plan reached its term in September 2017, and the Company can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of December 31, 2024, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_z72kPdVLTBSa" title="Number of shares authorized for issuance">6,000,000</span> shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z4Wi2XuWHCaj" title="Common shares available for future issuances">38,968</span> shares available for future issuances under the 2017 Plan at December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrC0JdCtfhf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option activity under the Plan for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zlaCSBTAzPV" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg. Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Life</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfB5FzVbX7u3" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">2,711,317</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKK8xsJohr84" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">6.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDkSXeEVsfh5" style="text-align: right" title="Number of shares, options granted">152,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwA8ODvYxwhj" style="text-align: right" title="Weighted average exercise price, options granted">17.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zolUrV8Mc36i" style="text-align: right" title="Number of shares, options exercised">(281,812</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zr5irCkJ21ga" style="text-align: right" title="Weighted average exercise price, options exercised">7.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPat6npACtR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(113,406</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhLXmTCQWdz2" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited">13.51</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQ4iu7BYE1l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,469,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z2KD2vItrpCb" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLsnDuIYiHYh" title="Weighted average. remaining contractual life, options outstanding">3.19</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZqIY5oZQtU1" style="text-align: right" title="Aggregate intrinsic value, options outstanding">67,035,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIs2Gx0vDsLg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,226,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhFm51Y0eAq7" style="text-align: right" title="Weighted average exercise price, options exercisable">5.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUhrcpCFpruf" title="Weighted average. remaining contractual life, options exercisable">2.59</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zh8PjOR0tX15" style="text-align: right" title="Aggregate intrinsic value, options exercisable">62,413,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLEMHpOFSBD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,438,378</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpaAe7b9b3oh" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zAG1ag5uF7R7" title="Weighted average. remaining contractual life, options vested and expected to vest">3.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRZPk2RM8BZ" style="text-align: right" title="Aggregate intrinsic value, options exercisable">66,501,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option activity under the Plan for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg. Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Life</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_za6AJj2Kwjec" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">3,027,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn8gH8qDJ486" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvRO7hdmahi" style="text-align: right" title="Number of shares, options granted">135,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zunKTZcc59yf" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">17.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zoTSe7a4pMTb" style="text-align: right" title="Number of shares, options exercised">(355,148</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfKAPGIUTuW5" style="text-align: right" title="Weighted average exercise price, options exercised">7.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zTRyd1QKQcDf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(96,736</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIuBQEGajnN7" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zH4vOGEWBjY" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zk2AuoZuv52j" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWfRJ7p7uJtg" title="Weighted average. remaining contractual life, options outstanding">4.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJbxrxzhBImb" style="text-align: right" title="Aggregate intrinsic value, options outstanding">14,303,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlrPL0tqfWE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpkeyn9sqto1" style="text-align: right" title="Weighted average exercise price, options exercisable">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zAYSoRtC0e75" title="Weighted average. remaining contractual life, options exercisable">3.45</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkcm40BRcab7" style="text-align: right" title="Aggregate intrinsic value, options exercisable">13,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd7tBtGo8Mah" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,673,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjDuyjF24fik" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zReoOnyIwgm" title="Weighted average. remaining contractual life, options vested and expected to vest">3.93</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQFdfmFJhyOh" style="text-align: right" title="Aggregate intrinsic value, options exercisable">14,243,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zvNleZ8dHFoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value in the tables above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on December 31, 2024 and 2023, based on the closing price of the Company’s common stock of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT8g2pGtR5I4" title="Closing price of common stock price per share">33.55</span> and $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTJWCt4Fb4L4" title="Closing price of common stock price per share">11.20</span>, respectively, on that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The intrinsic value of the options exercised in 2024 and 2023 was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231_zz9OxvYFGp31">7,011,000</span> and $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231_z86OrTepZyfj">4,580,000</span>, respectively. During 2024 and 2023, the Company recognized <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_do_c20240101__20241231_z2PY9DBnoHga" title="Recognized tax benefit from stock options exercised"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_do_c20230101__20231231_zWBiccpvfDkj" title="Recognized tax benefit from stock options exercised">no</span></span> tax benefit from stock options exercised during these periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2024, the Company granted stock options to certain employees. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zGgAc331DLf3" title="Vesting term description">The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees during the year ended December 31, 2024 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years.</span> Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The Company calculates expected volatility based solely on the historical volatilities of the common stock of the Company. The expected term of options granted was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureFactor_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zI3cgkSOzLLb" title="Forfeiture factor rate">10</span>%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOzV5OJYrF3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zHFav0AmHr6i" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAWI1Pw8QLXl" style="white-space: nowrap; width: 12%; text-align: right" title="Weighted-average fair value of options granted">11.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9sTi1RIhtw9" style="white-space: nowrap; width: 12%; text-align: right" title="Weighted-average fair value of options granted">11.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected terms (in years)</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMK9fCpOtwsj" title="Expected terms (in years)">6.11</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zh7EXSxlwQf5" title="Expected terms (in years)">6.11</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2mUGAwa5e8j" title="Expected volatility minimum">68</span> – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Q3W91gzjZ7" title="Expected volatility maximum">73</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znadrk6YFt6h" title="Expected volatility minimum">68</span> – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWIfpegXcvyj" title="Expected volatility maximum">70</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ezBtEHpybl" title="Risk-free interest rate minimum">3.72</span> – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVSkC0fAPss2" title="Risk-free interest rate maximum">4.48</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zatyasrIiSWl" title="Risk-free interest rate minimum">3.59</span> – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmjv0JEqk38g" title="Risk-free interest rate maximum">4.80</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8a9TwWIHkx5" style="white-space: nowrap; text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1956">-</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zipIDUNL0f73" style="white-space: nowrap; text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zhjDaHu8zPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b> </b></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z7NSodzoXwz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in">The following table summarizes information about stock options outstanding and exercisable at December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ziWMBH8OnWG9" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 92%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Outstanding</b></span></td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Exercisable</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Range of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Prices</b></p></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<br/> Outstanding</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life in Years</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br/> Average<br/> Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<br/> Exercisable</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br/> Average<br/> Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 23%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4GFU6LMlcN9" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM1ufwOp6yQl" title="Range of Exercise Prices, maximum">1.70</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9kA8VXefROd" style="width: 12%; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">31,942</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zzTcwFuVWRF7" title="Weighted Average Remaining Contractual Life in Years">2.71</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkFJlg7CIGI4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.68</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkZXbEvZCBUk" style="width: 12%; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">31.942</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSWER8ORk6N" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.68</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFF5dBDjmDcf" title="Range of Exercise Prices">1.73</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6GR4MihFNqb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsi2lgJEffek" title="Weighted Average Remaining Contractual Life in Years">3.00</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zUN7nKI3F7Hk" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.73</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeTkbbgz1hM1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">250,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNn3mvjwfKq9" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.73</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFfMELWcIFK4" title="Range of Exercise Prices">2.23</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJDXFdad62X3" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">270,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4g76Xdl9xEh" title="Weighted Average Remaining Contractual Life in Years">2.09</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zHjpDaidhDC4" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">2.23</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ8xrTrxLBDg" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">270,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7dQHb0o3jI1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.23</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zse1GK8fXyM5" title="Range of Exercise Prices, minimum">2.40</span>- $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zXbr708Hy0Xg" title="Range of Exercise Prices, maximum">2.60</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0uH41Mu6Kb8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">14,068</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUMdXuWw72H" title="Weighted Average Remaining Contractual Life in Years">2.07</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zEwxtzzqjMc5" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">2.57</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zb7yGoJTsD7d" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">14,068</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMa41yGtdjZk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.57</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlbkaeGQaSwj" title="Range of Exercise Prices">3.95</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zBF4iNvaxtH8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">308,500</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zKDX4w6uqyQ6" title="Weighted Average Remaining Contractual Life in Years">1.25</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_ztZXxeyFwKx6" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.95</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zca8hLtJy0hh" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">308,500</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrOPeT5IV0s1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">3.95</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zu2kXdLgJ6tg" title="Range of Exercise Prices, minimum">4.49</span>- $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zlk4dg79uAE5" title="Range of Exercise Prices, maximum">5.72</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBqKWGOgoDGi" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">92,300</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zjtEHC3Wmhe" title="Weighted Average Remaining Contractual Life in Years">4.61</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zHcJrdxk8ZC6" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.53</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeTteEScetl9" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">92,300</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zSJ4dbOT4wo8" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.53</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zDIN7cIJpzL2" title="Range of Exercise Prices">6.30</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2QzovA3MCH2" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">285,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zKzbXceGCgFl" title="Weighted Average Remaining Contractual Life in Years">4.14</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zIxno0jEoe5g" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">6.30</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zSNMQyyUlga1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">285,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3H8Zdfyei4h" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">6.30</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zn3EUDSiSh7i" title="Range of Exercise Prices, minimum">6.75</span>- $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zx7sUUoWLTjl" title="Range of Exercise Prices, maximum">7.26</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zFgDpj9mGoV4" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">44,006</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zOsShfqHM1f1" title="Weighted Average Remaining Contractual Life in Years">7.41</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z8Yi7HCqpbqd" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">6.84</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zP0VqFjS5kDl" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">21,319</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zMYIcZD2XyRa" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">6.79</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zuuDFDXWag7b" title="Range of Exercise Prices">7.30</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zUNvZRwEIDnd" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">274,500</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zFIQT9BhHyWa" title="Weighted Average Remaining Contractual Life in Years">5.01</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zqNoDhZWrxof" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.30</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJKz8Bmkr4N1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">274,500</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zjhbmqBCKPlk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.30</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zDEibZEjFeHi" title="Range of Exercise Prices, minimum">7.60</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQeLUNnAvpN" title="Range of Exercise Prices, maximum">45.64</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zXKRkd1ADGvf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">898,783</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHK8oczWBYAc" title="Weighted Average Remaining Contractual Life in Years">3.06</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zIMwaVrrv9sg" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">10.09</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zLtJoqdpQHUg" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">679,229</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zkBp6QdIZATk" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.10</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231_zXt0xtmM1l46" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231_zSl8ISGpzX03" title="Range of Exercise Prices, maximum">45.64</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zHOil1qj3Tmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">2,469,099</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zIyDV6ejzRgl" title="Weighted Average Remaining Contractual Life in Years">3.19</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231_zwquQeLIX8r2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-size: 10pt">6.49</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zhtPXv1tDVNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable"><span style="font-size: 10pt">2,226,858</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231_zKqds6BLCnKk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-size: 10pt">5.52</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8A0_z24NZIQY9dUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, there was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLjyI6l3qrp9" title="Unrecognized compensation expense related to unvested stock options granted under the plan">2,158,000</span> of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3BRPrVZw1ge" title="Expense expected to recognize over the weighted-average remaining vesting period">2.73</span> years. The stock-based compensation for all stock options was $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zz6YExANPTX8" title="Stock-based compensation">624,000</span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPsuVaQnqms5" title="Stock-based compensation">782,000</span> during the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Performance Stock Units</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grants During the Year Ended December 31, 2023</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In April 2023, the Company granted an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230401__20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zPNMgHqHSgUb" title="Number of Shares, PSUs granted">1,567,913</span> PSUs to members of its senior management including Mark Baum, Chief Executive Officer, Andrew Boll, Chief Financial Officer, and John Saharek, Chief Commercial Officer, which are subject to the satisfaction of certain market-based and continued service conditions (the “2023 PSUs”). The vesting of the 2023 PSUs require (i) a minimum of a two-year service period and (ii) during a five-year term, the achievement and maintenance of Company common stock price targets for ten consecutive trading days ranging between $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlOC6Fh6Maj9" title="Share price">25.00</span> to $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ5Oce8RT3Xa" title="Share price">50.00</span> per share, separated into four separate tranches as described further in the table below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_897_eus-gaap--ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_zQbSGhHWhER3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zdyzXjrkViAe" style="display: none">SCHEDULE OF PERFORMANCE STOCK UNITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Tranche</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Target Share Price*</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Tranche 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zAmR4YTNcta6" style="width: 12%; text-align: right" title="Tranche of shares">223,988</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_fKg_____zBlT05dxTGYb" style="width: 12%; text-align: right" title="Share price">25.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zFkRnPvYmdC4" style="text-align: right" title="Tranche of shares">335,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_fKg_____zwd5O8dAjpDg" style="text-align: right" title="Share price">35.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tranche 3</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zpFV6pA2WEA3" style="text-align: right" title="Tranche of shares">447,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_fKg_____zvgNqmxUh2lf" style="text-align: right" title="Share price">45.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 4</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_zwaeMj5zPrId" style="text-align: right" title="Number of Shares">559,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_fKg_____zxtbKnEMTre5" style="text-align: right" title="Target Share Price">50.00</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 20px; text-align: right"><span id="xdx_F04_zL3o470pClli" style="font-size: 10pt">*</span></td> <td style="text-align: justify"><span id="xdx_F1B_zyYh64fw6RQ1" style="font-size: 10pt">Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price. </span></td></tr> </table> <p id="xdx_8AE_zcO5jY3EzJx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate fair value of the 2023 PSUs was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zZYa7cCAt6T8" title="Share-based compensation shares fair value">29,106,000</span> using a Monte Carlo Simulation with a <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zibdfFTG9qk6" title="Fair value, year::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl2141">five</span></span>-year life, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z08iMQHaW4yg" title="Volatality rate">65</span>% volatility and a risk-free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zhxrWYxoX9ml" title="Risk free intrest rate">10.34</span>%. This amount is being amortized over a <span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardDerivedServicePeriod_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zhU9M3kj0nZb" title="Derived service period::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl2147">two</span></span>-year derived service period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zH8xARDteN59" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zpXEWgAblHOj" style="display: none">SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">PSUs unvested – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNUu3K5dX0V7" style="width: 12%; text-align: right" title="Number of Shares, unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Mfa0HRTRml" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">18.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zwhFxSomQhhi" style="text-align: right" title="Number of Shares, PSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl2155">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z57xuLKxnllh" style="text-align: right" title="Weighted average grant date fair value, PSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfzS3B1u4kZc" style="text-align: right" title="Number of Shares, PSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl2159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zq1hfmH9L0je" style="text-align: right" title="Weighted average grant date fair value, PSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDYPpU7oers3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2163">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7qpP1em8XCb" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2165">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ziuzOGVPA1Dh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zIUN6voYsi1l" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">PSUs unvested – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zxoRDKU1XBu1" style="width: 12%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zvFDnfMvrkeb" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zaBNAtEJ9Tx8" style="text-align: right" title="Number of Shares, PSUs granted">1,567,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zdddLnPqZBh6" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">18.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3d6Qc4SaqP7" style="text-align: right" title="Number of Shares, PSUs vested">(1,567,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zR0fJaoMufTg" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">6.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSJVelj69E0f" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2183">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz3Az8tR8B37" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFTfcYbTe9t" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zdDDMUu49Nif" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zqwXiltuFcA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the total unrecognized compensation expense related to unvested PSUs was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNKr2DeVVJJk">7,276,000</span> which is expected to be recognized over a weighted-average period of <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zUp3pfitIGd6">0.25</span> years, based on estimated vesting schedules. The stock-based compensation for PSUs was $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zxki3AEnfXB7">14,553,000</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zbLw8fGpK2sd">13,753,000</span> during the years ended December 31, 2024 and 2023, respectively. During 2024 and 2023, the Company recognized <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_do_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_z9xIBxhtT979" title="Recognized tax benefit from the vesting"><span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zU1GrW3FXaK3" title="Recognized tax benefit from the vesting">no</span></span> tax benefit from the vesting of PSUs during these periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>Restricted Stock Units</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grants During the Year Ended December 31, 2024</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2024, the Company’s non-employee members of the Board of Directors were granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zlbunugxDnk4" title="Shares issued of restricted common stock, shares">43,961</span> time-based vesting RSUs with a fair market value of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20240101__20241231__srt--TitleOfIndividualAxis__custom--DirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbYTx2BKjbL5" title="Number of restrcited shares, value">790,000</span>, which vest in equal quarterly installments over one year. The Company also granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfyIm60iP8R6" title="Number of shares granted">283,870</span> time-based vesting RSUs with a fair market value of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4sLSKDuAql2" title="Number of restrcited shares, value">7,286,000</span> to certain employees and consultants. Vesting terms for RSUs granted to employees and consultants during the year ended December 31, 2024 generally vest in equal installments over <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--RangeAxis__srt--MinimumMember_zTNCcZ4uflVf" title="Weighted-average period years::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2207">three</span></span> or <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--RangeAxis__srt--MaximumMember_zQhmv3UPJWPa" title="Weighted-average period years">four years</span> and vest in equal quarterly installments over one year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grants During the Year Ended December 31, 2023</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2023, the Company’s non-employee members of the Board of Directors were granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zy3wTVYs7ZY7" title="Shares issued of restricted common stock, shares">41,301</span> time-based vesting RSUs with a fair market value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__srt--TitleOfIndividualAxis__custom--DirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW5Qrw9rlHn3" title="Number of restrcited shares, value">800,000</span>, which vest in equal quarterly installments over one year. The Company also granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlxZ6KnYwpc8" title="Number of shares granted">86,873</span> time-based vesting RSUs with a fair market value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmF4DDqxt2tj" title="Number of restrcited shares, value">697,000</span> to certain employees, which vest in full on the <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zs4mv6hxgSY5" title="Number of restrcited shares, description">third anniversary of the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zK0ubbFfrrmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z2Fie5HUSC7k">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">RSUs unvested – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z1gVHKtrGVe" style="width: 12%; text-align: right" title="Number of Shares, unvested, outstanding, beginning balance">363,029</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_zDt5PyDpVmdc" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">9.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zE74UqW4gBw4" style="text-align: right" title="Number of Shares, RSUs granted">327,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zaEirJdEIOb3" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">24.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_z5pxPXLl0yD3" style="text-align: right" title="Number of Shares, RSUs vested">(327,998</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_z2Wq1JXdnan6" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">10.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_z7GQorodX5P8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(9,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zJt8327zVa39" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">11.64</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_z1XCiahEqxol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, unvested, outstanding, ending balance">353,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zb62eicW9ed4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">22.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">RSUs unvested – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231_zNSWEUeCG9t3" style="width: 12%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">493,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zKiIZo3hC2ri" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231_zGgQlMm4EVKi" style="text-align: right" title="Number of Shares, RSUs granted">128,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zxLYJRF9LsB8" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">11.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231_z5qZvaV7ATCe" style="text-align: right" title="Number of Shares, RSUs vested">(175,643</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_ztBo3vK0Fc0g" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">8.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231_znM9NF0xSyo7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(83,308</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zzoSQx2Hs7z7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">6.84</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231_zMRJ1xoTo875" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">363,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zteVNJD3EB71" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">9.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zjqegUxPJLU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzlivCkHH8Bc" title="Unrecognized compensation expense">7,703,000</span> which is expected to be recognized over a weighted-average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjx46TA4dOYj" title="Weighted-average period years">1.85</span> years, based on estimated vesting schedules. The stock-based compensation for RSUs was $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyhSGSTxdikb" title="Stock-based compensation">2,442,000</span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zu4wyTHru8I6" title="Stock-based compensation">1,161,000</span> during the years ended December 31, 2024 and 2023, respectively. During 2024 and 2023, the Company recognized a tax benefit of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoIgdE8dVFj7" title="Tax benefit from stock options exercised">12,000</span> and $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvQLctvkFnw" title="Tax benefit from stock options exercised">0</span>, respectively, from the vesting of RSUs during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zsBLckl8hjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded total stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zrLTY2fCr4V6" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231_zJOVXg5tpD8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zKU48IlniAlj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zZoah1i7VHE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Employees – selling, general and administrative</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">14,812,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">13,279,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNF0zwLSbVy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employees – R&amp;D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,722,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,662,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zfgtk7mDRlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Directors – selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFHGzWI1is98" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Consultants – selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">285,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zcfjuHNBjkLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,619,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,696,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z88QcA84FWFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 5000000 5000000 0.001 0.001 0 0 0 0 50000000 50000000 0.001 0.001 152102 1110000 152102 1.70 25.86 32955 39710 1.70 8.00 44860 90000 7.37 29107 1205000 45000 26520 18480 197000 150000 90164 59836 638000 30000 17384 12616 135000 50000 32452 17548 187000 57517 3872 41126 8000 17.75 3887324 64520000 4480000 1567913 0.50 1.75 616984 11273000 168963 21620 65148 379000 65148 1.70 8.50 62367 180000 8.99 77167 40466 849000 55558 90000 6.00 25521 8921 189000 10222 20000 4.16 6485 3293 41000 23000 13398 9602 142000 88000 52821 35179 519000 43023 6000000 38968 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zrC0JdCtfhf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option activity under the Plan for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zlaCSBTAzPV" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg. Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Life</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfB5FzVbX7u3" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">2,711,317</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKK8xsJohr84" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">6.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDkSXeEVsfh5" style="text-align: right" title="Number of shares, options granted">152,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwA8ODvYxwhj" style="text-align: right" title="Weighted average exercise price, options granted">17.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zolUrV8Mc36i" style="text-align: right" title="Number of shares, options exercised">(281,812</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zr5irCkJ21ga" style="text-align: right" title="Weighted average exercise price, options exercised">7.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPat6npACtR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(113,406</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhLXmTCQWdz2" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited">13.51</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQ4iu7BYE1l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,469,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z2KD2vItrpCb" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLsnDuIYiHYh" title="Weighted average. remaining contractual life, options outstanding">3.19</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZqIY5oZQtU1" style="text-align: right" title="Aggregate intrinsic value, options outstanding">67,035,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIs2Gx0vDsLg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,226,858</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhFm51Y0eAq7" style="text-align: right" title="Weighted average exercise price, options exercisable">5.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUhrcpCFpruf" title="Weighted average. remaining contractual life, options exercisable">2.59</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zh8PjOR0tX15" style="text-align: right" title="Aggregate intrinsic value, options exercisable">62,413,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLEMHpOFSBD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,438,378</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpaAe7b9b3oh" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zAG1ag5uF7R7" title="Weighted average. remaining contractual life, options vested and expected to vest">3.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRZPk2RM8BZ" style="text-align: right" title="Aggregate intrinsic value, options exercisable">66,501,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option activity under the Plan for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Avg. Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Life</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_za6AJj2Kwjec" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">3,027,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn8gH8qDJ486" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvRO7hdmahi" style="text-align: right" title="Number of shares, options granted">135,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zunKTZcc59yf" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">17.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zoTSe7a4pMTb" style="text-align: right" title="Number of shares, options exercised">(355,148</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfKAPGIUTuW5" style="text-align: right" title="Weighted average exercise price, options exercised">7.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zTRyd1QKQcDf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(96,736</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIuBQEGajnN7" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zH4vOGEWBjY" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zk2AuoZuv52j" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWfRJ7p7uJtg" title="Weighted average. remaining contractual life, options outstanding">4.00</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJbxrxzhBImb" style="text-align: right" title="Aggregate intrinsic value, options outstanding">14,303,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlrPL0tqfWE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpkeyn9sqto1" style="text-align: right" title="Weighted average exercise price, options exercisable">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zAYSoRtC0e75" title="Weighted average. remaining contractual life, options exercisable">3.45</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkcm40BRcab7" style="text-align: right" title="Aggregate intrinsic value, options exercisable">13,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd7tBtGo8Mah" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,673,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjDuyjF24fik" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zReoOnyIwgm" title="Weighted average. remaining contractual life, options vested and expected to vest">3.93</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQFdfmFJhyOh" style="text-align: right" title="Aggregate intrinsic value, options exercisable">14,243,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2711317 6.25 152500 17.36 281812 7.23 113406 13.51 2469099 6.49 P3Y2M8D 67035000 2226858 5.52 P2Y7M2D 62413000 2438378 6.35 P3Y1M13D 66501000 3027701 5.90 135500 17.81 355148 7.36 96736 7.49 2711317 6.25 P4Y 14303000 2432826 5.55 P3Y5M12D 13760000 2673670 6.15 P3Y11M4D 14243000 33.55 11.20 7011000 4580000 0 0 The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees during the year ended December 31, 2024 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. 0.10 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOzV5OJYrF3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zHFav0AmHr6i" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAWI1Pw8QLXl" style="white-space: nowrap; width: 12%; text-align: right" title="Weighted-average fair value of options granted">11.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9sTi1RIhtw9" style="white-space: nowrap; width: 12%; text-align: right" title="Weighted-average fair value of options granted">11.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected terms (in years)</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMK9fCpOtwsj" title="Expected terms (in years)">6.11</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zh7EXSxlwQf5" title="Expected terms (in years)">6.11</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2mUGAwa5e8j" title="Expected volatility minimum">68</span> – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Q3W91gzjZ7" title="Expected volatility maximum">73</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znadrk6YFt6h" title="Expected volatility minimum">68</span> – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWIfpegXcvyj" title="Expected volatility maximum">70</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ezBtEHpybl" title="Risk-free interest rate minimum">3.72</span> – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVSkC0fAPss2" title="Risk-free interest rate maximum">4.48</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zatyasrIiSWl" title="Risk-free interest rate minimum">3.59</span> – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmjv0JEqk38g" title="Risk-free interest rate maximum">4.80</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8a9TwWIHkx5" style="white-space: nowrap; text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1956">-</span></td><td style="text-align: left"> </td><td> </td> <td style="white-space: nowrap; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zipIDUNL0f73" style="white-space: nowrap; text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td><td style="text-align: left"> </td></tr> </table> 11.46 11.49 P6Y1M9D P6Y1M9D 0.68 0.73 0.68 0.70 0.0372 0.0448 0.0359 0.0480 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z7NSodzoXwz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in">The following table summarizes information about stock options outstanding and exercisable at December 31, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ziWMBH8OnWG9" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 92%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Outstanding</b></span></td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Exercisable</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Range of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Prices</b></p></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<br/> Outstanding</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life in Years</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br/> Average<br/> Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number<br/> Exercisable</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br/> Average<br/> Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 23%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4GFU6LMlcN9" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zM1ufwOp6yQl" title="Range of Exercise Prices, maximum">1.70</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9kA8VXefROd" style="width: 12%; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">31,942</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zzTcwFuVWRF7" title="Weighted Average Remaining Contractual Life in Years">2.71</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkFJlg7CIGI4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.68</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zkZXbEvZCBUk" style="width: 12%; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">31.942</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSWER8ORk6N" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.68</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zFF5dBDjmDcf" title="Range of Exercise Prices">1.73</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6GR4MihFNqb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zsi2lgJEffek" title="Weighted Average Remaining Contractual Life in Years">3.00</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zUN7nKI3F7Hk" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.73</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeTkbbgz1hM1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">250,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNn3mvjwfKq9" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.73</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFfMELWcIFK4" title="Range of Exercise Prices">2.23</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJDXFdad62X3" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">270,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4g76Xdl9xEh" title="Weighted Average Remaining Contractual Life in Years">2.09</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zHjpDaidhDC4" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">2.23</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJ8xrTrxLBDg" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">270,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z7dQHb0o3jI1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.23</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zse1GK8fXyM5" title="Range of Exercise Prices, minimum">2.40</span>- $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zXbr708Hy0Xg" title="Range of Exercise Prices, maximum">2.60</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0uH41Mu6Kb8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">14,068</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUMdXuWw72H" title="Weighted Average Remaining Contractual Life in Years">2.07</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zEwxtzzqjMc5" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">2.57</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zb7yGoJTsD7d" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">14,068</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMa41yGtdjZk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.57</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlbkaeGQaSwj" title="Range of Exercise Prices">3.95</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zBF4iNvaxtH8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">308,500</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zKDX4w6uqyQ6" title="Weighted Average Remaining Contractual Life in Years">1.25</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_ztZXxeyFwKx6" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.95</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zca8hLtJy0hh" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">308,500</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrOPeT5IV0s1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">3.95</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zu2kXdLgJ6tg" title="Range of Exercise Prices, minimum">4.49</span>- $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zlk4dg79uAE5" title="Range of Exercise Prices, maximum">5.72</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBqKWGOgoDGi" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">92,300</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zjtEHC3Wmhe" title="Weighted Average Remaining Contractual Life in Years">4.61</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zHcJrdxk8ZC6" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.53</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeTteEScetl9" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">92,300</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zSJ4dbOT4wo8" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.53</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zDIN7cIJpzL2" title="Range of Exercise Prices">6.30</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2QzovA3MCH2" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">285,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zKzbXceGCgFl" title="Weighted Average Remaining Contractual Life in Years">4.14</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zIxno0jEoe5g" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">6.30</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zSNMQyyUlga1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">285,000</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3H8Zdfyei4h" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">6.30</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zn3EUDSiSh7i" title="Range of Exercise Prices, minimum">6.75</span>- $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zx7sUUoWLTjl" title="Range of Exercise Prices, maximum">7.26</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zFgDpj9mGoV4" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">44,006</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zOsShfqHM1f1" title="Weighted Average Remaining Contractual Life in Years">7.41</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z8Yi7HCqpbqd" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">6.84</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zP0VqFjS5kDl" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">21,319</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zMYIcZD2XyRa" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">6.79</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zuuDFDXWag7b" title="Range of Exercise Prices">7.30</span></span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zUNvZRwEIDnd" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">274,500</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zFIQT9BhHyWa" title="Weighted Average Remaining Contractual Life in Years">5.01</span></span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zqNoDhZWrxof" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.30</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJKz8Bmkr4N1" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">274,500</span></td> <td> </td> <td> </td> <td><span style="font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zjhbmqBCKPlk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.30</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zDEibZEjFeHi" title="Range of Exercise Prices, minimum">7.60</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQeLUNnAvpN" title="Range of Exercise Prices, maximum">45.64</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zXKRkd1ADGvf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">898,783</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHK8oczWBYAc" title="Weighted Average Remaining Contractual Life in Years">3.06</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zIMwaVrrv9sg" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">10.09</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zLtJoqdpQHUg" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">679,229</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zkBp6QdIZATk" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.10</span></td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231_zXt0xtmM1l46" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231_zSl8ISGpzX03" title="Range of Exercise Prices, maximum">45.64</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zHOil1qj3Tmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">2,469,099</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zIyDV6ejzRgl" title="Weighted Average Remaining Contractual Life in Years">3.19</span></span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231_zwquQeLIX8r2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding"><span style="font-size: 10pt">6.49</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231_zhtPXv1tDVNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable"><span style="font-size: 10pt">2,226,858</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231_zKqds6BLCnKk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-size: 10pt">5.52</span></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 1.47 1.70 31942 P2Y8M15D 1.68 31.942 1.68 1.73 250000 P3Y 1.73 250000 1.73 2.23 270000 P2Y1M2D 2.23 270000 2.23 2.40 2.60 14068 P2Y25D 2.57 14068 2.57 3.95 308500 P1Y3M 3.95 308500 3.95 4.49 5.72 92300 P4Y7M9D 5.53 92300 5.53 6.30 285000 P4Y1M20D 6.30 285000 6.30 6.75 7.26 44006 P7Y4M28D 6.84 21319 6.79 7.30 274500 P5Y3D 7.30 274500 7.30 7.60 45.64 898783 P3Y21D 10.09 679229 8.10 1.47 45.64 2469099 P3Y2M8D 6.49 2226858 5.52 2158000 P2Y8M23D 624000 782000 1567913 25.00 50.00 <p id="xdx_897_eus-gaap--ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_zQbSGhHWhER3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zdyzXjrkViAe" style="display: none">SCHEDULE OF PERFORMANCE STOCK UNITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Tranche</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Target Share Price*</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Tranche 1</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zAmR4YTNcta6" style="width: 12%; text-align: right" title="Tranche of shares">223,988</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_fKg_____zBlT05dxTGYb" style="width: 12%; text-align: right" title="Share price">25.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zFkRnPvYmdC4" style="text-align: right" title="Tranche of shares">335,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_fKg_____zwd5O8dAjpDg" style="text-align: right" title="Share price">35.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tranche 3</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zpFV6pA2WEA3" style="text-align: right" title="Tranche of shares">447,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_fKg_____zvgNqmxUh2lf" style="text-align: right" title="Share price">45.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 4</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20240101__20241231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_zwaeMj5zPrId" style="text-align: right" title="Number of Shares">559,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20241231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_fKg_____zxtbKnEMTre5" style="text-align: right" title="Target Share Price">50.00</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 20px; text-align: right"><span id="xdx_F04_zL3o470pClli" style="font-size: 10pt">*</span></td> <td style="text-align: justify"><span id="xdx_F1B_zyYh64fw6RQ1" style="font-size: 10pt">Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price. </span></td></tr> </table> 223988 25.00 335981 35.00 447975 45.00 559969 50.00 29106000 0.65 0.1034 <p id="xdx_892_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zH8xARDteN59" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zpXEWgAblHOj" style="display: none">SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">PSUs unvested – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNUu3K5dX0V7" style="width: 12%; text-align: right" title="Number of Shares, unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z2Mfa0HRTRml" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">18.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zwhFxSomQhhi" style="text-align: right" title="Number of Shares, PSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl2155">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z57xuLKxnllh" style="text-align: right" title="Weighted average grant date fair value, PSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfzS3B1u4kZc" style="text-align: right" title="Number of Shares, PSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl2159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zq1hfmH9L0je" style="text-align: right" title="Weighted average grant date fair value, PSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDYPpU7oers3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2163">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z7qpP1em8XCb" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2165">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ziuzOGVPA1Dh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zIUN6voYsi1l" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">PSUs unvested – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zxoRDKU1XBu1" style="width: 12%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zvFDnfMvrkeb" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zaBNAtEJ9Tx8" style="text-align: right" title="Number of Shares, PSUs granted">1,567,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zdddLnPqZBh6" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">18.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3d6Qc4SaqP7" style="text-align: right" title="Number of Shares, PSUs vested">(1,567,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zR0fJaoMufTg" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">6.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSJVelj69E0f" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2183">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz3Az8tR8B37" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFTfcYbTe9t" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zdDDMUu49Nif" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1567913 18.56 1567913 18.56 1567913 6.45 1567913 18.56 1567913 6.45 1567913 18.56 7276000 P0Y3M 14553000 13753000 0 0 43961 790000 283870 7286000 P4Y 41301 800000 86873 697000 third anniversary of the grant date. <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zK0ubbFfrrmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z2Fie5HUSC7k">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">RSUs unvested – January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z1gVHKtrGVe" style="width: 12%; text-align: right" title="Number of Shares, unvested, outstanding, beginning balance">363,029</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231_zDt5PyDpVmdc" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">9.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zE74UqW4gBw4" style="text-align: right" title="Number of Shares, RSUs granted">327,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zaEirJdEIOb3" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">24.64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_z5pxPXLl0yD3" style="text-align: right" title="Number of Shares, RSUs vested">(327,998</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_z2Wq1JXdnan6" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">10.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_z7GQorodX5P8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(9,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zJt8327zVa39" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">11.64</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_z1XCiahEqxol" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, unvested, outstanding, ending balance">353,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231_zb62eicW9ed4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">22.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">RSUs unvested – January 1, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231_zNSWEUeCG9t3" style="width: 12%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">493,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zKiIZo3hC2ri" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231_zGgQlMm4EVKi" style="text-align: right" title="Number of Shares, RSUs granted">128,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zxLYJRF9LsB8" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">11.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231_z5qZvaV7ATCe" style="text-align: right" title="Number of Shares, RSUs vested">(175,643</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_ztBo3vK0Fc0g" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">8.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231_znM9NF0xSyo7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(83,308</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zzoSQx2Hs7z7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">6.84</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231_zMRJ1xoTo875" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">363,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zteVNJD3EB71" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">9.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 363029 9.23 327831 24.64 327998 10.22 9750 11.64 353112 22.55 493806 7.99 128174 11.68 175643 8.67 83308 6.84 363029 9.23 7703000 P1Y10M6D 2442000 1161000 12000 0 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zsBLckl8hjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded total stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zrLTY2fCr4V6" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231_zJOVXg5tpD8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zKU48IlniAlj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zZoah1i7VHE6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Employees – selling, general and administrative</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">14,812,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">13,279,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zNF0zwLSbVy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employees – R&amp;D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,722,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,662,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zfgtk7mDRlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Directors – selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zFHGzWI1is98" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Consultants – selling, general and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">285,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zcfjuHNBjkLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,619,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,696,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 14812000 13279000 1722000 1662000 800000 688000 285000 67000 17619000 15696000 <p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zLhZvzaSCco6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 16. <span id="xdx_82B_zsnJoQkeNF38">INCOME TAXES </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zWPdVrPWxwe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to taxation in the U.S., New Jersey, Tennessee, and various other states. The Company’s income tax provision consists of the following for the years ended December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zRhK2VtEg4j5" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zuXVHwwlTUD7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zyUJGz0NIdU3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zA6d1Ryrbmqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzp3T_zfPmgXlzFhDl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">46,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2300">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzp3T_zTfhQDw83ir4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">115,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">701,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzp3T_maITEBzQH8_zM1UiB5Tj9te" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">161,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">701,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_ziJFC9pbGZKh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zmEOeJR8CRt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2312">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_z6KiTaHnwrs1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzJuM_maITEBzQH8_zRlTPU4LEpq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total deferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2318">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzQH8_zD6aXgTXJ3ki" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">161,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zdbeeI8gV5P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zAf0etR9Jsci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income tax provision to the income tax provision is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbvL0CYEzUZh" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zx8fAMaHe4R3" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zty5VamAsV63" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zzugHjxduzS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zaX5CavXC7L5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State tax benefit, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.49</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.77</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maKL001_zXOB7nr1iTW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.87</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.02</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maKL001_zz0wf6uzbJ2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.61</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.93</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration_pid_dp_uPure_maKL001_zIrAhN0FxC3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Excess Employee remuneration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.95</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30.83</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maKL001_zWOkZqTVQ5Ti" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Melt loan settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2340">-</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.52</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKL001_zQiT30mgH5M9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.97</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_pid_dp_uPure_maKL001_zXdjG31Q6bia" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.09</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11.71</td><td style="text-align: left">)%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msKL001_zOIRN598XMX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research and development tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.66</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.53</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps_pid_dp_uPure_maKL001_zF7AEvzUTfa8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Provision-to-return true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.75</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.72</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKL001_znLPsFVPuYA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other true-ups</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1.87</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(0.43</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_uPure_z34oKkXw0Fhk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zMEb6ZyLBZJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8.59</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5.71</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zMisRvSmkxvc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.88</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFupoZ9SU8m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zKj0shER4Ev1">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zUR5eu2fGSBg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zrRb1sGoivPc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz5SE_zIPwnATP8TP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">NOL</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,448,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,669,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_maDTANz5SE_z2LyjG28V4H" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,753,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTANz5SE_zg1zWEwoMas9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_maDTANz5SE_zizrl0sBxQwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">655,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANz5SE_zKPCXrE3Y6h4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Deferred stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,523,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_di_msDTANz5SE_zzKILjOHNlFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Eton</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInInvestments_iI_maDTANz5SE_zalmUcEncbYb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Melt investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,405,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsFederalBenefitOfStateReserves_iI_maDTANz5SE_zUxs385JYalc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Federal benefit of state ASC740-10 reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsLimitations_iI_maDTANz5SE_zGayCSzOtJGd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Limitation Under 163(j)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,605,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,893,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations_iI_maDTANz5SE_z6YZBKQ5WpTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Section 174 capitalized expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations_iI_maDTANz5SE_zlc2QUajuJLf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">ASC 842 lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,304,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,710,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations_iNI_di_msDTANz5SE_zmcTvHprbHK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">ASC 842 ROU asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,121,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,582,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz5SE_maDTALNzuBa_zexhimcv89vg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total deferred tax assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">17,610,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">15,631,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzuBa_zwzLmiluoqP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17,610,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,631,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzuBa_zEZSeYxkUqk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zcPVyxSMJYqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20240101__20241231_zNJEkMspDHic" title="Valuation allowance">1,979,000</span> during 2024 and decreased by $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_zwKA62ZjBo1d" title="Valuation allowance">1,391,000</span> during 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the Company had federal and state net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20241231_ziiYzm8WMs0l" title="Federal net operating loss carryforwards">27,669,000</span>, which will begin to expire in <span id="xdx_90C_ecustom--StateNetOperatingLossExpirationDate_c20240101__20241231_zW5D6QcWNQD9" title="State net operating loss expiration date">2036</span> for federal purposes, unless previously utilized, and will begin to expire for state purposes in 2028. In addition, <span id="xdx_907_ecustom--FederalNetOperatingLossCarryforwardDescription_c20240101__20241231_zKDthhwSii58" title="Federal net operating loss carryforward description">the Company has federal net operating loss carryforward of $2,875,000 generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the Company had federal and state research and development credit carryforwards of approximately $<span id="xdx_902_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zRSDf4hKO6oi" title="Research and development tax credits">577,000</span> and $<span id="xdx_907_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zEcJw6MKy6Q5" title="Research and development tax credits">99,000</span>, respectively, which will begin to expire in <span id="xdx_908_ecustom--FederalAndStateResearchAndDevelopmentTaxCreditsExpirationDate_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ReasearchAndDevelopmentMember_zf6a55Bq6pjh" title="Federal and state research and development tax credits expiration date">2031</span>, unless previously utilized. For state purposes, the state research and development credit carryforwards can be carried over indefinitely.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Utilization of the net operating losses and research and development carryforwards may be subject to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforward that can be utilized annually to offset future taxable income and tax liabilities. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024 and 2023, the Company had approximately $<span id="xdx_905_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20241231_zO1rTNMiHbPf" title="Unrecognized tax benefits effective tax rate">2,858,000</span> and $<span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20231231_zPxns07JeQOh" title="Unrecognized tax benefits effective tax rate">2,822,000</span>, respectively of unrecognized tax benefits which, if fully recognized, would decrease its effective tax rate. Interest or penalties of <span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20241231_zFHz6DwcFGB2" title="Unrecognized tax benefits">$69,000</span> and $<span id="xdx_906_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_c20231231_zDEAoSUbY5B9" title="Unrecognized tax benefits">40,000</span> were accrued relating to unrecognized tax benefits as of December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89D_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zpfQ9V9J4Ssc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the change in the unrecognized tax benefits balance for the years ended December 31, 2024 and 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbCvXjboYS1j" style="display: none">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zVV7uyRnLep3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Federal &amp; State Tax</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_zeXisWZcBONg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: justify">Balance at January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,822,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_z3NSEwP9ZAWd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions for tax positions related to current year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zoDkG5UiBroc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Additions/(reductions) for tax positions related to prior years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z7592FR5o1W6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,858,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zVyRMowIl5c8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Federal &amp; State Tax</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_zRbQWH7OzjK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2448">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw45SxrCdMR9" style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: justify">Additions for tax positions related to current year</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">36,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zaHMsvgo5tgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Additions/(reductions) for tax positions related to prior years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">                 2,786,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z0wnIWNGlx68" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zHKapRP9K9A9" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zWPdVrPWxwe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to taxation in the U.S., New Jersey, Tennessee, and various other states. The Company’s income tax provision consists of the following for the years ended December 31, 2024 and 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zRhK2VtEg4j5" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zuXVHwwlTUD7" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zyUJGz0NIdU3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zA6d1Ryrbmqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzp3T_zfPmgXlzFhDl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">46,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2300">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzp3T_zTfhQDw83ir4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">115,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">701,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzp3T_maITEBzQH8_zM1UiB5Tj9te" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">161,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">701,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_ziJFC9pbGZKh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zmEOeJR8CRt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2311">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2312">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_z6KiTaHnwrs1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzJuM_maITEBzQH8_zRlTPU4LEpq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total deferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2318">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzQH8_zD6aXgTXJ3ki" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">161,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 46000 115000 701000 161000 701000 161000 701000 <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zAf0etR9Jsci" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income tax provision to the income tax provision is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbvL0CYEzUZh" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zx8fAMaHe4R3" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zty5VamAsV63" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zzugHjxduzS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zaX5CavXC7L5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State tax benefit, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.49</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.77</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maKL001_zXOB7nr1iTW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.87</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.02</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maKL001_zz0wf6uzbJ2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.61</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.93</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration_pid_dp_uPure_maKL001_zIrAhN0FxC3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Excess Employee remuneration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5.95</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30.83</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maKL001_zWOkZqTVQ5Ti" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Melt loan settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2340">-</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.52</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKL001_zQiT30mgH5M9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.97</td><td style="text-align: left">%</td></tr> <tr id="xdx_404_ecustom--EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_pid_dp_uPure_maKL001_zXdjG31Q6bia" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.09</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11.71</td><td style="text-align: left">)%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msKL001_zOIRN598XMX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research and development tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.66</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.53</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps_pid_dp_uPure_maKL001_zF7AEvzUTfa8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Provision-to-return true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.75</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.72</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKL001_znLPsFVPuYA3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other true-ups</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1.87</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(0.43</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_uPure_z34oKkXw0Fhk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8.59</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zMEb6ZyLBZJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8.59</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5.71</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zMisRvSmkxvc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.88</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFupoZ9SU8m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zKj0shER4Ev1">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zUR5eu2fGSBg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zrRb1sGoivPc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz5SE_zIPwnATP8TP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">NOL</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,448,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,669,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_maDTANz5SE_z2LyjG28V4H" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,753,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTANz5SE_zg1zWEwoMas9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_maDTANz5SE_zizrl0sBxQwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">655,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANz5SE_zKPCXrE3Y6h4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Deferred stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,523,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_di_msDTANz5SE_zzKILjOHNlFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Eton</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInInvestments_iI_maDTANz5SE_zalmUcEncbYb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Melt investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,405,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsFederalBenefitOfStateReserves_iI_maDTANz5SE_zUxs385JYalc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Federal benefit of state ASC740-10 reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsLimitations_iI_maDTANz5SE_zGayCSzOtJGd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Limitation Under 163(j)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,605,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,893,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations_iI_maDTANz5SE_z6YZBKQ5WpTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Section 174 capitalized expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations_iI_maDTANz5SE_zlc2QUajuJLf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">ASC 842 lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,304,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,710,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations_iNI_di_msDTANz5SE_zmcTvHprbHK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">ASC 842 ROU asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,121,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,582,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz5SE_maDTALNzuBa_zexhimcv89vg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total deferred tax assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">17,610,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">15,631,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzuBa_zwzLmiluoqP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17,610,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,631,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzuBa_zEZSeYxkUqk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.2100 0.2100 -0.0249 0.0077 0.0187 -0.0802 -0.0861 0.1993 -0.0595 -0.3083 -0.0452 0.0171 0.0297 0.0009 -0.1171 -0.0266 -0.0053 -0.0075 0.0172 -0.0187 -0.0043 0.0766 -0.0859 -0.0859 0.0571 -0.0093 -0.0288 <p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFupoZ9SU8m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zKj0shER4Ev1">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zUR5eu2fGSBg" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zrRb1sGoivPc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz5SE_zIPwnATP8TP6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 70%; text-align: justify">NOL</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,448,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,669,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_maDTANz5SE_z2LyjG28V4H" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,753,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTANz5SE_zg1zWEwoMas9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_maDTANz5SE_zizrl0sBxQwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">655,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANz5SE_zKPCXrE3Y6h4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Deferred stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,523,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_di_msDTANz5SE_zzKILjOHNlFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Eton</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--IncomeTaxBasisDifferenceInInvestments_iI_maDTANz5SE_zalmUcEncbYb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Basis difference in Melt investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,405,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsFederalBenefitOfStateReserves_iI_maDTANz5SE_zUxs385JYalc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Federal benefit of state ASC740-10 reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsLimitations_iI_maDTANz5SE_zGayCSzOtJGd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">Limitation Under 163(j)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,605,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,893,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations_iI_maDTANz5SE_z6YZBKQ5WpTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify">Section 174 capitalized expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,276,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations_iI_maDTANz5SE_zlc2QUajuJLf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: justify">ASC 842 lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,304,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,710,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations_iNI_di_msDTANz5SE_zmcTvHprbHK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">ASC 842 ROU asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,121,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,582,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz5SE_maDTALNzuBa_zexhimcv89vg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total deferred tax assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">17,610,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">15,631,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzuBa_zwzLmiluoqP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17,610,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,631,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzuBa_zEZSeYxkUqk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2411">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2448000 4669000 1753000 1637000 443000 854000 655000 220000 1523000 1059000 583000 3620000 3405000 104000 88000 4605000 2893000 2276000 1261000 2304000 1710000 2121000 1582000 17610000 15631000 17610000 15631000 1979000 1391000 27669000 2036 the Company has federal net operating loss carryforward of $2,875,000 generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income 577000 99000 2031 2858000 2822000 69000 40000 <p id="xdx_89D_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zpfQ9V9J4Ssc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the change in the unrecognized tax benefits balance for the years ended December 31, 2024 and 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbCvXjboYS1j" style="display: none">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zVV7uyRnLep3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Federal &amp; State Tax</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_zeXisWZcBONg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: justify">Balance at January 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,822,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_z3NSEwP9ZAWd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions for tax positions related to current year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zoDkG5UiBroc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Additions/(reductions) for tax positions related to prior years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z7592FR5o1W6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,858,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zVyRMowIl5c8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Federal &amp; State Tax</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_zRbQWH7OzjK9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2448">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw45SxrCdMR9" style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: justify">Additions for tax positions related to current year</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">36,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zaHMsvgo5tgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Additions/(reductions) for tax positions related to prior years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">                 2,786,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z0wnIWNGlx68" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2822000 5000 32000 2858000 36000 2786000 2822000 <p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zVZq4DkHFAhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 17. <span id="xdx_820_za0LdlsqShJ9">EMPLOYEE SAVINGS PLAN</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating employees to deposit into tax deferred investment accounts up to <span id="xdx_906_ecustom--PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_dp_c20240101__20241231_zAU0GXmvyMq2" title="Percentage of salary deposits in tax deferred investment account">100</span>% of their salary, subject to annual limits. The Company makes certain matching contributions to the plan in amounts up to <span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20240101__20241231_ziE09qZKNdBk" title="Percentage of contributions made by the company">4</span>% of the participants’ annual cash compensation, subject to annual limits. The Company contributed approximately $<span id="xdx_906_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240101__20241231_zO8VXRvXxoni" title="Contributions by the company">953,000</span> and $<span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230101__20231231_zTwWCWG4dgtf" title="Contributions by the company">594,000</span> to the plan during the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b> </b></p> 1 0.04 953000 594000 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zazWbrtUH3Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 18. <span id="xdx_825_zB4MmfKDuera">COMMITMENTS AND CONTINGENCIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Legal</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>General and Other</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of business, the Company is involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See also Part I, Item 1A. Risk Factors<i>. </i>The Company describes legal proceedings and other matters that are/were significant or that it believes could become significant in this footnote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company records accruals for loss contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of a liability that has been accrued previously.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s legal proceedings involve various aspects of its business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. Typically, a number of the matters pending against the Company are at early stages of the legal process, which in complex proceedings of the sort the Company face often extend for several years. While it is not possible to accurately predict or determine the eventual outcomes of matters that have not concluded, an adverse determination in one or more of these matters (whether discussed in this footnote or not) currently pending may have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows. Legal costs incurred for loss contingencies are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain recent developments concerning the Company’s legal proceedings it believes are or were material to its business and other matters are discussed below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Ocular Science, Inc. et. al</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2021, ImprimisRx, LLC, a subsidiary of the Company, filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. (together, “OSRX”) in the U.S. District Court for the Southern District of California, asserting claims for copyright infringement, trademark infringement, unfair competition and false advertising (Lanham Act). Since July 2021, the complaint had been amended and OSRX added counterclaims alleging ImprimisRx, LLC was violating the Lanham Act with false advertising. The Court granted cross motions for summary judgement on each party’s Lanham Act claims thus leaving only ImprimisRx, LLC’s copyright infringement, trademark infringement and unfair competition claims for trial. Following a jury trial in November 2024, a jury found OSRX acted with malice, fraud, or oppression, willfully engaging in trademark infringement and unfair competition under California and federal law and ImprimisRx, LLC received a $<span id="xdx_903_eus-gaap--ProceedsFromLegalSettlements_c20241101__20241130_zPbE3ag9Bdog" title="Legal settlements">34,900,000</span> jury verdict award, which includes $<span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20241101__20241130_zT6QfiRUAM2k" title="Punitive damages">20,400,000</span> in punitive damages and $<span id="xdx_908_eus-gaap--LossContingencyDamagesSoughtValue_c20241101__20241130_z4PBSKIm2hH2" title="Actual damages">14,500,000</span> in actual damages. Due to uncertainty regarding probability of collection, the Company did not record any gains associated with the verdict award during the year ended December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Product and Professional Liability</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. The Company utilizes traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Indemnities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. Several of the Company’s asset purchase and license agreements contain customary representations, warranties, covenants and confidentiality provisions, and also contain mutual indemnification obligations related primarily to performance under the respective agreements. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Asset Purchase, License and Related Agreements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>FDA Approved Product Acquisitions</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In recent years, the Company has acquired commercial and product rights to various FDA approved ophthalmic medications and products through asset purchase, licenses, supply and/or other related agreements. In general, in exchange for product and commercial rights these agreements provide the counterparties with certain upfront and contingent milestone payments typically related to certain annual sales amounts and manufacturing events, and in certain cases, per unit transfer prices and royalties on sales of some of the products. During the years ended December 31, 2024 and 2023, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseandRelatedAgreementsMember_zMwazTXiEiQj">4,126,000</span> and $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseandRelatedAgreementsMember_z8xeojPqmgz6">647,000</span>, respectively, were incurred under these agreements as royalty expenses. During the year ended December 31, 2024, $<span id="xdx_900_ecustom--UpfrontAndMilestonePayments_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseandRelatedAgreementsMember_zKsJoS7OH2lk" title="Upfront and milestone payments">37,000,000</span> was incurred under these agreements related to upfront and milestone payments under these agreements. During the year ended December 31, 2023, the Company amended the Sintetica Agreement to allow for early payment of previously accrued amounts for commercial related milestones associated with sales of IHEEZO in exchange for a $<span id="xdx_90D_ecustom--ReductionInMilestoneAmounts_c20230101__20231231_zK5f8633nnnb" title="Reduction in milestone amounts">550,000</span> reduction in the milestone amounts due, and as a result of this amendment, the Company reduced the intangible asset value associated with IHEEZO by $<span id="xdx_907_ecustom--ReductionInMilestoneAmounts_c20230101__20231231_zoKbi7Bw5Fn1" title="Reduction in milestone amounts">550,000</span> and paid the remaining commercial milestone amount of $<span id="xdx_90D_ecustom--PaymentForMilestone_c20230101__20231231_zUYhbKsY1wnf" title="Payment for milestone">4,450,000</span>. As of December 31, 2024, the remaining contingent consideration payable pursuant to these agreements were not considered probable and reasonably estimable and therefore, no amount was accrued related to these contingent obligations during the year ended December 31, 2024. At the time contingent consideration payable becomes probable and reasonably estimable the additional consideration, if any, paid will be allocated to the assets based on their initial estimated fair values as a percent of the total purchase price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <i>Formulation Acquisitions</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors, innovator companies and related parties (the “Inventors”) through multiple asset purchase agreements and license agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In consideration for the acquisition of these intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of a milestone, generally consisting of: (1) a payment payable within 30 to 45 days after the issuance of the first patent in the U.S. arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. During the years ended December 31, 2024 and 2023, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementsMember_zWAZs9ND8O5d">1,234,000 </span>and $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementsMember_zo38NuijJyhd">1,130,000</span>, respectively, were incurred under these agreements as royalty expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <b>Contract Manufacturing</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into manufacturing agreements with respect to third-party contract manufacturers for its FDA approved pharmaceutical products. Some of these contract manufacturing agreements require minimum annual order amounts. The Company had committed to pay approximately $<span id="xdx_904_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20241231_z8NeYmk4XJjl" title="Payment of minimum annual order amounts">2,728,000</span> related to contract manufacturing agreements for the year ended December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cybersecurity Incident</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, the Company became aware of a cybersecurity incident that involved unauthorized access of an employee’s email account. Through this unauthorized access the threat actor was able to fraudulently divert Company funds to its bank account. The Company, along with its external cybersecurity experts, fully investigated and assessed the impact of the incident and notified, and is cooperated with, federal law enforcement. The Company detected the incident in a time that management believes minimized any financial, operational or reputational risk to the Company. During the year ended December 31, 2024, the Company recorded a loss of $<span id="xdx_903_eus-gaap--LossContingencyLossInPeriod_c20240101__20241231_zx43SuTxNO2f" title="Loss contingency">271,000</span> associated with this event and management does not believe any additional loss will be recorded. At no point was the Company’s ability to generate revenues disrupted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 34900000 20400000 14500000 4126000 647000 37000000 550000 550000 4450000 1234000 1130000 2728000 271000 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_z9p4zHPWbLF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.75in"><b>NOTE 19. <span id="xdx_82B_zzs9lFWYmcz5">SEGMENTS AND CONCENTRATIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, the Company operated its business on the basis of a single reportable segment due to the lack of discrete, precise financial information available to the chief operating decision maker (“CODM”). The CODM is the Chief Executive Officer. The CODM does not review segment assets when assessing segment performance and deciding how to allocate resources. During 2024, refinements were made to the financial reporting information and the Company began reporting on <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zhD5tNzzOcMh" title="Number of reportable segments">two</span> reportable segments which were generally determined based on the decision-making structure of the Company and the grouping of similar products and services: Branded and ImprimisRx.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The <b><i>Branded </i></b>segment includes activities of the Company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of our branded products.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The <b><i>ImprimisRx</i></b> segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Segment contribution for the segments represents net revenues less cost of sales, certain general and administrative expenses, selling and marketing expenses, and research and development expenses. The Company does not evaluate the following items at the segment level:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), Board of Directors and principal executive officers and other like shared expenses.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Other select revenues and operating expenses including research and development expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zudlFwF14Qak" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Segment net revenues, segment operating expenses and segment contribution information consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z2TZXx0HTMYf" style="display: none">SCHEDULE OF SEGMENT NET REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_z9AWdKl8ua9k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z5H4yyxC3Fs" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231_z599OSpRcBWi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_z6fDySjRaQck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">115,120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">83,499,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,619,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zxSmOTq4SNDh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2501">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwL0T16kGt8a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,499,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199,614,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_iN_di_z4fBQXupTsxf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,667,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,578,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(49,245,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_zD2efjfiuF0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,448,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,369,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2CHujN9jUyf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQMl4rzLjvgb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,301,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,607,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,908,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNnbiLCy6Sri" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,890,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">386,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,276,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingExpenses_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zWjbpSI4LBhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,257,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,928,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">61,185,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingExpenses_pp0p0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zAKo3kcDr1b6" style="text-align: right" title="Operating expenses">43,409,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingExpenses_pp0p0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentAggregationResearchAndDevelopmentMember_zXkGBJgT9XHg" style="border-bottom: Black 1pt solid; text-align: right" title="Operating expenses">8,954,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_z0lxhSdmgbqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zFThhcuOFLo2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zvPZ8xbZcZs3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zXbP7f3aLADk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zFoaSrb0Shtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">37,512,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">79,935,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_ztF5Jy76gWZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zMbCCcvsFbnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,258,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,193,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zLrPp3qS0UUe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,662,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,978,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(39,640,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_zx2FoqxyAECc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,957,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,553,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zWauJycX0COf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_znRiPfeDuXtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,126,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,336,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zZ2pLyqWjzU8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">641,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">966,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,607,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingExpenses_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxiBTrLekwt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,829,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,781,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">41,610,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingExpenses_pp0p0_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zcKF6401RNyb" style="text-align: right" title="Operating expenses">36,134,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingExpenses_pp0p0_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentAggregationResearchAndDevelopmentMember_z3w1FCDY8lzd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating expenses">5,045,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zswIAtXlyrh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zdAPJtVPRkhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Substantially all revenue is attributable to the U.S. All long-lived assets at December 31, 2024 and 2023 were located in the U.S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_89A_ecustom--ScheduleOfSegmentReportingInformationTextBlock_zQeJL5pTqMO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenues by segment are further described as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zTd6cRNNLBY3" style="display: none">SCHEDULE OF REVENUES BY SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="text-align: center">For the Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">%</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">%</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">IHEEZO</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--IHEEZOMember_zJ7OvW2KLNa" style="width: 12%; text-align: right" title="Revenue">49,303,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--IHEEZOMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zSz0dl2GSsKg" style="width: 12%; text-align: right" title="Revenue percentage">25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--IHEEZOMember_zfgbm7EfXynj" style="width: 12%; text-align: right" title="Revenue">20,621,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--IHEEZOMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zCy5DfyEOMZf" style="width: 12%; text-align: right" title="Revenue percentage">16</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VEVYE</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--VEVYEMember_zickTyxbuDAf" style="text-align: right" title="Revenue">28,061,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--VEVYEMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zh4mhrD75tn9" style="text-align: right" title="Revenue percentage">14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--VEVYEMember_zJc1c19RwK8h" style="text-align: right" title="Revenue">1,766,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--VEVYEMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zyhwBJ0Si9si" style="text-align: right" title="Revenue percentage">1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other branded products</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherProductsMember_zR2GhW0Cc9ej" style="text-align: right" title="Revenue">37,836,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherProductsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zKQkWMCQILh1" style="text-align: right" title="Revenue percentage">19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherProductsMember_zmP8vAMriRVg" style="text-align: right" title="Revenue">15,125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherProductsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zqi9koUsoTC5" style="text-align: right" title="Revenue percentage">12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenue, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zBYLzJlA4jph" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">915,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zkRUzg81XUpg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">0</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zJiC0B7vGYM6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zZceO1GVwTd9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">10</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Branded revenue, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zBeM74GwsiRg" style="text-align: right" title="Revenue">116,115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z707SdUOVvtb" style="text-align: right" title="Revenue percentage">58</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zfpvmtsPFTH8" style="text-align: right" title="Revenue">50,258,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z64i5C2Zjyhd" style="text-align: right" title="Revenue percentage">39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">ImprimisRx revenue, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zNwtwq4zg2Tk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">83,499,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z1S9DRLeS5W2" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">42</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z1Q8ZX1v1kNl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">79,935,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zq6rujnVW5Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">61</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_zXH4QglO7kQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">199,614,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zI6s2pFk4RAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zbgVkNPokip4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zmQmwPSx5Ou2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A9_zn3tvKJ5FC89" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than IHEEZO, VEVYE, and one ImprimisRx product, no other products accounted for more than 10% of total revenues for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Customer and Supplier Concentrations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Substantially all of the Company’s Branded sales are made to third-party distributors who sell the products to pharmacies and to the end-users. There were two customers who comprised more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCp2I43OtxE2" title="Concentration risk percentage">10</span>% of the Company’s Branded revenues for the year ended December 31, 2024 and one customer who comprised more than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7eQvSaDDeJ1" title="Concentration risk percentage">10</span>% of the Company’s Branded revenues for the year ended December 31, 2023. There were no customers who comprised more than <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWAdxfFxhjcc" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqhvs4iKJch5" title="Concentration risk percentage">10</span></span>% of ImprimisRx revenues for the years ended December 31, 2024 and 2023. As of December 31, 2024 and December 31, 2023, accounts receivable from two customers and one customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSvP1tJA4x6j" title="Concentration risk percentage">94</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLj6UFL1MGZ5" title="Concentration risk percentage">80</span>%, respectively, of total consolidated accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received its active pharmaceutical ingredients from two and three main suppliers during the years ended December 31, 2024 and 2023, respectively. These suppliers collectively accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--ThreeSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zMs8cbfo9fZ6">42</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--ThreeSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zWxL56OmUz3d">64</span>% of active pharmaceutical ingredient purchases during the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 2 <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zudlFwF14Qak" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Segment net revenues, segment operating expenses and segment contribution information consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z2TZXx0HTMYf" style="display: none">SCHEDULE OF SEGMENT NET REVENUES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_z9AWdKl8ua9k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z5H4yyxC3Fs" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231_z599OSpRcBWi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_z6fDySjRaQck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">115,120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">83,499,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,619,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zxSmOTq4SNDh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2501">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zwL0T16kGt8a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,499,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199,614,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_iN_di_z4fBQXupTsxf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,667,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(27,578,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(49,245,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--GrossProfit_zD2efjfiuF0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,448,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,369,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2CHujN9jUyf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQMl4rzLjvgb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,301,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,607,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,908,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNnbiLCy6Sri" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,890,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">386,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,276,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingExpenses_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zWjbpSI4LBhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,257,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,928,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">61,185,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingExpenses_pp0p0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zAKo3kcDr1b6" style="text-align: right" title="Operating expenses">43,409,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingExpenses_pp0p0_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentAggregationResearchAndDevelopmentMember_zXkGBJgT9XHg" style="border-bottom: Black 1pt solid; text-align: right" title="Operating expenses">8,954,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_z0lxhSdmgbqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zFThhcuOFLo2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zvPZ8xbZcZs3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zXbP7f3aLADk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Branded</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">ImprimisRx</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zFoaSrb0Shtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Product sales, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">37,512,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">79,935,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_ztF5Jy76gWZg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2545">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zMbCCcvsFbnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,258,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,193,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zLrPp3qS0UUe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,662,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,978,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(39,640,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_zx2FoqxyAECc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,957,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,553,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zWauJycX0COf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_znRiPfeDuXtj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,126,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,336,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zZ2pLyqWjzU8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">641,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">966,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,607,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingExpenses_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxiBTrLekwt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,829,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,781,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">41,610,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingExpenses_pp0p0_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zcKF6401RNyb" style="text-align: right" title="Operating expenses">36,134,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingExpenses_pp0p0_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ReportableSegmentAggregationResearchAndDevelopmentMember_z3w1FCDY8lzd" style="border-bottom: Black 1pt solid; text-align: right" title="Operating expenses">5,045,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zswIAtXlyrh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 115120000 83499000 198619000 995000 995000 116115000 83499000 199614000 21667000 27578000 49245000 94448000 55921000 150369000 62301000 23607000 85908000 2890000 386000 3276000 29257000 31928000 61185000 43409000 8954000 8822000 37512000 79935000 117447000 12746000 12746000 50258000 79935000 130193000 12662000 26978000 39640000 37596000 52957000 90553000 18126000 29210000 47336000 641000 966000 1607000 18829000 22781000 41610000 36134000 5045000 431000 <p id="xdx_89A_ecustom--ScheduleOfSegmentReportingInformationTextBlock_zQeJL5pTqMO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenues by segment are further described as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zTd6cRNNLBY3" style="display: none">SCHEDULE OF REVENUES BY SEGMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="14" style="text-align: center">For the Years Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">%</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">%</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">IHEEZO</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--IHEEZOMember_zJ7OvW2KLNa" style="width: 12%; text-align: right" title="Revenue">49,303,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--IHEEZOMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zSz0dl2GSsKg" style="width: 12%; text-align: right" title="Revenue percentage">25</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--IHEEZOMember_zfgbm7EfXynj" style="width: 12%; text-align: right" title="Revenue">20,621,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--IHEEZOMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zCy5DfyEOMZf" style="width: 12%; text-align: right" title="Revenue percentage">16</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VEVYE</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--VEVYEMember_zickTyxbuDAf" style="text-align: right" title="Revenue">28,061,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--VEVYEMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zh4mhrD75tn9" style="text-align: right" title="Revenue percentage">14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--VEVYEMember_zJc1c19RwK8h" style="text-align: right" title="Revenue">1,766,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--VEVYEMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zyhwBJ0Si9si" style="text-align: right" title="Revenue percentage">1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other branded products</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherProductsMember_zR2GhW0Cc9ej" style="text-align: right" title="Revenue">37,836,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherProductsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zKQkWMCQILh1" style="text-align: right" title="Revenue percentage">19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherProductsMember_zmP8vAMriRVg" style="text-align: right" title="Revenue">15,125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherProductsMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zqi9koUsoTC5" style="text-align: right" title="Revenue percentage">12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other revenue, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zBYLzJlA4jph" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">915,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--ProductOrServiceAxis__custom--OtherRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zkRUzg81XUpg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">0</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherRevenueMember_zJiC0B7vGYM6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">12,746,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--OtherRevenueMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zZceO1GVwTd9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">10</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Branded revenue, net</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zBeM74GwsiRg" style="text-align: right" title="Revenue">116,115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z707SdUOVvtb" style="text-align: right" title="Revenue percentage">58</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember_zfpvmtsPFTH8" style="text-align: right" title="Revenue">50,258,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BrandedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z64i5C2Zjyhd" style="text-align: right" title="Revenue percentage">39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">ImprimisRx revenue, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zNwtwq4zg2Tk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">83,499,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_z1S9DRLeS5W2" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">42</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z1Q8ZX1v1kNl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">79,935,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember_zq6rujnVW5Ul" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue percentage">61</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_zXH4QglO7kQk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">199,614,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zI6s2pFk4RAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zbgVkNPokip4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zmQmwPSx5Ou2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue percentage">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 49303000 0.25 20621000 0.16 28061000 0.14 1766000 0.01 37836000 0.19 15125000 0.12 915000 0 12746000 0.10 116115000 0.58 50258000 0.39 83499000 0.42 79935000 0.61 199614000 1 130193000 1 0.10 0.10 0.10 0.10 0.94 0.80 0.42 0.64 <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_z2ftW9foryJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 20. <span id="xdx_821_zPFeaEVASELh">SUBSEQUENT EVENTS</span></b><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February and March 2025, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYCNnjT9Ywze" title="Number of stock issued"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250301__20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQcLl6PGDgk5" title="Number of stock issued">2,743</span></span> shares of common stock and received proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromStockOptionsExercised_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7qobHkWQGu9" title="Proceeds from stock option exercised"><span id="xdx_900_eus-gaap--ProceedsFromStockOptionsExercised_c20250301__20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPioZo1azVg3" title="Proceeds from stock option exercised">23,000</span></span> upon the exercise of options to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250201__20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zY81YeWh1x1a" title="Number of stock option exercised"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250301__20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7fb7Zvf2X17" title="Number of stock option exercised">2,743</span></span> shares of common stock with exercise prices between $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zRhITjqt1Wu8" title="Exercise price"><span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_z0mlrQoRl96a" title="Exercise price">6.85</span></span> to $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zbCZZy0gzkYf" title="Exercise price"><span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_z7NoWTDzuCLb" title="Exercise price">15.17</span></span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2025, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlnKDCCUtskl" title="Number of stock issued">29,214</span> shares of its common stock underlying RSUs held by a director that ceased providing services to the Company. The RSUs had previously vested, including <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCe3VNCzDspe" title="Number of stock vested">8,046</span> RSUs during the year ended December 31, 2024, but the issuance and delivery of the shares were deferred until the director ceased providing services to the Company.</p> 2743 2743 23000 23000 2743 2743 6.85 6.85 15.17 15.17 29214 8046 Chargebacks and other allowances are included as an offset to accounts receivable in the consolidated balance sheets. Administrative Fees and Other Rebates, Prompt Payment Discounts and Returns are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Government Rebates are included in accrued government rebates and copay assistance in the consolidated balance sheets. Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price.